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ABSTRACT 
 
The overall goal of this project was to document and evaluate the technology of cancer 
vaccines, especially the newer more effective versions, to determine whether cancer vaccines are 
really worth the recent media hype, to document any problems associated with the technique, and 
to help prioritize future directions.  We performed a review of the research literature and 
conducted interviews with academic cancer researchers.  Based on the research performed for 
this project, our team’s overall conclusion is that, of the six major categories of cancer vaccines, 
the tumor infiltrating lymphocyte (TIL) and chimeric antigen receptor (CAR) type vaccines have 
shown the highest efficacies, with some CAR vaccines producing as high as 90% full cancer 
remissions in medium-sized (30 patient) studies.  We identified several directions for moving the 
field forward, including using combination vaccines (especially with antibodies for immune 
checkpoint inhibitors), adjuvants, recall antigens (if the vaccine is delivered into the skin), and 
identifying and using a patient’s own specific tumor neoantigens.  We recommend that funding 
be continued in the cancer vaccine area of research. 
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PROJECT GOALS 
 
 
The overall goal of this project was to document and evaluate the technology of cancer 
vaccines, especially the newer more effective versions, to determine whether cancer vaccines are 
really worth the recent hype, to document problems with the technique, and help prioritize future 
directions. 
 
The specific objectives were to: 
1 Develop a comprehensive assessment of the scientific experiments that led to the 
development of cancer vaccines, and document the key animal and clinical studies that 
have been done with them.  
2 Characterize what key scientific stakeholders believe are the strengths, weaknesses, 
reliability, usefulness, and cost of this new technology, and any other concerns. 
3 Evaluate all of the obtained evidence and prioritize the remaining problems. 
4 Recommend potential solutions to any remaining problems, and prioritize future 
experiments. 
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EXECUTIVE SUMMARY 
 
Cancer is a genetic disease caused by mutations in DNA. The mutations can occur in 
growth factor genes, growth related pathways, or tumor suppressor genes, but regardless of the 
site of the mutation the outcome is uncontrolled cell growth. Cancer survival statistics have 
improved in the past several decades due to more accurate and sensitive detection techniques, 
better drugs to block cell growth by a variety of mechanisms, and more precise surgical tools. 
But despite these advances and the money provided by the “War on Cancer” initiated by the 
National Cancer Act of 1971, cancer still remains the second leading cause of death following 
cardiovascular disease, so better therapies are needed.  
 
The subject of this IQP is a new form of therapy, cancer vaccines, which use the patient’s 
own immune system to help fight the tumor. Several types of cancer vaccines have been 
developed, including: 1) injecting peptides present on the surface of the tumor cell into the 
patient to help the immune system make antibodies and T-cells against the tumor, 2) forming 
antibodies against tumor-specific proteins outside the body, then injecting them into the patient 
(passive immunity) to fight the tumor, 3) forming antibodies against immune system inhibitors 
outside the body, and injecting them into a patient to activate their immune system against the 
tumor, 4) isolating dendritic cells (DC) from a patient, mixing them with tumor-specific proteins 
to commit the DC cells to those proteins, then injecting the DC cells back into the patient where 
they induce antibody and T-cell formation against the tumor, 5) isolating T-cells from a patient’s 
tumor that have already infiltrated the tumor (tumor infiltrating lymphocytes, TILs), expanding 
the TILs outside the body, and then injecting them back into the same patient, 6) engineering T-
cells to contain chimeric antigen receptors (CARs) that recognize a specific tumor antigen, and 
injecting the CAR cells back into the patient to lyse the tumor. 
 
Early cancer vaccine attempts did not work well, but the past few years have shown some 
spectacular successes, including complete cancer remissions in patients with very poor prognosis 
who had metastatic tumors resistant to all other current treatments.  So, the topic of cancer 
vaccines has become one of the hottest topics in all of cancer research.  But the new techniques 
appear to come with problems, including high costs in the cases of personalized vaccines, the 
induction of side-effects in some cases, and they do not work well in all patients. The overall 
goal of this project is to document and evaluate this new technology, to determine whether 
cancer vaccines are really worth the recent hype, to document problems with the technique, and 
help prioritize future directions. 
 
The specific objectives of this IQP were to: 1) Develop a comprehensive assessment of 
the scientific experiments that led to the development of cancer vaccines, and document the key 
animal and clinical studies that have been done with them.  2) Characterize what key scientific 
stakeholders believe are the strengths, weaknesses, reliability, usefulness, and cost of this new 
technology, and any other concerns. 3) Evaluate all of the obtained evidence and prioritize the 
remaining problems.  4) Recommend potential solutions to any remaining problems, and 
prioritize future experiments.  To accomplish objective-1, we performed a review of the current 
literature, including reputable academic journal articles, relevant books, scholarly websites, and 
other pertinent materials.  To accomplish objective-2, we conducted a set of interviews with 
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various academic researchers.  The interviewees included individuals working with 
mitochondrial disease patients, individuals performing IVF or MRT procedures, bioethics 
experts, and MRT legal experts.  The purpose of the interviews was to determine the 
interviewees full range of opinions on MRT, and to solicit their help gauging the strengths and 
weaknesses of this new technology.  After performing the Literature Review and interviews, the 
group synthesized all of the information collected to ascertain the strength of the evidence for 
and against MRT, and created recommendations for approval of MRT in the U.S. and for further 
research. 
 
Cancer Introduction 
 
Cancer is a disease caused by uncontrolled division of abnormal cells in the body.  
Cancer is a name given to a collection of related diseases, all sharing this uncontrolled cell 
division. It can begin almost anywhere in the human body, and there are over one-hundred 
different variations. The extra cells form growths called tumors.  Some cancers form solid 
tumors, while others, such as leukemia, form diffuse tumors.  Malignant tumors spread into, or 
invade, nearby tissues, or can break off and travel to distant places in the body through the blood 
or the lymph system to form new tumors.  Benign tumors do not spread into, or invade, nearby 
tissues.  
 
Cancer is the second leading cause of death worldwide, second only to cardiovascular 
disease.  According to the Centers for Disease Control and Prevention, there were approximately 
584,881 cancer related fatalities in the U.S. in 2013 (CDC, 2015). Each year, there are 
approximately 1,597,000 new cancer diagnoses in the U.S. (Cooper and Hausman, 2013). From 
the prostate gland, to the thyroid glands, the lungs, or the kidney, these malignancies 
symptomatically grow and strongly affect health. Sometimes the symptoms are not manifested 
until tumor growth is advanced, making it difficult to diagnose.  
 
Tumor treatments vary widely, depending on the location and type. Benign tumors in a 
safe area of the body that do not cause organ disruption are sometimes left alone and watched 
carefully for switching to a cancerous state. If a tumor is cancerous, treatment options include 
chemotherapy (the use of chemical drugs to block DNA replication or other key cancer 
processes), radiation (to kill rapidly dividing cells), surgery (to remove the tumor), targeted 
cancer therapy (drugs that interfere with specific molecules a tumor needs to grow), and biologic 
therapy (i.e. cancer vaccines, the subject of this IQP).  
 
With respect to cancer vaccines, an important point to note in this section is that the types 
of proteins present on the surface of a tumor cell can vary for each patient. Cancer is a genetic 
disease caused by changes to genes that control the way our cells function, especially how they 
grow and divide.  These genetic changes can occur as we age, as random errors inserted during 
DNA replication, can occur as a result of carcinogens (such as tobacco smoke or radiation, our 
two best characterized carcinogens), or can be inherited from our parents.  Each person’s cancer 
has a unique combination of genetic changes, and additional changes occur as the tumor grows, 
so this makes designing a cancer vaccine against a single protein difficult.  Recent “personalized 
medicine” therapies use second-generation DNA sequencing technology to sequence the DNA of 
a patient’s tumor to identify neo-antigens, new proteins specific to that tumor that might provide 
a target for the vaccine.   
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Our review of the literature in this area uncovered the desire of some individuals to 
design a “universal cancer vaccine” that would be effective against all forms of cancer.  
However, our research indicated that cancer vaccines are directed against antigens known to be 
present on one type of tumor (CD19 in B-cell tumors), or (because cancer cells evolve within the 
patient) against neo-antigens on the surface of a patient’s specific tumor cells.  To determine 
whether a universal vaccine is possible, we interviewed two leading cancer researchers, and both 
indicated this is not likely given the variability in antigens displayed by different types of tumors.  
 
Immunology Introduction 
 
The immune system is composed of a network of cells, tissues, and organs whose main 
purpose is to protect the body from disease and infection. Cells in the immune system recognize 
problems within the body, communicate with other cells, and perform various beneficial 
functions (NIAID, 2015). One of the main functions of the immune system is to distinguish self 
from non-self (foreign antigens): to protect the body from invading pathogens and eliminate 
altered cells (as with cancer) (Shultz and Grieder, 1987).  
 
The immune system is divided into two major subdivisions: innate immunity and 
adaptive immunity (NIAID, 2015).  Innate immunity is the part of the immune system that is 
ready for immediate maximal response when an infection is first detected. It constitutes the first 
two lines of a three-line defense system. The first line of defense is non-specific, and begins with 
physical and chemical surface barriers, such as the skin, sweat, tears, saliva, respiratory tract 
mucous, stomach acid, and urine.  If pathogens are able to get past the first line of the innate 
defense, the second line of the innate defense is activated which includes the use of immunity 
defensive cells, defensive proteins, inflammation, and fever. The cells involved in the second 
line of defense include several types of white blood cells (leukocytes), including natural killer 
cells (NKs), mast cells, eosinophils, basophils, and the phagocytic cells including macrophages, 
neutrophils, and dendritic cells (DCs).  These cells recognize molecular patterns present on the 
surface of bacteria and fungi, and act to engulf them (or aid other cells that engulf and kill them).  
 
 Adaptive immunity is the third line of defense. If a pathogen survives the nonspecific 
innate defenses, the body will react with a more advanced response to specifically target the 
pathogen. The adaptive immune system is known as the antigen-specific immune response. Once 
contact has been acquired with a pathogen, it activates the B and T-lymphocytes, each boosted 
by humoral mediators such as cytokine hormones (NCBI, 2001). Once engaged by a foreign 
antigen (usually one presented by an antigen presenting cell) the B or T-cell matures to commit 
to that specific antigen.  The immune cells that are most importance to our cancer vaccine topic 
are antigen-presenting cells (including dendritic cells) and T-cells. 
 
Dendritic Cells (DCs):  Discovered in 1973 in mice (Steinman and Cohn, 1973), 
dendritic cells (DCs) are important components of the mammalian immune system.  They get 
their name from their branched appearance at specific stages of their development. DC’s are 
potent “professional” antigen-presenting cells; their main function is to recognize foreign 
antigens (usually small epitope domains of proteins) on the surface of invading pathogens (and 
sometimes cancer cells), process the antigen within the cell, and then present it on its surface to 
other cells of the immune system (T-cells and B-cells) so they can commit to recognizing that 
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particular foreign antigen and attack the tumor to reduce its mass (Banchereau and Steinman, 
1998; Sallusto and Lanzavecchia, 2002; Trombetta and Mellman, 2005). Half of the 2011 Nobel 
Prize in Physiology or Medicine went to Ralph M. Steinman "for his discovery of the dendritic 
cell and its role in adaptive immunity" (The Nobel Prize, 2011). Because of this antigen 
presentation function, DCs are used in some types of cancer vaccines to induce an immune 
response against an antigen on the surface of a patient’s tumor cell.   
 
T-Cells:  T-cells (also termed T-lymphocytes) are a type of nucleated white blood cell 
that functions in cellular immunity. They are distinguished from other lymphocytes, such as B-
cells and natural killer cells (NK cells), by the presence of a T-cell receptor (TCR) on their cell 
surface which recognizes presented antigen and commits the cell against it. They are called T-
cells because they mature in the thymus (although some T-cells also mature in the tonsils) 
(Alberts et al., 2002). There are several types of T-cells, each with a different function: helper 
(CD4+), cytotoxic (CD8+), memory, suppressor, mucosal associated, and gamma delta T-cells.          
With respect to cancer vaccines, tumor infiltrating lymphocytes (TILs) are a type of T-cell 
found in tumors that help kill it. High levels of TILs in tumors are often associated with a better 
clinical outcome for the patient (Vanky et al., 1986). TILs isolated from tumors usually include 
both CD4+ (helper T-cells) and CD8+ (cytotoxic killer T-cells, CTLs).  TILs circulate through 
the bloodstream, recognize the tumor and infiltrate it.  The CD4+ cells secrete cytokines to 
stimulate the immune system, while the CTLs directly lyse the tumor cell.  
 
Peptide Injection Vaccines 
 
The simplest type of cancer vaccine involves directly injecting purified proteins into a 
patient to stimulate the patient’s own immune system to clear the tumor cells.  The injected 
peptide usually represents a protein (or a part of it) present on the surface of the patient’s own 
tumor cells. The injected proteins are usually previously characterized as present on all cells of a 
particular type of tumor (for example prostate-specific antigen for prostate cancer).  More 
recently, in a form of personalized medicine, the proteins are identified directly from a patient’s 
tumor cells by whole exome DNA sequencing to identify neo-antigens. The injected protein is 
hopefully recognized by the patient’s immune system as foreign. This recognition is by antigen 
presenting cells (APCs) that present the protein to B-cells (which mature to make antibodies 
against the peptide) and present it to T-cells (which mature to make cytotoxic T-lymphocytes to 
home in on the cancer cells containing the peptide). Relatively few success studies of this type 
exist because the approach appears to be less effective than DC, TIL, and CAR vaccines. 
 
An example experiment in the peptide vaccine category is a 2006 Phase-II clinical study 
performed on 28 patients with metastatic androgen-independent prostate cancer (Arlen et al., 
2006).  The patients received a peptide vaccine consisting of a vaccinia virus encoding PSA 
tumor antigen (specific for the tumor cells), followed by boosters with a fowlpox virus also 
encoding the PSA antigen.  Their data demonstrated a 3.33-fold increase in T-cell response to the 
peptide (PSA) after 3 months, and the median progression-free survival increased to 6.1 months 
compared to 3.7 months for the controls. But there were no full remissions, as seen in some of 
the newer forms of cancer vaccines.   
 
A future trend in the peptide vaccine area is to inject peptide mixtures.  For example, a 
2012 study done in Tubingen, Germany was the first immune vaccine for renal cell carcinoma 
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(RCC) (Walter et al., 2012).  The clinical Phase-I/II study consisted of an injection of 11 
different multiple tumor associated peptides (TUMAPs) the authors previously determined were 
naturally present on the surface of the RCC tumor cells, and most importantly, the peptides were 
antigenic when injected into humans.  The Phase-I data showed that an induction of T-cell 
responses against multiple TUMAPs correlated best with disease control, and the vaccine 
appeared to be safe.  The Phase-II data confirmed that an immune response against multiple 
cancer peptides correlates with longer patient survival.   But again, there did not appear to be any 
long-term full cancer remissions. 
 
Monovalent Antibody Vaccines 
 
The second type of cancer vaccine involves injecting antibodies previously made against 
a specific tumor protein. This type of “passive immunity” does not activate the patient’s own 
immune system to create the antibodies, but instead provides the antibodies by a bio-engineering 
process.  The antibodies combine with the protein on the surface of tumors to create antigen-
antibody complexes, which are then recognized and cleared from body by other cells of the 
immune system, such as macrophages or T-cells.  Monovalent antibodies recognize only one 
type of epitope on a protein (portion of a protein).  Most natural antibodies produced by the body 
in response to an infection are of this type, and both arms of the “Y” shaped antibody molecule 
recognize the same antigen. Anti-tumor monoclonal antibodies (mAbs) represent a major 
advance in cancer therapy, and in the past decade at least 6 different mAbs have been approved 
by the FDA for treating cancer, and more are in development (Taylor et al., 2007).   
 
In this approach, the antibodies are made in advance against a protein previously 
determined to be present on a cancer cell.  Examples of this type of vaccine are antibodies made 
against CD19, CD20, or CD22 on the surface of B-cells for fighting B-cell tumors (such as 
leukemia), overactive B-cells (autoimmune disorders, transplant rejection), or dysfunctional B-
cells. The first antibody approved for cancer treatment in the U.S. was Rituximab, a mAb 
against CD20. It was initially FDA approved in 1997 to treat non-Hodgkin lymphomas resistant 
to chemotherapy (Maloney et al., 1997). Several studies have used it in clinical trials with 
various success.  For example, one 40 patient study showed a 95% response rate, 55% complete 
responses, and 40% partial remissions (Czuczman, 1999). Another study of 39 patients at one 
year showed an overall response rate of 72%, 18% with complete responses, and 77% showing a 
progression-free patient survival (Hainsworth, 2000).  Another study of 33 patients with 
aggressive non-Hodgkin’s lymphoma showed an overall response rate of 94%, with 61% with a 
complete response, and 33% with a partial response (Vose et al., 2001). Similar data has been 
obtained for a mAb against CD22 on B-cells.  For example, a study done with 90 patients 
suffering from refractory acute lymphoblastic leukemia (ALL) (with a very poor prognosis) 
showed that patients treated with Inotuzumab had an overall response rate of 58% (19% 
complete response, 30% complete response with no platelet recovery, and 9% became stable 
enough with the antibody treatment to have a bone marrow transplant and showed a complete 
cancer remission) (Kantarjian et al., 2013). 
 
The monovalent antibody category of cancer vaccine is also represented by Herceptin 
(also known as Trastuzumab or Herclon).  This antibody was the second mAb approved for 
cancer treatment in the U.S. and interferes with the HER2/neu receptor over-expressed on some 
types of cancer cells.  Typical clinical trial results in this category are represented by a study of 
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234 patients with metastatic breast cancer showing that the treatment provided a longer time to 
disease progression (median 7.4 vs 4.6 months; p<0.001), a higher rate of objective response 
(50% vs 32%, p<0.001), a longer duration of response (median, 9.1 vs 6.1 months; p<0.001), a 
lower rate of death at 1 year (22% vs 33%, p=0.008), longer survival (median survival 25.1 vs 
20.3 months; p=0.046), and a 20% reduction in the risk of death (Slamon et al., 2001).  
 
Although the treatments in this category sometimes prolonged a patient’s life, full 
remissions were not common.  The reported “complete responses” (full immune involvement) 
are not the same as “complete cancer remissions”, as have been seen recently with TIL and CAR 
vaccines (discussed below).  A trend seen throughout the entire cancer vaccine field is the design 
of antibodies against inhibitory receptors present on immune cells (to activate them).  An 
example of this is Siglec CD22, an inhibitory receptor located on B-cells which is activated in 
leukemia.  Our interview with a cancer researcher using antibodies against CD22 indicated he 
felt this was a good target because it is activated on so very few cell types.  So, this allows a 
highly selective targeting to the tumor, and limited damage to normal cells, and will likely be 
continued in the future. 
 
Bivalent Antibody Vaccines 
 
Bivalent (or bi-specific) antibodies recognize two different epitopes by the same antibody 
molecule. The best characterized example of this bivalent approach is antibody Blinatumomab, 
where one antibody arm recognizes CD19 (to attach to B-cells whose numbers are elevated in 
leukemia), and the other arm recognizes CD3 on the surface of T-cells to bring them into close 
proximity with the cancer cell to kill it.  Researchers sometimes term this antibody a “bi-specific 
T-cell engager” (BiTE).  Studies designed to directly compare the activities of monospecific 
versus bispecific antibodies have shown the latter have higher potency, improved anti-tumor 
activity, lower dosing, and lower costs of production compared to other antibody formats 
(Molhol et al., 2007). 
 
 Examples of the spectacular successes with the bi-specific cancer vaccine approach 
include the treatment of 9 patients with acute lymphoblastic leukemia with Blinatumomab, of 
which 4 achieved complete remission after their first cycle of treatment, 2 showed a complete 
remission after the second cycle (Schlegel et al., 2014).  And in another study, 189 patients with 
B-cell acute lymphoblastic leukemia (B-ALL) showed that after two treatments, 81 of the 189 
patients (43%) showed complete cancer remission. 
 
In addition to CD19 x CD3 bispecific antibodies, other bispecific antibodies include CD3 
(T-cell binder) x glioma marker (Nitta et al., 1990), folate receptor (ovarian cancer cells) x CD3 
(Canevari et al., 1995), CD16 x CD30 for Hodgkin’s disease (Hartmann et al., 1997), CD319 x 
CD28 for B-cell lymphomas (Daniel et al., 1998), CD64 x Fc-Receptor for B-cell lymphomas 
(Honeychurch et al., 2000), CD30 x CD64 for Hodgkin’s lymphoma (Borchmann et al., 2002).   
 
 One problem identified in our Lit Review in this area was with CD19 vaccines for 
leukemia, where all B-cells are removed from the body, not just cancerous B-cells.  Normal B-
cells are required for antibody production.  To gain more information on this potential problem, 
we interviewed a researcher using CD19 antibodies to treat leukemia, who indicated that 
occasionally they see serious opportunistic infections due to the lack of antibody production, but 
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these are considered a necessary evil compared to the very high death rates that result from 
leukemia.  Our review of the literature also identified combined vaccines as a trend in the field, 
and our interviews with BiTE bi-specific antibody users indicated they agreed, and liked the idea 
of using BiTE in combination with a CAR vaccine.  Originally, it was not clear for the CD3 
portion of BiTE whether it activated the T-cells or simply served to bridge the cancer cell (bound 
to the CD19 antibody portion) to a T-cell, to bring the two into close enough proximity to allow 
the T-cell to kill the cancer cell.  Our interviews with researchers who use BiTE indicated it is 
the latter….the bispecific antibody makes physical bridge between a cancer cell and a T-cell 
simply to bring them close together. 
 
Immune Checkpoint Vaccines 
 
          One of the most exciting advances in cancer vaccine research in the past decade is the 
discovery that T-cells that have migrated into a patient’s tumor in the body’s attempt to fight the 
tumor often become inactivated by the tumor.  Proteins present on the tumor surface (such as 
PD-1 and CTLA-4) engage inhibitory receptors on the surface of the T-cells to inactivate them 
(reviewed in: Toplian et al., 2012). To overcome this immune suppression, scientists are 
researching the use of antibodies against the inhibitory receptors to “block the blocker” and re-
activate the T-cells to attack the cancer. The immune system blockers discovered to date include 
programmed death-1 (PD-1) and cytotoxic T-lymphocyte-associated protein-4 (CTLA-4).  This 
approach provides a new and exciting approach to cancer vaccines that is different than all other 
approaches. 
 
The most researched anti-PD-1 monoclonal antibody is Nivolumab (marketed as 
Opdivo).  Nivolumab has been approved by the FDA for treating squamous non-small cell lung 
cancer, and several other studies have investigated its use for treating melanomas (Topalian et 
al., 2014), Hodgkin’s lymphoma (Ansell et al., 2015), and non-small cell lung cancer (Gettinger 
et al., 2015; Rizvi et al., 2015; Tanner, 2015).  Another well characterized antibody in this 
category is Ipilimumab, an antibody against CTLA-4.  CTLA-4 acts as an "off" switch when 
bound to ligands CD80 or CD86 on the surface of antigen presenting cells (Walunas et al., 
1994).  Some scientists have experimented with combination vaccines using both anti-PD-1 and 
antib-CTLA-4 antibodies.  This combination approach appears to be even more successful than 
using single antibody approaches.  For example, one study done with the combination showed 
that treatment of melanoma patients with a combination of Nivolumab (PD-1 inhibitor) and 
Ipilimumab (CTLA-4) showed that 80% of the patients had a significant tumor reduction 
(Wolchok et al. 2013).  
 
Our review of the literature showed that activating the immune system by blocking these 
checkpoint inhibitors can sometimes lead to autoimmunity (where the immune system is 
stimulated to react with the body’s own tissues) or inflammation (Melero et al., 2007).  And in 
some cases the treatments led to grade-3 and 4 (serious) side-effects, although most of the side-
effects appeared to be relatively mild, transient, and treatable. So these potential problems should 
be monitored, and the treatment stopped if necessary.  Our review of the literature also showed 
that some scientists obtained promising synergistic effects when they combined checkpoint 
vaccines with antibodies directed against tumors.  We verified this point in an interview with a 
researcher who used PD-1 antibodies who agreed that combining a PD-1 approach with for 
example Herceptin antibody for breast cancer would be a good idea. 
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Dendritic Cell Vaccines 
  
          Tumor cells in the body are poor antigen-presenting cells. Tumor cells are derived from 
normal cells by DNA mutation, so most of the proteins on their surface look like “self” to the 
immune system, and are ignored allowing the tumor to grow.  Only a small portion of the cancer 
DNA mutations create “neo-antigens” that are unique to the patient’s tumor, and these provide 
excellent candidates for cancer vaccine designs.  Even when tumor cells contain unique neo-
antigens on their surface, dendritic cells (DCs) are still required to process the neo-antigen and 
present it to the immune system to generate active B-cell and T-cell responses against the tumor 
(Palucka and Banchereau, 2012). Animal experiments (discussed in our Lit Review) have shown 
that DC cells are a required component of the body’s immune attack against cancer, and are 
required for activating CD8+ T-cells that infiltrate and attack the tumor.  The aim of a DC-type 
tumor vaccine is to induce DC cells to present tumor antigens on their surface to stimulate the 
formation of immune cells, especially CD8+ tumor infiltrating lymphocytes (TILs) or cytotoxic 
T-lymphocytes (CTLs) that recognize, infiltrate, and attack the tumor (Davis et al., 2003; 
Steinman and Banchereau, 2007; Koski et al., 2008; Schuler, 2010; Ueno et al., 2010). In an ex 
vivo approach, the DC cells are usually isolated from a cancer patient’s peripheral blood 
mononuclear cells (PBMCs) using various techniques and are cultured to expand their numbers.  
The DCs are then “pulsed” (mixed) with foreign tumor antigen (either purified antigen or entire 
tumor cells themselves), and are then injected back into the patient where they hopefully migrate 
to the lymph nodes to engage B-cells and T-cells to commit them against the tumor antigen. In a 
less used in vivo approach, DC cells in the body are induced to take up tumor-specific antigens, 
and the antigen-presentation is done naturally to stimulate the T-cells. 
 
The first DC cancer vaccine approved for use in the U.S. by the FDA was Provenge (also 
called Sipuleucel-T or APC8015). Provenge is a DC-type vaccine designed for prostate cancer, 
which is the second leading cause of cancer death in men (after skin cancer) (Ledford, 2015). 
Provenge consists of autologous (taken from the same patient) peripheral blood mononuclear 
cells (PBMCs) (that includes DCs) taken from the patient by leukapheresis. The PBMCs are 
cultured to increase their numbers.  They are then mixed for 2 days in vitro with a recombinant 
fusion protein (PA-2024) that contains prostatic acid phosphatase (PAP) (expressed in a majority 
of prostate adenocarcinomas) (Goldstein, 2002) linked to granulocyte macrophage colony 
stimulating factor (GM-CSF) (to help activate the immune system). After the DCs are pulsed or 
primed against PA-2024, the DCs process the antigen within the cell and present it on their 
surface. The DC cells are perfused back into the same patient over a 30 minute period.  Once in 
the body, the DCs migrate to the lymph nodes and present the tumor antigen to B-cells and T-
cells to activate them against the prostate cancer.  The results of Provenge are mixed.  Early 
experiments demonstrated that CTLs had been formed against the tumor cells, and that PSA 
levels dropped, but the survival statistics were relatively unimpressive compared to controls, for 
example increasing from 4.9 months survival before treatment to 7.9 months after treatment 
(Beinart et al., 2005). A randomized, double-blind, placebo-controlled phase-III clinical trial of 
Provenge, testing a total of 225 patients with advanced prostate cancer found an average 33% 
reduction in death rate over the test period for the patients receiving Provenge versus the placebo 
(p=0.011), a significant outcome, but the study did not report long term remissions (Higano et 
al., 2009).  Another double-blind, placebo-controlled, multi-center trial on 341 Provenge patients 
versus 171 placebo patients showed an average 22% reduction of death in the Provenge group, 
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with survival extending from 21.7 months to 25.8 months (an improvement of only 4.1 months) 
(Kantoff et al., 2010). Adverse effects included chills, fever, and headache. So, the Provenge 
Phase-III results were not as dazzling as hoped for, but they did provide a proof-of-principle that 
cancer vaccines can improve lifespan in a large cohort of patients. 
 
The DC vaccine approach has also been applied to patients with malignant melanoma. 
Melanoma is a type of skin cancer that forms from pigment-containing melanocytes in the skin 
(Bajetta et al., 2002). Although it is less common than other types of skin cancers, melanoma is 
much more deadly if not detected early, causing the vast majority (75%) of skin cancer deaths 
(Jerant et al., 2000).  As with the Provenge findings, most of the early experiments reported on 
the formation of anti-tumor CTLs that were capable of destroying cancer cells in vitro.  A more 
recent study of 7 patients with stage IV (advanced) melanoma showed that 6 of the 7 patients had 
sustained T-cell responses (against the tumor), and of those 6 patients, 1 patient showed 
complete remission, and 2 showed partial remission (Carreno et al., 2013). Strong improvement 
correlations were observed for patients perfused with DC cells producing the hormone IL-12, 
screening for DC cells that are functional enough to produce IL-12 (or supplementing the 
vaccine with IL-12) might help improve DC vaccine outcomes.  Very recently, this same team 
used a personalized medicine approach to identify and vaccinate against “neo-antigens” present 
only in a patient’s own tumor cells (Carreno et al., 2015), so this approach likely will be further 
researched in the future.    
 
DC vaccines have also been applied to glioblastomas, the most common and aggressive 
primary brain tumor for adults (Stupp et al., 2005). Because these tumors have a finger-like 
shape that protrudes into healthy tissue, it is very difficult to completely remove the tumor by 
surgery without damaging healthy brain tissue (ABTA, 2014). The median survival time after 
standard treatment is less than 2 years (Johnson and O’Neill, 2012).  An example DC study with 
this type of cancer on 9 glioblastoma patients showed the median survival time of the DC group 
was 455 days compared to 257 days for the control group (Yu et al., 2001), but no complete 
remissions were reported.  In another example study, 19 patients were treated with DC cells 
loaded with glioma-associated antigen (GAA) and supplemented with a synthetic adjuvant 
poly(I:C).  58% showed a positive immune response against the antigen, 9 patients (47%) had no 
sign of tumor progression for at least 12 months, 1 patient showed sustained complete cancer 
remission (Okada et al., 2011).  
 
Some scientists argue that the DC vaccine clinical trials performed so far have produced 
relatively disappointing results compared to the full remissions seen with the TIL and CAR 
studies, and that a full potential of DC cancer vaccines has not yet been achieved (Koski et al., 
2008).  Our review of the literature identified several trends for improving vaccine strategies, 
including: 1) combining the vaccines with immune stimulatory hormones, like IL-12. 2) Creating 
combination vaccines composed of DC’s primed to tumor antigens plus antibodies against 
checkpoint inhibitors CTLA-4.  3) Using a personalized medicine approach to sequence the 
exomes of a patient’s tumor to identify neo-antigens unique to that patient for priming the 
vaccine against.  Within this area it is especially important to identify which neo-antigens are 
immune-dominant (of the new neo-antigens synthesized by a tumor and located on the cell 
surface, which ones are more likely to produce an immune response when used to charge a 
vaccine, these should be used for the vaccine).  This key point of immune-dominance was 
verified by several of our interviews in this area.  4) Improving the speed at which this DNA 
sequencing can be done to decrease the time to therapy.  5) Using adjuvants, such as poly-(I:C), 
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to boost the immune response.  This important approach was verified by us in an interview with 
a researcher who uses poly(I:C) as adjuvant, who verified that the adjuvants should in the future 
be combined with checkpoint inhibitors. 6) Using pre-injections of a “recall antigen” such as 
tetanus toxoid Td which has been shown to increase DC migration to lymph nodes to improve 
the immune response.  This important point was validated in an interview we had with a 
researcher using tetanus toxoid as a recall antigen at the injection site of the cancer vaccine, but 
he indicated this only works when injecting the cancer vaccine into the skin, not when injecting 
the DC cells directly into lymph nodes.  7) Identifying biomarkers for which type of patient is 
most likely to respond to a vaccine.  8) Supplementing the vaccines with other cellular 
components of the immune system, such as natural killer cells (NKs) which have recently been 
shown to help other cells present antigens.  This latter point is especially interesting, because one 
of our interviews with an NK researcher indicated they recently discovered that NK’s work in 
conjunction with DC cells to help the latter present antigens more efficiently to the immune 
system.  So, the use of mixed cell type vaccines might be a field of the future. 
 
TIL Cancer Vaccines 
 
          T-cell therapy, sometimes referred to as adoptive cell therapy (ACT), has several 
advantages over any form of vaccine that relies solely on the production of T-cells in vivo, 
including:  1) Very large numbers of T-cells can now be grown in vitro (up to 1011 cells).  2) The 
T-cells can be selected in vitro for those that recognize tumor antigens.  3) T-cell growth in vitro 
by-passes any negative regulation those cells might encounter in vivo, for example from PD-1 or 
CTLA-4. 4) The patient can be treated with traditional chemotherapy to support the tumor 
therapy prior to the cell infusion.  5) The T-cells can be genetically engineered in vitro to express 
chimeric antigen receptors (CARs) (discussed below) that directly recognize tumor proteins 
without relying on MHC-type antigen presenting cells.   
 
The use of TILs to treat cancer was pioneered by Dr. Steven Rosenberg at the National 
Cancer Institute (for a review, see Rosenberg and Dudley, 2009). In this technique, autologous 
lymphocytes are isolated from a patient’s tumor and grown to very large numbers in vitro. In 
some cases, prior to the TIL treatment the patients are given chemotherapy to deplete native 
lymphocytes that can suppress the function of the perfused TILs. Once lympho-depletion is 
completed, patients are then infused with their own TILs supplemented by hormones such as 
interleukin-2 (IL-2). The vast majority of research on TIL cells, and several ongoing clinical 
trials have been conducted using TILs to treat patients with metastatic melanoma (Dudley et al., 
2008; Besser et al., 2010; Rosenberg et al., 2011; Radvanyi et al., 2012; Pilon-Thomas et al., 
2012). 
 
One TIL experiment that caught the world’s attention was performed by Steven 
Rosenberg’s team in 2011 on 93 patients with advanced metastatic melanoma treated with 
autologous TIL cells and supplemented with IL-2 (Rosenberg et al., 2011).  95% of the patients 
had ongoing cancer from prior chemotherapy treatments. Their data showed that 20 of the 93 
patients (22%) achieved complete cancer remission, and 19 of the 20 regressions remained intact 
beyond 3 years! The 3 and 5-year survival rates for the 20 remission patients were 100% and 
93%, respectively.  The same team also developed a new screening approach for identifying 
newly mutated proteins present in melanomas using whole-exome DNA sequencing of tumor 
DNA followed by bioinformatics to identify mutations present in the tumor protein-coding 
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regions not present in normal tissue (Robbins et al., 2013). The method avoided the labor-
intensive methods of synthesizing and screening cDNA libraries. And in 2014 they analyzed TIL 
cells isolated from tumors using deep sequencing techniques to determine which cancer antigens 
the TIL cells recognized and whether any TILs expressed inhibitory receptors (Gros et al., 2014). 
Their data indicated that 6 of 6 tumors contained TILs directed against neo-antigens, indicating 
that neo-antigens likely are the best target for future experiments.  And all 6 tumors contained 
TILs positive for negative immune receptors PD-1, LAG-3, and TIM-3, indicating that the TILs 
in their in vivo state were functionally impaired by the tumor.  Thus, antibody therapy designed 
against the negative regulators might improve vaccine effectiveness.   
 
TIL cells have also been used to treat other kinds of cancer besides melanomas, including 
epithelial and ovarian cancers epithelial cancer (Tran et al., 2014), and ovarian cancer (Robins et 
al., 2013).  
 
CAR Cancer Vaccines 
 
Chimeric antigen receptors (CARs) (also known as chimeric T-cell receptors or chimeric 
immune-receptors), are artificially engineered T-cell receptors that provide a specific binding 
affinity to the T-cell containing it. In the case of cancer immunotherapy, CARs are typically 
engineered to have a monoclonal antibody-like affinity for a specific tumor antigen, and do not 
rely on antigen presentation to recognize the antigen.  In this approach, an engineered CAR gene 
is delivered inside the T-cells in vitro using retroviral vectors, the CAR is expressed on the cell 
surface, and the engineered T-cells are delivered back into the same patient (reviewed in: Pule et 
al., 2003; Lipowska-Bhalla et al., 012; Curran et al., 2012).  The types of CAR structures used 
have evolved over the years, but the current CAR structure includes a mAb single-chain variable 
fragment derived from an anti-tumor mAb (which recognizes the tumor), a co-stimulatory 
domain (like CD28 that activates the T-cells and helps them survive in vivo), a hydrophobic 
domain that spans the lipid bilayer on the surface of the CAR cell, and one to three cytoplasmic 
tail domains (like TCR-zeta) that activate the CAR cell once it engages the tumor cell. Thus, 
structurally, CARs combine the powerful properties of highly specific antigen recognition (the 
mAb-like portion), with stimulation to increase T-cell survival (CD28), with T-cell signaling 
activation to kill the cancer cell, all combined in a single engineered receptor molecule (Sadelain 
et al., 2009). Once the CAR binds its tumor cell target, it sends a signal inside its T-cell to 
activate it to kill the tumor cell. 
 
The early foundation for the CAR field was laid by Israeli immunologist Zelig Eshhar, 
but the technique was further refined by other big-name cancer researchers like Steven 
Rosenberg (National Cancer Institute), Carl June (University of Pennsylvania), and Michel 
Sadelain (Memorial Sloan-Kettering Cancer Center).  Commenting on the technique for 
transforming the T-cells with foreign DNA, Michel Sadelain stated, “It took me 3 to 4 years to 
learn to transfer genes [into T-cells] at more than 0.5%.  Today we can take a high school student 
and in an afternoon they know how to take T-cells and blast genes into all of them” (Couzin-
Frankel, 2013). 
 
By far, the most successful application of CAR vaccines to date is against CD19 on the 
surface of B-cells that are elevated in leukemia (reviewed in: Kochenderfer and Rosenberg, 
2013). Engineering T-cells to target CD19 has provided some of the most striking successes in 
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the entire cancer vaccine field. Several labs converged on the CD19 antigen for two good 
reasons: 1) it is universally expressed on the surface of all leukemic B-cells, and 2) although 
normal B-cells are also killed by the anti-CD19 treatment, such cells are not absolutely required 
for patient survival (antibodies can be provided passively, or the patient can undergo a bone 
marrow transplant after ridding the cancer cells).  Early CAR experiments focused on altering 
and improving the design of the CAR receptor, quickly finding out that without the CD28 co-
stimulatory domain, the perfused CAR cells quickly die off.   
 
The breakout year for CAR treatments was 2011. Early studies with CAR cells had 
shown some success, but in 2011, Carl June’s group at the University of Pennsylvania (one of 
the founders of the CAR field) published two studies on their design of a CAR against CD19 and 
its use to treat 3 patients with advanced chronic lymphocytic leukemia (CLL). The first study 
(Porter et al., 2011), showed that the injected CAR cells expanded at least 1000-fold in the 
patients, migrated to the bone marrow, continued to produce functional CARs for at least 6 
months, each CAR cell destroyed about 1,000 cancer cells, one of the 3 treated patients showed 
complete remission (33%). In the second paper (Kalos et al., 2011), two of 3 patients (66%) 
showed complete remission, and they remained in remission two years later in June of 2013 
(Couzin-Frankel, 2013).  These two 2011 studies, although done on relatively few patients, were 
later attributed by Carl June as breaking open the CAR funding for his entire research team, and 
the National Cancer Institute reversed their earlier moratorium on funding CAR research.  An 
interesting follow-up 2013 study (Grupp et al., 2013), showed that of 2 children with relapsed 
and refractory acute lymphoblastic leukemia (ALL) (normally a very poor prognosis) using CAR 
cells targeting CD19, 1 of the 2 children (50%) showed a complete remission.  This paper 
observed that the patient that relapsed developed cancer cells no longer expressing CD19, so this 
evolution problem should be monitored in the future.  Also in 2013, a team headed by Drs. 
Michel Sadelain and Renier Brentjens (Brentjens et al., 2013) showed spectacular success when 
5 of 5 patients (100%) with relapsed B-cell acute lymphoblastic leukemia (B-ALL) (normally 
with a very poor prognosis) showed a rapid tumor eradication, and appear to have no residual 
disease as assayed by deep sequencing PCR (although one patient eventually relapsed). With 
respect to side-effects, some patients showed significant cytokine elevations, but those 
incidences were treatable with steroid therapy. So, the treatment appeared to be generally well 
tolerated.  
 
Additionally in 2013, a team headed by Dr. Kochenderfer (of Steven Rosenberg’s team at 
the National Cancer Institute), published their findings of a clinical trial of allogeneic T-cells 
genetically engineered to express CAR targeting the B-cell antigen CD19 (Kochenderfer et al., 
2013). Their study tested 10 patients that had malignancy persisting after initial bone marrow 
transplants and standard lymphocyte infusions. No new chemotherapy was done to any of the ten 
patients prior to the CAR T-cell infusions, so the patients were not lymphocyte-depleted at the 
time of infusions. The data showed that three of the 10 treated patients had regressions of their 
previously untreatable malignancies. One patient with chronic lymphocytic leukemia (CLL) 
obtained complete remission after the T-cell infusion, while another CLL patient had tumor lysis 
syndrome as his leukemia regressed. They discovered that none of the patients developed graft-
versus-host disease (GVHD). PCR showed the presence of the CD19-CAR gene in the blood of 
eight of the ten patients. This study showed that the CAR approach can cause regression of B-
cell malignancies previously resistant to standard treatments without causing graft versus host 
disease. 
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 In one of the most spectacular experiments in all cancer vaccine research, in 2014, Dr. 
Grupp’s team at the Children’s Hospital of Philadelphia and their main collaborator Dr. Carl 
June of the University of Pennsylvania (Maude et al., 2014) treated 30 patients (children and 
adults) with relapsed acute lymphoblastic leukemia (ALL) with CD19-directed CAR cells and 27 
of 30 patients (90%) showed complete remission at 6 months!  This is quite a success story 
compared to the relatively weak data obtained in the early cancer vaccine papers. With respect to 
side-effects, all 30 patients developed cytokine-release syndrome (CRS) (27% with severe CRS), 
but the problem was effectively treated with anti-interleukin-6 receptor antibody (tocilizumab), 
and the patients remained in cancer remission.  
 
       Although the release of cytokine hormones from the engineered CAR T-cells is normally 
viewed as desirable, and is one measure of their successful in vivo function, the production of 
very high levels of cytokines is viewed as a “cytokine storm” which can be fatal.  One 2010 
paper from Rosenberg’s team reported the death of a patient five days after receiving second-
generation CAR T-cells (Morgan et al., 2010). The authors speculated that the large number of 
perfused T-cells localized in the patient’s lung immediately after the perfusion, triggering 
cytokine release by recognizing a receptor on the lung cells. So, this study emphasizes the 
importance of restricting T-cell infusions to those designed against cancer neo-antigens 
whenever possible, that are specific for the tumor cells whenever possible, to avoid CAR 
interactions with natural proteins. 
  
Our review of the T-cell literature identified several problems, some of which were 
followed up in interviews: 1) The best patient survivals appear to occur in patients with the 
highest TIL load in the tumor, so this underscores the importance of producing large numbers of 
T-cells for a vaccine.  2) Some of the best cancer remissions occurred by enriching the TILs for a 
subset of TILs committed against neo-antigens, so perhaps in the future, although this approach 
is labor intensive, this enrichment approach should be tested further.  Our interview with a neo-
antigen expert in the TIL area indicated they have found neo-antigens in all tumors they have 
investigated.  So, the neo-antigen approach seems like it would apply to all types of cancer.  We 
also questioned another interviewee about the speed at which this individualized medicine 
approach takes, as time is critical for patients with advanced cancer. He replied that it currently 
takes about 10 weeks to make a personalized vaccine, with 6 of those weeks spent on identifying 
and synthesizing the neo-antigen peptides.  Another interviewee pointed out that he has already 
shortened the time down to 6 weeks overall.  So, this critical neoantigen identification process 
appears to be improving with continuing advances in DNA sequencing and synthetic chemistry.  
Another interviewee in this area made an important point that a tumor that is too young might 
contain only a few mutations, which is not sufficient for a targeted therapy.  So, the age of the 
tumor may also be important.  The interviewee also noted that it is important for the neoantigen 
to be present on most of the patient’s tumor cells, not just a few, or they won’t be eliminated.  3) 
With ovarian cancer, the TILs appeared to be committed to a variety of neo-antigens, not just one 
type.  So, fighting these types of cancer might require broadly expanding all types of TILs 
directed against a variety of antigens. 
 
Based on the research performed for this project, our team’s overall conclusion is that, of 
the six major types of cancer vaccines, the tumor infiltrating lymphocyte (TIL) and chimeric 
antigen receptor (CAR) type vaccines have shown the highest efficacies, with some CAR 
vaccines producing as high as 90% cancer remissions in medium-sized (30 patient) studies.  We 
identified several ways for moving the field forward, incuding using using combination vaccines 
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(especially combined with antibodies for immune checkpoint inhibitors), adjuvants, recall 
antigens (when injecting the vaccine into the skin), and isolating and using a patient’s own 
specific tumor neoantigens.  We recommend that funding be continued in this interesting area of 
research. 
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LITERATURE REVIEW 
 
Part-1: Introduction to Cancer 
Anthony Kassas 
 
 
Cancer is a disease caused by uncontrolled division of abnormal cells in the body.  
Cancer is a name given to a collection of related diseases, all sharing this uncontrolled cell 
division. Cancer can begin almost anywhere in the human body, and there are over one-hundred 
different variations of this anomalous cell progression. The extra cells form growths called 
tumors.  Some cancers form solid tumors, while others, such as leukemia, form diffuse tumors.  
Malignant tumors spread into, or invade, nearby tissues, or can break off and travel to distant 
places in the body through the blood or the lymph system to form new tumors.  Benign tumors 
do not spread into, or invade, nearby tissues.  
 
Cancer is the second leading cause of death worldwide, second only to cardiovascular 
disease.  According to the Centers for Disease Control and Prevention, there were approximately 
584,881 cancer related fatalities in the U.S. in 2013 (CDC, 2015). Each year, there are 
approximately 1,597,000 new cancer diagnoses in the U.S. (Cooper and Hausman, 2013, Table 
18.1). From the prostate gland, to the thyroid glands, the lungs, or the kidney, these malignancies 
symptomatically grow and strongly affect our health. Sometimes the symptoms are not 
manifested until tumor growth is advanced, making it difficult to diagnose.  
 
A tumor, also known as a neoplasm, is defined as an abnormal mass of tissue which may 
be solid or fluid-filled. A tumor does not necessarily mean cancer; tumors can be benign (not 
cancerous), pre-malignant (pre-cancerous), or malignant (cancerous). “There are many different 
types of tumors and a variety of names for them – their names usually reflect their shape and the 
kind of tissue they appear in. Put simply, a tumor is a kind of lump or swelling, it does not 
necessarily pose a health threat” (Medical News Today, 2015). Malignant tumors are defined by 
their ability to metastasize to different parts of the body, which worsens patient prognosis. Any 
unexpected growth within the body has the potential to disrupt major organ operation, blood 
flow, or mechanical operation. Medical News Today further states that “according to experts, 
there is no clear dividing line between cancerous, precancerous and non-cancerous tumors” 
(Medical News Today, 2015).  Benign or non-progressive tumors do not metastasize, but some 
types of benign tumors indeed have the ability to change and become cancerous. Premalignant 
tumors are those that are soon to become a malignant growth. Examples of premalignant growths 
include: leukoplakia, actinic keratosis, and dysplasia of the cervix. Diagnoses can be obtained by 
excisional biopsies, incisional biopsies, or needle aspiration biopsies.  
 
 
Tumor Formation 
 
The formation of a tumor requires that a normal cell undergo at least six fundamental 
steps (Hanahan and Weinberg, 2011): 1) sustaining the ability to proliferate (usually by 
switching on proliferative signal transduction), 2) evading growth suppressors, including 
immune evasion, 3) resisting cell death (upregulating anti-apoptotic proteins), 4) enabling 
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immortality (upregulating telomerase and other factors that allow DNA to continue to replicate), 
5) inducing angiogenesis (the tumor needs to expand its blood supply to receive nutrients), and 
6) activating metastasis (acquiring the ability to move throughout the body and colonize the new 
location).  
 
Step-2 mentioned above, involving immune evasion, is an important topic to this IQP 
project that focuses on immune therapy.  Normally the immune system recognizes and removes 
dividing foreign bodies in our bodies, but tumors represent our own cells and are sometimes 
recognized as self.  So, a key problem for immune vaccines is to identify neoantigens, new 
proteins (or smaller epitopes) created specifically on the surface of tumor cells that we can 
design antibodies against to help fight the tumor.  In addition, recent evidence indicates that 
tumors have the ability to suppress our immune system.  For example some tumors produce 
proteins such as PD-1 or CTLA-4 that suppress a T-cell attack.  So, second-generation cancer 
vaccines sometimes include antibodies against PD-1 or CTLA-4 to “block the blockers” to 
activate the immune system to clear the tumors. 
 
With respect to metastasis, Hanahan and Weinberg state that “as normal cells evolve 
progressively to a neoplastic state, they acquire a succession of these hallmark capabilities, and 
that the multistep process of human tumor pathogenesis could be rationalized by the need of 
incipient cancer cells to acquire the traits that enable them to become tumorigenic and ultimately 
malignant” (Hanahan and Weinberg, 2011). They also state that once a malignant tumor is 
established, metastasis occurs in a sequence of discrete steps, known as an invasion-metastasis 
cascade. Metastasis is the beginning point for cell replication in different locations of the body. 
“Metastasis begins with local invasion, then intra-vasation by cancer cells into nearby blood and 
lymphatic vessels, transit of cancer cells through the lymphatic and hematogenous systems, 
followed by escape of cancer cells from the lumina of such vessels into the parenchyma of 
distant tissues, the formation of small nodules of cancer cells, and finally the growth of 
micrometastatic lesions into macroscopic tumors, this last step termed ‘colonization” (Hanahan 
and Weinberg, 2011). 
 
 
Cancer Causes 
 
Cancer is a genetic disease caused by changes to genes that control the way our cells 
function, especially how they grow and divide.  These genetic changes can occur as we age as 
errors inserted during DNA replication, can occur as a result of carcinogens (such as tobacco 
smoke or radiation, the two best characterized carcinogens), or can be inherited from our parents.  
Each person’s cancer has a unique combination of genetic changes, and additional changes occur 
as the tumor grows, so this makes designing an immune vaccine difficult.  Recent therapies use 
second generation DNA sequencing technology to sequence the DNA of a patient’s tumor to 
identify proteins specific to that tumor to provide a target for the vaccine.  Some of the mutations 
may have nothing to do with causing the cancer, they may merely be the result of the cancer’s 
increased cell division and a reduced DNA correcting apparatus.  But even these mutations could 
serve as a target for immune therapy if the mutated protein resides on the cell surface. 
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Tumor Treatments 
 
Tumor treatments vary widely, depending on whether cancer cells are present, the 
location of the tumor, and the type of tumor. Benign tumors in a safe area of the body that do not 
cause organ disruption are sometimes left alone and watched carefully for switching to a 
cancerous state. If a tumor is cancerous, treatments might include chemotherapy (the use of 
chemical drugs to block DNA replication or other key cancer processes), radiation (to kill rapidly 
dividing cells), surgery (to remove the tumor), targeted cancer therapy (drugs that interfere with 
specific molecules a tumor needs to grow), and biologic therapy (i.e. cancer vaccines, the subject 
of this IQP).  
 
Treatment is sometimes effective when cancer is discovered in its early stages. For 
example, according to the American Cancer Society, the 5-year survival rate for melanoma when 
diagnosed early is around 98%, but once it has spread to other parts of the body, the 5-year 
survival rate drops to about 16% (CDC, 2015). But late stages of cancer are often untreatable, 
and the physician instead focuses on symptom treatments. 
 
 
Example Cancers Discussed Later in this Report 
 
 The subject of this IQP report is cancer vaccines.  Specific types of cancer have been 
investigated with this type of therapy, so this section of the Lit Review will focus on a few 
specific types of cancer that we will encounter later in the report. 
 
 
Prostate Cancer 
 
Among men, prostate cancer is the second leading type of malignancy diagnosed, second 
only to skin cancer.  And with respect to cancer deaths, prostate cancer is second only to lung 
cancer (Cancer.org, 2015).  The American Cancer Society estimates that in 2015, there will be 
about 220,800 new prostate cancer cases, and about 27,540 deaths.  About 1 man in 7 will be 
diagnosed with prostate cancer during his lifetime.  Prostate cancer occurs mainly in older men; 
about 60% of the cases are diagnosed in men over 65, with an average age of diagnosis around 
66.  Although prostate cancer can be a serious disease, most men do not die from it. In fact, more 
than 2.9 million men in the U.S. diagnosed with prostate cancer are still alive today. 
 
Predisposition to prostate cancer can be genetically inherited (as familial-derived prostate 
cancer, the most prevalent) or it can be spontaneous.  According to doctors Jan-Erick Damber 
and Gunnar Aus, “One obvious possible reason for this is the inheritance of genes that cause 
prostate cancer, some of which show high penetrance, whereas other genes show polymorphism 
and low penetrance” (Damber and Aus, 2008). Some genes are thought to correlate with prostate 
cancer. The first gene locus identified was the hereditary prostate cancer locus-1 (HPC1) (Smith 
et al., 1996), and that locus contains a strong candidate gene RNASEL (Wiklund et al., 2004). 
Other genes linked to prostate cancer have also been identified, but they occur at a lower 
frequency in the population so are thought to be less important: PON1, CAPZB, MSR1, CHEK2, 
RNASEL, and EPAC2 (reviewed in: Dong, 2006). According to a Swedish study, a high body-
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mass index (BMI) strongly correlated with death associated with prostate cancer, but less with its 
incidence (Andersson et al., 1997).  Fat intake did not correlate with increased incidence.  
 
With respect to prostate cancer treatments, if caught in its early stages, it grows so slowly 
that many physicians take a “wait and see” attitude towards its management.  But as is typical of 
most cancers, it is more difficult to stop once it reaches advanced stages. According to Tsivian et 
al. (2012), “conventional treatment of prostate cancer is blindfolded; the disease is typically 
treated on the basis of histological evidence obtained through random sampling of the prostate 
gland”. The American Cancer Society points out a variety of treatment options, including 
expectant management, surgery, radiation therapy, cryosurgery, hormone therapy, chemotherapy, 
vaccine treatment, and bone-directed treatment. These treatment options apply to other types of 
cancers as well. Precise-targeting approaches and treatment methods are becoming more popular, 
especially following the advent of precise imaging techniques such as ultrasound and 
multiparametric MRI. This precise imaging technique allows the use of minimally invasive 
techniques. Focal therapy is known as “the application of an organ-sparing approach for a 
disease that has been traditionally treated with radical, whole-gland therapies” (Tsivian et al., 
2012).  With respect to this IQP, the first cancer vaccine approved for use in the U.S. by the FDA 
was Provenge (also called Sipuleucel-T or APC8015), a DC-type vaccine designed for prostate 
cancer.   
 
Breast Cancer 
 
On the other side of the gender spectrum, breast cancer is the second most diagnosed 
cancer in women following skin cancer, and causes the second highest number of deaths after 
lung cancer (Cancer.org, 2015).  In 2015, about 231,840 new cases of invasive breast cancer are 
expected to be diagnosed in U.S. women, and 60,290 new cases of non-invasive (in situ) breast 
cancer (Cancer.org, 2015).  Breast cancer is also seen in men, but with far less frequency.  The 
formation of a lump within the breast or underarm that persists after a menstrual cycle is often 
the first symptom of breast cancer.  A research study has shown that heightened estrogen 
hormone levels increases the risk of developing breast cancer (WebMD, 2015).  Breast cancer 
has genetic components.  According to WebMD, “a woman whose mother, sister, or daughter 
has had breast cancer is two to three times more likely to develop the disease, particularly if 
more than one first-degree relative has been affected (WebMD, 2015).  Researchers have 
identified two genes responsible for some instances of familial breast cancer, BRCA1 and 
BRCA2, and approximately 7% of breast cancer cases are caused by mutations in those genes 
(Claus et al., 1996). 
 
Treatments for breast cancer vary depending on the discovery time and stage.  Important 
variables include the size of the host breast, histological grade of the tumor, the age of the 
patient, the lympho-vascular invasion rate, and other factors. “Choices of adjuvant treatment are 
based on parameters defined by molecular characterization of breast cancer subtypes, or by 
approximations to this classification using traditional clinical-pathological features. Clinicians 
should consider cases within the various distinct sub-populations in order to properly select the 
most ‘personalized’ adjuvant therapeutic approach. Sensitivity to chemotherapy and/or targeted 
agents in subtypes of breast cancers are predictable based upon gene pathway alterations and 
associated gene products” (Curigliano et al., 2012). As with prostate cancer, breast cancer is 
important to treat before metastasis, to prevent uncontrollable metastatic takeover. Some 
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management plans include mastectomy or breast-conserving surgery. Radiotherapy and 
chemotherapy are utilized to clear micro-metastases that can spread throughout the body. 
Pharmaceuticals can be used to lower estrogen levels, preventing the potential cell division of 
estrogen-dependent tumor cells (Grimsey, 2003). 
 
 
Leukemia 
 
Leukemia is a cancer of the bone marrow, lymphatic system, or other blood-forming 
organs which results in the production of increased numbers of immature or abnormal white 
blood cells.  Some forms of leukemia are more common in children, while others predominate in 
adults. According to the Leukemia Research Foundation, approximately 176,000 new cases are 
expected this year in the United States, 310,000 Americans are living with leukemia,  
731,000 Americans are living with Hodgkin’s or non-Hodgkin’s lymphoma, 88,490 people are 
living with myeloma, and about 55,000 deaths will result from blood cancer this year (Leukemia 
Research Foundation, 2015). Directly impacting the blood cells, leukemia originates within the 
tissues where blood cells form, usually the bone marrow. The outcome is to produce less 
functional white blood cells to fight infection, or less functional red blood cells to carry oxygen 
from the lungs to the rest of the body, or fewer platelets to clot the blood. According to the 
National Cancer Institute, “Leukemia is either acute or chronic. Acute leukemia is a fast-growing 
cancer that usually gets worse quickly. Chronic leukemia is a slower-growing cancer that gets 
worse slowly over time. The treatment and prognosis for leukemia depend on the type of blood 
cell affected and whether the leukemia is acute or chronic” (National Cancer Institute, 2015). 
The American Cancer Society (2015) classifies leukemia into four types: acute myeloid 
leukemia, chronic myeloid leukemia, acute lymphocytic leukemia, and chronic lymphocytic 
leukemia. Myeloid leukemia differs from lymphocytic leukemia with respect to the development 
location (myeloid cells versus lymphocytic cells).  
 
Leukemia has a wide range of symptoms, including: anemia, swollen lymph nodes, 
petechiae, or an enlarged live or spleen (American Cancer Society, 2015). Treatments of all four 
types of leukemia include chemotherapy (especially for acute leukemia) and/or corticosteroids. 
Some therapies are applied post-remission to kill any leukemia cells remaining after a primary 
treatment (National Cancer Institute, 2015). Chronic leukemia is more commonly treated with 
radiation to treat swollen lymph nodes. Relative to the subject of this IQP, more recent advances 
that have been extremely effective include combining chemotherapy with monoclonal antibodies 
against CD19, a protein present on the surface of B-cells to use the patient’s immune system to 
help rid the cancer cells (National Cancer Institute, 2015).  
 
 
Lung Cancer 
 
Lung cancer is the leading cancer killer in both men and women in the United States, 
causing more deaths than colorectal, breast, and prostate cancers combined. In 2015, an 
estimated 158,040 Americans are expected to die from lung cancer, accounting for 
approximately 27% of all cancer deaths (American Lung Association, 2015). Cancer of the lung 
is usually categorized in two ways, based upon the growth and spreading: small cell lung cancer 
(SCLC) or non-small cell lung cancer (NSCLC). According to American Cancer Society, SCLC 
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is named “for the small size of the cancer cells as seen under a microscope. SCLC often starts in 
the bronchi near the center of the chest, it tends to grow and spread quickly, and it has almost 
always spread to distant parts of the body before it is found” (American Cancer Society, 2015). 
Non-small cell lung cancer is divided into three categories: adenocarcinoma, squamous cell 
carcinoma, and large cell carcinoma. These categories are based upon size as seen in a 
microscope, shape, and chemical make-up.  Both types have similar treatments.  
 
The paramount risk factor for developing lung cancer is smoking. Cells that line the lung 
are increasingly exposed to carcinogens when inhaling smoke from a cigarette or polluted air. 
The increased risks are also present for individuals exposed to second hand smoke present from 
other smokers.  Lung cancer is also caused by exposure to radioactive radon gas in the 
environment. 
 
 
Melanoma 
 
The deadliest form of skin cancer is melanoma.  Melanoma is a type of skin cancer that 
forms from pigment-containing melanocytes in the skin (Bajetta et al., 2002). Although it is less 
common than other types of skin cancers, melanoma is much more deadly if not detected early, 
causing the vast majority (75%) of skin cancer deaths (Jerant et al., 2000). According to the skin 
cancer foundation, melanoma is “the most dangerous form of skin cancer, these cancerous 
growths develop when unrepaired DNA damage to skin cells (most often caused by ultraviolet 
radiation from sunshine or tanning beds) triggers mutations (genetic defects) that lead the skin 
cells to multiply rapidly and form malignant tumors” (Skin Cancer Foundation, 2015). 
Melanoma is commonly traced back to intense ultra-violet radiation exposure and a genetic 
predisposition to the disease.  As with other cancers, melanoma is treatable if recognized early. 
But as it moves to other parts of the body, it can be lethal. The Skin Cancer Foundation estimates 
that in 2015 approximately 135,000 new cases of melanoma in the US will be diagnosed, 73,870 
of these will be invasive melanomas, with about 42,670 in males and 31,200 in women (Skin 
Cancer Foundation, 2015).  
 
The treatments for melanoma range from surgical excisions of the affected and 
surrounding areas of the skin and chemotherapy.  More recently, immunotherapy and immune-
checkpoint blockade therapies have been devised, and are the subject of this IQP.  In some cases, 
advanced melanomas have been sent into complete remission using dendritic cell (DC) vaccines, 
and these will be discussed later in the report. 
 
 
Part-1 Conclusion 
 
Cancer is a genetic disease caused by mutations in growth factor genes, growth related 
signal transduction pathways, or tumor suppressor genes (making them non-functional). Cancer 
survival statistics have improved over the past several decades, due to more accurate and 
sensitive detection techniques, better drugs to block growth by a variety of mechanisms, and 
more precise surgical tools.  But in spite of these advances, cancer still remains the second 
leading cause of death following cardiovascular disease, so better therapies are needed. The 
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subject of this IQP is a new form of therapy that uses the patient’s own immune system to help 
fight the tumor, and this will be discussed in the next several sections. 
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Part-2: Introduction to the Immune System 
Danielle Healy 
 
 
 This IQP project focuses on recent successes fighting cancer with immune vaccines, so 
brief introductions to cancer and the immune system are needed. The previous Lit Review 
section focused on cancer, and this section focuses on the immune system. The immune system 
is composed of a network of cells, tissues, and organs whose main purpose is to protect the body 
from disease and infection. Cells in the immune system recognize problems within the body, 
communicate with other cells, and perform their various beneficial functions (NIAID, 2015).  
 
  One of the main functions of the immune system is to distinguish self from non-self 
(foreign antigens), to protect the body from invading pathogens and eliminate altered cells (as 
with cancer) (Shultz and Grieder, 1987). The immune system is divided into two major 
subdivisions: innate immunity and adaptive immunity (NIAID, 2015). 
 
Innate Immunity  
 
 Innate immunity is that part of the immune system that is ready for immediate maximal 
response when an infection is detected. It constitutes the first two lines of a three-line defense 
system. The first line of defense is non-specific, and begins with physical and chemical surface 
barriers (Science Learning Hub, 2015). The skin is an obvious physical barrier to the entrance of 
microbes, and is the largest organ of the vertebral body. It also acts as a chemical barrier with its 
acidic pH, discouraging the growth of organisms via its sweat and oil glands secretions. Tears 
wash away irritating substances and microbes, and with the help of lysozyme digest the bacterial 
cell wall to help kill many bacteria. Saliva washes microbes from the teeth and mucous 
membranes of the mouth. The respiratory tract traps organisms with mucus and uses cilia to 
sweep away trapped organisms. The stomach uses acid to kill organisms, and the urinary bladder 
uses urine to wash away microbes from the urethra. The large intestine uses normal bacterial 
inhabitants to monitor invaders. (NIAID, 2015) 
 
 If pathogens are able to get past the first line of defense, the second line of defense is 
activated which includes the use of defensive cells, defensive proteins, inflammation, and fever. 
The cells involved in the second line of defense include several types of white blood cells 
(leukocytes): natural killer cells, mast cells, eosinophils, basophils, and the phagocytic cells 
including macrophages, neutrophils, and dendritic cells (UIC, 2004).  These cells recognize 
molecular patterns present on the surface of bacteria and fungi, and act to engulf them (or aid 
other cells that engulf and kill them). Some types of cancer fighting treatments such as 
chemotherapy or radiotherapy can lower the neutrophil count in the body, leaving the cancer 
patient more susceptible to bacterial or fungal infections (Cancer.Net, 2012). 
 
 
Adaptive Immunity 
 
 Adaptive immunity is the third line of defense. If a pathogen survives the nonspecific 
innate defenses, the body will react with this more advanced subdivision of immunity to 
specifically target the pathogen. The adaptive immune system is known as the antigen-specific 
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immune response. Once contact has been acquired with a pathogen, it activates the B and T-
lymphocytes, each boosted by humoral mediators such as cytokine hormones (NCBI, 2001). 
Once engaged by a foreign antigen (usually one presented by an antigen presenting cell) the B or 
T-cell matures to commit to that specific antigen. 
 
B-Lymphocytes (B-cells) 
 
 B-lymphocytes, or B-cells, are produced in the bone marrow (from which they derive 
their name). Their primary function is to make antibodies against a foreign invader.  As shown in 
Figure-1, when a foreign antigen presented by an antigen presenting cell (discussed in a later 
section) is recognized by a B-cell (diagram left) the B-cell becomes activated and processes the 
antigen (diagram center).  B-cell receptors (BCR), located on the outer surface of the cell, 
transmit signals inside the B-cell to activate it, causing a clonal expansion and antibody 
production. With the aid of cytokine hormones (IL-2 and IL-4) and helper T-cells, the B-cell 
becomes a mature plasma cell which manufactures and secretes antibodies against the foreign 
antigen (diagram right).  Memory cells are also created that have a longer half-life, and respond 
to the antigen if presented again in a later infection (NIH, 2008).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-1: Diagram of B-Cell Function and Antibody Production.  Shown are 
the main steps in B-cell function, including the recognition of foreign antigens 
presented by antigen presenting cells (diagram left), maturation into plasma cells 
as aided by helper T-cells (diagram center), and antibody production and 
secretion (diagram right) (NIH, 2008). 
 
 
The antibodies produced by mature plasma cells, also referred to as immunoglobulin, can 
be divided into five classes: IgM, IgD, IgG, IgA, and IgE. They function to bind to (coat or 
opsonize) the specific pathogen to promote phagocytosis.  They also promote complement 
fixation to activate the complement cascade to destroy antibody-bound pathogens (RCN, 2013). 
IgG is the most abundant type of antibody in the blood, constituting about 80% of all serum 
antibodies.  IgM is the largest antibody, and is secreted by B-cells early in the infection.  IgA is 
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present in serum, mucus, saliva, tears, sweat and milk.  IgE functions to bind mast cells. IgD 
helps serve as an antigen receptor early in the infection. (NIH, 2008) 
 
 
T-Lymphocytes (T-cells)  
 
 T-lymphocytes, or T-cells, are white blood cells developed in the thymus gland (from 
which they derive their name). Their main function is to attack the body’s cells already 
containing the foreign invaders, or to help other T-cells do so. T-cells contain T-cell-receptors 
(TCRs) on their surfaces that detect foreign antigens presented by antigen presenting cells (NIH, 
2008). Once a pre-T-cell has engaged an antigen presenting cell, the cytokines IL-12 and IFN-
gamma help the cells proliferate and differentiate into mature T-cells. 
 
 There are three main types of T-cells: helper T-lymphocytes, cytotoxic T-lymphocytes 
(CTLs), and regulatory T-cells (National Multiple Sclerosis Society, 2015). Helper T-
lymphocytes are extremely versatile cells, and function in many roles in the adaptive immune 
system. Four types of helper T-cells have been identified: Th1, Th2, Tfh, and Th17. T-cells are 
formed in a so-called type-1 Th1 response, which also forms B-cells (Figure-2). Th1 cells 
participate in both cell-mediated immunity and humoral (antibody-mediated) immunity. Th1 
cells are created when a pre-Th cell (brown in the diagram) binds an antigen presenting cell 
(purple).  The antigen presenting cell then secretes interleukin 12 (IL-12) as well as IFN-gamma 
(diagram upper left). These hormones cause pre-Th cells to differentiate into a Th1 cell (green), 
which further differentiates into both T-cells (lower left) (cellular immunity) and B-cells (lower 
right) (humoral immunity). If the pre-Th cell matures in the presence of IL-2 and IL-4 hormones 
(upper right), it matures into a Th2 cell (blue) thus further differentiating into only B-cells (lower 
right) (humoral immunity).  In addition to their main differentiation role, Th1 cells also secrete 
hormones TNF-beta and IFN-gamma to further support the immune system.  The production of 
cellular immunity is considered the “most potent weapon against intracellular pathogens” (RCN, 
2014). 
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Figure-2: Diagram of Th1 and Th2 Immune Responses. Pre-Th cells (brown) 
engage antigen presenting cells (purple).  In the presence of hormones IL-12 and 
IFN-gamma (upper left), the pre-Th cell differentiates into a Th1 cell (green) that 
further differentiates into both T-cells (lower left) (cellular immunity) and B-cells 
(humoral immunity) (lower right).  In the presence of IL-2 and IL-4 (upper right) 
the Pre-Th cell matures into a Th2 cell (blue), which further differentiates into 
only into a B-cell (humoral immunity). (RCN, 2014) 
  
 Tfh cells, also known as follicular helper T-cells, are CD4+ helper T-cells located in the 
follicles. When they are exposed to antigen-presenting cells and cytokines which become bound 
to their TCR, transcription factor Bc1-6 becomes activated, causing the T-cell to form an 
immunological synapse (connection) with B-cells expressing the antigen fragments in class II 
histocompatibility molecules that match their TCR. Th2 cells helps B cells by enabling them to 
develop antibody-secreting plasma cells. (RCN, 2014) 
 
 Th17 cells are a subset of CD4+ T-cells located on the boundary of the external and 
internal environments. When exposed to antigen-presenting cells that bind to their TCR and 
cytokines, Th17 cells activate a nuclear retinoid receptor which leads to the synthesis and 
secretion of IL-17, and increased synthesis of the plasma membrane receptor for the interleukin 
IL-23, causing rapid proliferation. Th17 cells help protect the surfaces against extracellular 
bacteria, and are a potent effector for autoimmune disorders. (RCN, 2014) 
 
 Cytotoxic T-cells, also called cytotoxic T-lymphocytes (CTLs), are a type of T-cell that is 
programmed to kill host cells infected with foreign pathogens such as virus-infected cells, cells 
infected with intracellular bacterial or protozoal parasites, allografts, or cancer cells (NIH, 2008; 
RCN, 2011). This type of T-cell is of strong interest to this IQP project because they directly 
cause tumor cell lysis and are sometimes used for immunotherapy.  CTLs that infiltrate a tumor 
to help lyse it are called tumor infiltrating lymphocytes (TILs).  CTLs have two ways of 
becoming activated (Figure-3, upper three rows): 1) a CD8+ CTL (orange cell with green 
receptor, right side) can become activated by a foreign antigen on the surface of, for example, a 
virus-infected cell (pink cell) while being stimulated by IL-2 hormone secreted from a CD4+ 
helper T-cell responding to the same virus (orange cell with pink receptor, diagram upper right).  
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2) A CTL cell can become activated by engaging a foreign antigen presented by a professional 
antigen presenting cell, such as a dendritic cell (pink cell with dendritic extensions, diagram 
center).  (RCN, 2011) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-3: Diagram of the Two Modes of Activation of Cytotoxic T-Cells and 
the Mechanism for Killing Target Cells. Shown are the two main modes of 
CTL activation (upper three rows), and mechanism of target cell killing (lowest 
row).  A CD8+ CTL cell can become activated by engaging foreign antigen on 
the surface of, for example a virus infected cell, while responding to IL-2 
secreted from a CD4+ helper T-cell.  Alternatively a CD8+ CTL can become 
activated by engaging a professional antigen presenting cell, such as a dendritic 
cell.  When killing a target cell, the CTL can secrete perforin and granzymes onto 
the target cell to induce permeability and apoptosis. Or alternatively, a FasL 
ligand on the surface of the CTL (yellow) can engage fas receptor (blue) on the 
target cell to activate caspases within the target cell, resulting in apoptosis. 
(UOH, 1997) 
 
Once a CTL is committed to a particular antigen and is bound to a cell containing that 
antigen, it has two ways of killing its target cell (Figure-3, lower row).  The first mechanism for 
killing includes the use of perforin and granzymes (blue spheres inside the CD8+ orange cell, 
lower left diagram). Perforins are cytoplasmic granules discharged by exocytosis once a CTL 
binds its target. Once a dozen or more granules have inserted themselves into the plasma 
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membrane of a target cell (such as a tumor cell), they form a pore (orange surface protein in the 
pink virus infected cell) allowing granzymes to enter (dark pink matter inside the pink virus-
infected cell). Granzymes are serine proteases that work inside the cell in two ways: Granzymes-
A, once inside the cell, enter the mitochondria to cut a subunit of complex I protein that 
functions in respiration, and this kills the cell.  Granzymes-B cleave caspase precursors to 
activate them, causing the cancer cell to undergo apoptosis.  The second mechanism used by 
CTLs for killing target cells involves FasL/Fas killing (yellow/blue receptors, lower diagram). 
All CTLs express the Fas ligand (FasL) (known as the death activator) (yellow surface protein on 
the CD8+ cell) on their surface.  Most targeted cells express a receptor for FasL known as Fas 
(blue receptor on viral infected cell). When CTLs recognize and bind to their target, FasL is 
upregulated (more FasL is secreted to the CTL surface) which binds more Fas on the target cell.  
Activation of the signaling pathway of FasL bound to Fas receptor results in cell death by 
apoptosis. (RCN, 2011) 
 
When fighting cancer, the adaptive immune response typically responds with a cell-
mediated response.  Effector helper T-cells help activate naïve CTLs which forms both memory 
CTLs that continue surveillance of the body and form effector CTLs that lyse the targeted cancer 
cells (Cancer Research Institute, 2003; Veseley et al., 2011). In addition, the tumor cells can be 
identified by antibodies against surface proteins to create complement-mediated cytotoxicity 
(Spurrell and Lockley, 2014).  
 
 Regulatory T-cells are important in avoiding immune-mediated pathology and limiting 
the expansion of the effector T-cell population (for example following an infection). Originally, 
regulatory T-cells were called suppressor T-cells because they suppress both humoral and 
cellular immunity. Figure-4 shows the formation of regulatory T-cells within the adaptive 
immune system.  Natural regulatory T-cells (green in the diagram) increase the expression of 
CD25+ as they migrate from the thymus.  Inducible regulatory T-cells (purple) form from naïve 
CD8+ cells (yellow) in the presence of antigen. These inhibitory T-cells are naturally stimulated 
by inflammation and disease processes such as autoimmunity and cancer to help inactivate both 
cellular and humoral immunity. (Shevach and Davidson, 2015) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-4: Diagram of the Formation of Regulatory T-cells.  Shown in the diagram are three 
types of T-cells migrating out of the thymus: CD25+ natural regulatory T-cells (green), naïve 
CD8+ cells (yellow), and naïve CD4+ cells (brown). The CD8+ naïve T-cells can differentiate 
into CD8+ inducible regulatory T-cells (turquoise). (Shevach and Davidson, 2015) 
36 
 
Hematopoietic Stem Cells (HSCs) 
 
 Hematopoietic Stem Cells (HSCs) are multipotent progenitor cells responsible for the 
production of all the cellular components of the blood. They create billions of blood cells within 
the vertebrate immune system (R&D Systems, 2015). Sources of HSCs include bone marrow, 
peripheral blood, umbilical cord blood, fetal hematopoietic systems, and embryonic stem/germ 
cells. HSCs have many characteristics that makes them well suited for treating leukemia patients 
in bone marrow transplants, or making cancer vaccines (Gschweng et al., 2014). HSCs are 
sometimes identified as having CD34+ on their surface (Figure-5), and the cells they 
differentiate into are usually fully functional red blood cells, white blood cells, and platelets.  
Two types of HSCs have been discovered through rate studies: long-term HSCs (top row in the 
diagram) and short-term HSCs (second row in the diagram). Both types of HSCs are derived 
from bone marrow, and can renew themselves (circular arrows in the diagram), but short-term 
HSCs cannot renew themselves for long periods of time. (R&D Systems, 2015) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-5: Diagram of the Role of Hematopoietic Stem Cells in Hematopoiesis.  Long-
lived HSCs (top row, blue) form shorter-lived HSCs (second row, blue), which form 
Progenitor Cells (third row) that differentiate further into all other blood cells. (Wang & 
Wagers, 2011) 
 
 
Antigen Presenting Cells (APCs)  
 
 Antigen Presenting Cells (APCs) are specialized white blood cells that help fight off 
foreign invaders by presenting antigens on their surface that are recognized by other components 
of the immune system (discussed above) to help them commit to that specific antigen during 
adaptive immunity (Wellness, 2015). When a foreign antigen is first detected by an APC, it is 
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engulfed by the APC, and proteases inside the cell break it down into smaller peptides. The 
processed antigen is then transported back to the surface of the APC and bound with either an 
MHC class I or II molecule. This antigen-MHC complex is then recognized by B-cells and T-
cells to help them commit to that particular type of antigen (Kimball’s Biology Pages, 2013).  
 
 APCs are classified as two types: professional and non-professional (Figure-6).  
Professional APCs (diagram upper panel) such as dendritic cells, macrophages, or B-cells, 
express the foreign antigen via MHC class I molecules on their surface, and are the only type to 
activate naïve helper T-cells. The interaction between MHC-1-presented antigen and B-cells and 
T-cells is very strong (upper panel, diagram center).  Non-professional APCs (such as fibroblast 
cells, thymic epithelial cells, thyroid epithelial cells, glial cells, pancreatic beta cells, and 
vascular endothelial cells) (diagram lower panel) present antigen via MHC class II molecules, in 
a weaker type interaction to B-cell and T-cell receptors. (Garland Science, 2001) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-6: Diagram of the Functional Differences Between Professional and Non-
Professional Antigen-Presenting Cells.  The upper panel denotes professional APCs 
with their high affinity interaction with B and T-cells, while the lower panel denotes non-
professional APCs and their lower affinity interaction with target cells.  (Wellness, 2015) 
 
 
Dendritic Cells (DCs) 
 
 DC’s are of special concern to this IQP because they are used as DC vaccines in cancer 
immune-therapy for some types of cancer.  As mentioned above, DCs are a type of professional 
antigen-presenting cell whose main function is to process foreign antigens and present them on 
their surface via MHC-1 molecules to B-cells and T-cells to induce them to commit to that 
antigen (Figure-7).  DC’s at some developmental stages grow a branched morphology from 
which they get their name (dendritic for tree).  DC’s are also known as accessory cells of the 
mammalian immune system. They act as messengers between the innate immunity (recognizing 
and internalizing foreign antigens) and the adaptive immune system (antigen presentation to B-
cells and T-cells).  DC’s are present in tissues that are in contact with the external environment, 
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such as the skin (where they are known as Langerhans cells) and the inner lining of the nose, 
lungs, stomach and intestines. Immature DCs (also known as veiled cells) are high in endoyctic 
activity and low in T-cell activation potential, and are sometimes found in the bloodstream 
(RCN, 2013). DCs express pattern recognition receptors (PRRs) on their surface, and are 
constantly scanning for invading pathogens. When one is detected, DCs engulf the pathogen as 
part of the innate immune system.  DCs also process the antigen and present it via MHC-1 and 
become activated (NPG, 2015). Once activated, they migrate to the lymph nodes where they 
interact with T-cells and B-cells to initiate adaptive immunity.  Because they migrate, DC’s are 
distinguished from follicular dendritic cells (FDCs) that do not migrate (discussed below).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-7: Interaction Between Dendritic Cells (DCs) and T-Cells. The interaction 
between DCs (purple cell) and T-cells (green cell) to activate them involves three signals. 
The first signal (bright red) is derived from the interaction between the MHC class I 
molecule  (green) on the DC cell which processes and presents foreign antigens to the T-
cell receptors (TCR) (dark purple).  The second signal (orange) results from the 
interaction between co-stimulatory molecules, CD80/86 on the DC (green) and CD28 
(turquoise) on the T-cell. Signal-3 (dark red) results from the secretion of IL-12 from the 
DC cell.  When these signals work together, they promote a strong T-helper-1 response 
(Th1) within responding T-cells. (Cambridge University Press, 2002) 
 
In cancer vaccines, a patient’s peripheral blood mononuclear cells (PBMCs) are isolated 
from his arm, and cultured in vitro.  The DC’s are isolated from this expanded PBMC culture, 
and then mixed in vitro with either tumor cells isolated from the patient or with purified tumor 
antigen (to expose the DCs to tumor antigens).  The DC’s process the tumor antigen and express 
it via MHC-1 on their surface.  The DC’s are then injected in large numbers back into the patient, 
where they engage B-cells (humoral immunity) and T-cells (cellular immunity) to activate both 
arms of the immune system against the cancer. 
 
Follicular dendritic cells (FDCs) are different than DCs.  FDCs are found in primary and 
secondary lymph tissues (lymph nodes, spleen) in the B-cell areas of the lymphoid tissue.  
Although FDCs have a dendritic morphology, they are not DCs.  They are not derived from 
HSCs like DCs, but are of mesenchymal origin.  FDCs are a non-migratory population that form 
a stable connection with follicular B-cell.  Opsonized antigens are displayed for long periods of 
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time without proteolysis or removal by phagocytic cells.  FDCs also express complement 
receptors CR1 (CD35) and CR2 (CD 21) (so they trap complement-coated antigens), and the Fc-
receptor FcγRIIb (CD32) (so they bind antibody-coated antigens). But FDCs lack MHC-1, so 
cannot capture non-opsonized antigens.  Follicular B-cells must bind FDCs or they undergo 
apoptosis.  FDCs also protect the body from autoimmunity by removing self-reactive B-cells. 
 
 Functionally, FDCs enable germinal center responses via antigen, chemokines, and 
survival factors (Van Nierop and de Groot, 2002) (Figure-8). Although FDCs are normally 
located in the follicles and stromal cells of secondary lymphoid organs, research has shown that 
“ectopic FDC formation can also be found in a number of autoimmune diseases and/or chronic 
inflammatory situations, which indicates development of FDCs is not restricted to secondary 
lymphoid organs but rather a matter of local conditions that drive a precursor cell type into FDC 
maturation” (Elseivier Inc., 2015). FDCs are important for the formation of B-cells that produce 
high-affinity antibodies against pathogens, as they present the foreign antigen on their surface for 
a long period of time. With respect to autoimmunity, B-cells that are able to bind are able to 
survive and produce antibodies, but B-cells against self-antigens do not bind FDCs and undergo 
apoptosis (NPG, 2015).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-8: Diagram of the Signaling of a Follicular Dendritic Cell with a Target Cell.  
Shown are some of the receptors and signaling molecules that participate in follicular 
dendritic cell (FDC) function.  The binding between the dendritic cell (light blue) and 
target cancer cell (B-cell lymphoma, light purple) is facilitated by the following 
interactions: ICAM-1 with LFA-1, VCAM-1 with VLA-4, and CD44 with an unknown 
receptor.  FDCs do not present antigens via MHC-1 molecules. (Elsevier Inc., 2015)  
 
 
Natural Killer Cells (NKs) 
 
 Natural killer cells (NKs) are effector lymphocytes of the innate immune system that 
monitor for cells containing MHC class 1 molecules present on most host cells, and attack cells 
that lack MHC-1. They also scan for cell stress markers on the cell surface of autologous cells 
and remove stressed cells (NPG, 2008). NKs constitute about 5-15% of the lymphocytic 
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circulating population, and are the most aggressive of all white blood cells in the entire immune 
system. A majority of NKs are located in peripheral blood, lymph nodes, spleen, and bone 
marrow; however, various chemoattractants have the ability to migrate NKs toward sites of 
inflammation (ScienceDaily, 2015). What makes NKs of use in the battle against cancer is that 
they have no immunological memory, so they do not have to recognize a specific antigen before 
releasing their toxins to destroy cells such as tumor cells, so long as the tumor cell is recognized 
as “foreign” by the NK (Thornthwaite, 2015).   
 
 In humans, two types of receptors regulate the recognition phase of NKs. One is 
composed of the receptors that are homologous to the C-type lectines, called the NK Regulation 
Complex (NKRC). The other is composed of Killer Cell Immunoglobulin-like receptors, also 
known as KIRs, which are shown on the NK cell surface as KIR2 and KIR3. The most 
predominant control of the NK cell activation comes from the CD94:NKG2. It contains both 
activating receptors (NKG2A-B) and inhibitor receptors (NKG2C-D) (Figure-9). When MHC1 
present on a non-foreign host cell binds with a NK cell receptor (diagram left side), it sends 
negative signals (veto) to inhibit activation of the NKC receptors to release the ligand (normal 
healthy host cell). When MHC1 is not dense enough (as for a bacterial cell lacking MHC-1), 
contains processed antigen (as with an antigen presenting cell containing pathogen), or is 
sufficiently altered (with some types of cancer) (diagram right side), then the decreased binding 
of altered MHC1 to the inhibitory receptor activates the NK cell, and it targets and kills the target 
cell (Vivier et al., 2008). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-9: Recognition of Host Cells by NKs.  The left diagram denotes an NK cell 
(purple) with its inhibitory receptor engaged by ligand (such as MHC-1) on a normal host 
cell (blue).  With the inhibitory receptor engaged, the NK cell releases the healthy host 
cell without destruction.  The right figure shows an NK cell whose inhibitory receptor is 
not engaged by a target cell (such as a tumor cell or a bacterial cell lacking MHC-1).  The 
inhibitory receptor not activated, so the NK cell becomes activated and kills target cell.  
(ScienceDaily, 2015) 
 
 
NKs are capable of two types of killing: lysis and apoptosis.  Lysis involves the release of 
cytotoxic molecules (such as Tumor Necrosis Factor, TNF) from NK granule membranes that 
41 
cause destruction of the target cell if the inhibitory receptor is not engaged (NPG, 2008).  NKs 
can also kill by apoptosis using perforins and granzymes (as discussed earlier with CTLs).  NKs 
contain small cytotoxic granules in their cytoplasm containing proteins called perforin and 
proteases called granzymes. When the NK cell releases perforin, it forms cylindrical pores in the 
target cell that act as an entrance for the granzymes.  The granzymes are serine proteases that 
work inside the cell to 1) enter mitochondria to cleave a subunit of complex I protein that 
functions in respiration, which kills the cell, and 2) to cleave caspase precursors to activate them, 
causing the cancer cell to undergo apoptosis.   
 
Unfortunately, some cancer cells have the ability to escape NK activity by encoding 
proteins that serve as ligands for the inhibitory NK receptors, thus keeping the NKs inactive 
against them (Vivier et al., 2008).  So, scientists are devising new methods for down-regulating 
these NK-inhibitory tumor ligands (Veseley et al., 2011; Cancer Research UK, 2014). 
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Part-3:  Cancer Vaccines: Peptide and  
Monovalent Antibody Injections 
Muhammad Siddiq  
 
 
The simplest types of cancer vaccines involve directly injecting purified proteins or 
antibodies into a patient to stimulate the patient’s own immune system to clear the tumor 
cells.  This section of the Lit Review will focus on this type of cancer vaccine. 
 
 
Peptide Injection Experiments 
 
In the case of peptide vaccines, the injected peptide (or a mixture of peptides) usually 
represents a protein (or a part of it) present on the surface of the patient’s own tumor cells.  This 
protein is identified directly from the patient’s tumor cells in a form of personalized medicine, or 
is previously known to be present on all cells of this type of tumor.  The injected protein is 
recognized by the patient’s immune system, including antigen presenting cells (APCs) that 
present the protein to B-cells (which mature to make antibodies against the peptide) and present 
it to T-cells (which mature to make cytotoxic killer cells to home in on cells containing the 
peptide).  Relatively few studies of this type exist because the approach has been replaced by 
DC, TIL, and CAR immune vaccines that appear to be more effective. 
 
In 2006, a Phase-II clinical study was performed on 28 patients with metastatic androgen-
independent prostate cancer (Arlen et al., 2006).  The patients received a peptide vaccine 
consisting of a vaccinia virus encoding PSA tumor antigen, followed by boosters with a fowlpox 
virus also encoding the PSA antigen.  The patients also received docetaxel as a type of 
chemotherapy that in mice had shown activity against androgen-insensitive prostate cancer.  The 
purpose of the study was to determine whether the docetaxcel affected the immune vaccine, 
whether the combination was safe, and whether the combination was effective.  Any patient with 
advancing cancer who had not previously received docetaxel was immediately provided it. 
An ELISPOT assay was used to monitor immune responses for PSA-specific T-cells.  Their data 
demonstrated a 3.33 fold increase in T-cell response to PSA after 3 months, and an increased 
immune response against other prostate tumor antigens.  Median progression-free survival on 
docetaxel plus vaccine was 6.1 months, compared to 3.7 months for controls. This study is 
significant because it is the first clinical trial to demonstrate that docetaxel can be administered 
safely with immunotherapy, and the combination improves patient survival, but further studies 
need to be conducted. 
 
In 2007, a team of scientists at the Unit of Immunotherapy of Human Tumors, Istituto 
Nazionale Tumori Foundation (Milan, Italy) reviewed the published literature related to the use 
of unique human tumor antigens in cancer vaccines (Parmiani et al., 2007).  In this review, the 
authors highlight the biological and clinical importance of identifying and using unique antigens 
against tumors, if they are known, to avoid cross immunity with normal patient cells.  They also 
summarize how knowledge of the unique tumor antigens can be applied to both active immune 
vaccines and adoptive immunotherapy. Because each patient’s tumor mutates DNA individually, 
personalized DNA sequencing likely will need to be performed to identify “neoantigens” that are 
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new to the patient’s tumor and not present in his own cells.  Tumor specific antigens were first 
identified fifty years ago in rodents, but their full molecular characterization was limited to a few 
of obtained in the last 20 years. Human studies on tumor neoantigens were relative sparse until 
recently.  
 
In 2012, an interesting peptide mixture experiment was performed by Dr. Harpreet Singh-
Jasuja’s team at Immatics Biotechnologies (Tubingen, Germany) (Walter et al., 2012).  The 
study represents the first immune vaccine for renal cell carcinoma (RCC).  It provides the team’s 
data from Phase-1 and -II clinical trials against RCC. The vaccine (IMA901) consisted of an 
injection of 11 multiple tumor associated peptides (TUMAPs) that the authors previously 
determined were naturally present on the surface of RCC’s and were antigenic when injected into 
humans.  In this study, they verified the peptides were present in patient’s own cancer tissue, and 
treated 96 patients who suffered from advanced stages of renal cell carcinoma.  The phase-I part 
showed that T-cell responses induced against multiple TUMAPs correlated with better disease 
control, and the vaccine appeared to be safe.  The phase-II part confirmed that an immune 
response to multiple cancer peptides correlates with longer patient survival.  Treatment with 
cyclophosphamide, a DNA alkylating agent that blocks the action of T-cells, confirmed that a T-
cell response was necessary for the improved patient survival.  They also assayed over 300 
serum biomarkers, and found that apolipoprotein A-1 (APOA1) and chemokine ligand-17 
(CCL17) best predicted a strong immune response to the IMA901 vaccine and best predicted 
patient survival.  The authors noted that a Phase-III clinical trial with IMA901 is currently 
ongoing.  This peptide injection study directly addressed two of the ongoing problems associated 
with cancer vaccines: 1) which tumor antigens are best to target, and 2) which biomarkers are 
best to follow as indicators of a strong vaccine response.  Their mixture of IMA901 RCC 
peptides proved to induce a strong immune response that improved patient outcomes, and they 
were able to identify two biomarkers as a way to follow vaccine efficacy.  It was not clear from 
the study whether the authors assayed for potential negative effects of the vaccine, so this might 
be worth following up in an interview. 
 
 In 2015, a review article discussed the topic of neoantigens and their importance to tumor 
therapies (Schumacher and Schreiber, 2015). This study summarized some of the recent 
technological innovations that have made it possible to dissect the immune response to patient-
specific neoantigens that arise as a consequence of tumor-specific mutations. The authors 
suggest that recognition of such neoantigens is a major factor in the activity of successful clinical 
immunotherapies. Neoantigen formation can act as biomarkers for tumor formation, and can 
provide a target for the development of therapeutic approaches to enhance T-cell reactivity 
against them.  Neoantigens will be discussed later in the report. 
 
 
Monovalent Antibody Experiments 
 
Instead of injecting peptides to induce an immune response, some scientists directly 
inject antibodies previously made against a tumor protein. This type of “passive immunity” does 
not activate the patient’s own immune system to create the antibodies, but instead provides the 
antibodies by a bio-engineering process.  The antibodies combine with the protein on the surface 
of tumors to create antigen-antibody complexes, which are then recognized and cleared from 
body by other cells of the immune system, such as macrophages or T-cells.   
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Monovalent antibodies recognize only one type of epitope (portion of a protein).  Most 
natural antibodies produced by the body in response to an infection are of this type, and both 
arms of the “Y” shaped antibody molecule recognize the same antigen. Anti-tumor monoclonal 
antibodies (mAbs) represent a major advance in cancer therapy. In the past decade, at least 6 
different mAbs have been approved by the FDA for treating cancer, and more antibodies are in 
development (Taylor et al., 2007). 
 
 
Antibodies Against CD20 for Leukemia, Lymphoma, and Autoimmune Disorders 
 
         The first antibody approved for cancer treatment in the U.S. was Rituximab (also known 
as Rituxan, MabThera, or Zytux). Rituximab is a monoclonal antibody directed against protein 
CD20 primarily found on the surface of B-cells. The antibody binds to B-cells, bringing them to 
the attention of the immune system and their removal.  This antibody is used to treat diseases 
with elevated B-cell numbers (leukemia and lymphoma), overactive B-cells (autoimmune 
disorders, transplant rejection), or dysfunctional B-cells. The antibody was developed by IDEC 
Pharmaceuticals (San Diego) as IDEC-C2B8. It was initially FDA approved in 1997 to treat non-
Hodgkin lymphomas resistant to chemotherapy based on its observed safety performance 
(Maloney et al., 1997). A U.S. patent was issued in 1998 and will expire in 2015. The antibody is 
currently marketed by Biogen Idec (Cambridge, MA) and Genentech (South San Francisco) in 
the U.S., by Hoffmann–La Roche in Canada and the EU, Chugai Pharmaceuticals in Japan, and 
AryoGen in Iran.  Because the antibody was approved in 1997, several studies have used it in 
clinical trials. 
 
In 1998, a team of scientists at the Toronto-Sunnybrook Regional Cancer Centre 
(Ontario, Canada) used Rituximab against CD20 on B-cells to treat patients with low-grade non-
Hodgkin’s lymphoma (Berinstein et al., 1998). Their previous phase I and II trials indicated the 
antibody had minimal toxicity and provided significant therapeutic effects against low grade 
non-Hodgkin’s lymphoma.  Their phase III study included 116 patients with recurrent low-grade 
lymphoma, who were treated with four infusions of Rituximab. 48% achieved a measurable 
tumor response, and 6% achieved complete tumor responses. 76% achieved ≥20% reduction in 
tumor volume.  Rituximb antibody was detected in all patients and increased throughout the 
treatment course. The half-life of the monoclonal antibody increased from 76.3 hours to 205.8 
hours by the end of the fourth infusion. It is important to note that a significant correlation was 
found between the median antibody concentration and the tumor response. The authors 
concluded that Rituximab is therapeutically effective against B-cell lymphoma, and some 
patients may even benefit from increased dosing. 
 
A 1999 article reported the first successful clinical trial combining a chimeric anti-CD20 
monoclonal antibody (Rituximab) with a standard-dose combination of chemotherapy in the 
treatment of patients with indolent B-cell lymphoma (Czuczman, 1999). In a 40 patient group, 
the study found a 95% overall response rate, with 55% complete remission and 40% partial 
remission.  In addition, seven of seven patients with follicular histologies achieving complete 
remission also showed positive PCR results for clearing of BCL-2 from the blood and marrow, 
suggesting an eradication of minimal residual disease. The author of this report concluded that 
based on its single-agent efficacy, excellent toxicity profile, and ability to be successfully 
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combined with combination chemotherapy; rituximab may be a very beneficial towards 
treatment of CD20-positive neoplasms. 
 
A 2000 study performed at the Sarah Cannon Cancer Center (Nashville, TN) investigated 
the ability of rituximab anti-CD20 mAb in 39 previously untreated patients with stage II-IV low-
grade non-Hodgkin’s lymphoma (Hainsworth, 2000).  The patients received rituximab at 375 
mg/m2 by intravenous infusion for four consecutive weeks, and were evaluated for responses at 
week six. Patients who exhibited stable disease or an objective response at 6 weeks received a 
repeat four-week course at six-month intervals for a maximum of four treatment cycles. In the 6 
week evaluation, 54% of the patients showed objective responses, and 36% had stable disease or 
minor responses. The response rates were similar in patients with follicular and small 
lymphocytic lymphoma (52% and 57%, respectively). At 1 year, the overall response rate was 
72%, with 18% showing complete responses, and 77% showing a progression-free survival. The 
treatment appeared to be well tolerated by the patients. It is noted in the evaluation that further 
follow-up evaluation of the patients will be important. 
 
Another study was done in 2001 by a team of scientists at the University of Nebraska 
Medical Center (Omaha, NE) who determined the safety and efficacy of the combination of the 
chimeric anti-CD20 antibody (Rituxan) supplemented with CHOP chemotherapy (a combination 
of cyclophosphamide, doxorubicin, vincristine, and prednisone) in patients with aggressive non-
Hodgkin’s lymphoma (NHL) (Vose et al., 2001). The study consisted of 33 patients with 
previously untreated advanced aggressive B-cell NHL who received six infusions of Rituxan 
(375 mg/m2 per dose) on day 1 of each cycle in combination with six does of CHOP 
chemotherapy given on day 3 of each cycle. The overall response rate was 94%, with 61% of the 
patients experiencing a complete response, 33% had a partial response, and two patients were 
classified has having progressive disease. 18 patients had an International Prognostic Index (IPI) 
score ≥ 2, for these patients the combination of Rituxan plus CHOP achieved an overall response 
rate of 89%, and a complete response of 56%. Within the median observation time of 26 months, 
29 of 31 responding patients remained in remission during this follow-up period, including 15 of 
16 patients with an IPI score ≥ 2. PCR was used to monitor the causing bcl-2 translocation in 
blood or bone marrow cells, and was positive at baseline in 13 patients, of 11 who did follow-up 
PCR all 11 had a negative bcl-status after therapy. Only one patient reconverted to bcl-2 
positivity, and all patients remain in clinical remission. The most frequent adverse events 
attributed to the Rituxan antibody were fever and chills, primarily during the first infusion. But 
the Rituxan did not seem to compromise the ability of patients to tolerate the CHOP 
chemotherapy, as all patients completed the entire six courses of the combination. This study is 
the first to demonstrate the safety and efficacy of the Rituxan chimeric anti-CD20 antibody in 
combination with standard-dose CHOP in the treatment of aggressive B-cell lymphoma.  
 
Another 2001 study was done by a team of scientists in Tours, France who published 
their findings using CD20 rituximab mAb against follicular non-Hodgkin lymphoma (NHL) 
(Colombat et al., 2001).  The study consisted of 50 patients with follicular CD20+ NHL and a 
low tumor burden, who were analyzed for clinical and molecular responses. The patients 
received four weekly infusions of rituximab at a dose of 375 mg/m2. The response rate after 50 
days was 73%, with 10 patients (20%) in complete remission, 3 patients in complete 
remission/unconfirmed, and 23 patients in partial remission. Ten patients had stable disease, and 
3 patients had progressing disease.  The results indicated that early molecular responses to the 
antibody can be sustained for up to 12 months, and the response highly correlates with 
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progression-free survival. A significant association was observed between molecular and clinical 
responses (p< 0.0001). A year into the study, 8% of the patients were in complete remission, 
39% in partial remission, and 50% had stable remission. Of the pool of patients, 32 were initially 
informative for polymerase chain reaction (PCR) data on bcl-2-Jh rearrangement. On day fifty, 
57% were negative for bcl-2-Jh rearrangement in peripheral blood and 31% were negative in 
bone marrow. After 12 months, 62% of patients were PCR-negative in peripheral blood.  This 
study provides a very successful use of a monovalent mAb against CD20 for fighting non-
Hodgkin lymphoma. 
 
Hainsworth (discussed above) followed up his earlier study with a second one in 2002 
(Hainsworth, 2002).  Again he analyzed the use of rituximab as a first-line treatment for patients 
with indolent non-Hodgkin’s lymphoma. The study was a community-based trial on 62 patients 
with stage II to IV indolent non-Hodgkin’s lymphoma (follicular or small lymphocytic) who had 
received no previous systemic therapy. All patients received rituximab at 375 mg/m2 weekly for 
four consecutive weeks, and were evaluated for responses at week 6. Patients who had an 
objective response or stable disease continued treatment every 6 months with repeat four-week 
courses of rituximab for a total of four treatment courses. The data indicated that at week 6, 47% 
had objective responses, and 45% had minor responses or stable disease. Following a second 
rituximab treatment, the major response rate increased from 47% to 65%, and the complete 
response rate increased from 7% to 27%. The author stated that progression-free survival was not 
measured in the study, but he stated it will be greater than 24 months. During the investigation, 
there was no observable toxicity with repeat courses of rituximab. The author concluded by 
saying that the initial response rate can be improved by using several scheduled maintenance 
courses of rituximab administered every six months. 
 
 
Antibodies Against HER2 
 
The second monoclonal antibody approved for cancer treatment in the U.S. was 
Herceptin (also known as Trastuzumab or Herclon). Herceptin is a monoclonal antibody that 
interferes with the HER2/neu receptor that is over-expressed on some types of cancer cells. It 
was first developed in the 1990’s by scientists Dr. Axel Ullrich and Dr. H. Michael Shepard at 
UCLA's Jonsson Comprehensive Cancer Center, with further refinements by Dr. Dennis Slamon 
(reviewed in Bange et al., 2001). The antibody is manufactured by Genentech, and it gained 
FDA approval in September 1998. Herceptin’s main use is to treat HER2-type breast cancers, but 
it is also used to treat other types of HER2 cancers such as colorectal and pancreatic cancers 
(Perez et al., 2002). HER2 receptors are embedded in the cell surface membrane, and after 
binding epidermal growth factor (EGF) ligands, communicate signals to stimulate cell 
proliferation. Over-expression of HER2 in cancers aids tumor cell division (reviewed in Hudis, 
2007).  
 
 A 1999 study evaluated the efficacy and safety of a recombinant humanized anti-HER2 
monoclonal antibody as a single agent in women with HER2-overexpressing metastatic breast 
cancer that had progressed after chemotherapy to metastatic disease (Cobleigh et al., 1999). They 
enrolled 222 women with HER2-overexpressing metastatic breast cancer that had progressed 
after one or two chemotherapy regimens. The patients received a loading dose of 4 mg/kg 
antibody intravenously, followed by a 2-mg/kg maintenance dose at weekly intervals. A blinded, 
independent response evaluation committee identified 8 complete, and 26 partial responses, 
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providing an overall response rate of 15%. The median response duration was 9.1 months, and 
the median survival duration was 13 months.  Among the most common adverse events were 
infusion-associated fever and/or chills, observed mostly during the first infusion in about 40% of 
the patients. Other side-effects commonly observed with chemotherapy were rarely seen, such as 
alopecia, mucositis, and neutropenia. The authors concluded that recombinant humanized anti-
HER2 monoclonal antibody administered as a single agent, produces durable objective responses 
and is well tolerated by women with HER2-overexpressing metastatic breast cancer that has 
progressed after chemotherapy for metastatic disease. 
 
A 2001 study in the Division of Hematology and Oncology at the UCLA School of 
Medicine (Los Angeles, CA) evaluated the efficacy and safety of trastuzumab in women with 
metastatic breast cancer that overexpressed HER2 (Slamon et al., 2001). 234 patients were 
randomly assigned to receive standard chemotherapy, and in another group 234 patients were 
assigned to receive standard chemotherapy plus trastuzumab. The results indicated that the 
addition of trastuzumab antibody to the chemotherapy regime provided a longer time to disease 
progression (median 7.4 vs 4.6 months; p<0.001), a higher rate of objective response (50% vs 
32%, p<0.001), a longer duration of response (median, 9.1 vs 6.1 months; p<0.001), a lower rate 
of death at 1 year (22% vs 33%, p=0.008), longer survival (median survival 25.1 vs 20.3 months; 
p=0.046), and a 20% reduction in the risk of death. The most important adverse event observed 
was cardiac dysfunction, occurring in 27% of the chemotherapy group, 8% of group given partial 
chemo, 13% of the group given paclitaxel and trastuzumab antibody; and 1% of the group given 
paclitaxel alone. It was noted that although the cardiotoxicity side effects were sometimes very 
severe, the symptoms generally improved using standard medical management. It was concluded 
that trastuzumab antibody increases the clinical benefit of first-line chemotherapy in metastatic 
breast cancer that overexpresses HER2. 
 
In 2002, a team of scientists in the Department of Surgical Oncology, The University of 
Texas M. D. Anderson Cancer Center (Houston, TX) published the results of their study 
investigating the molecular mechanisms by which Herceptin enhances the antitumor effects of 
taxol (Lee et al., 2002). They studied the effect of Herceptin treatment on p34Cdc2 kinase 
activation and apoptosis in taxol-treated human breast carcinoma cell lines MDA-MB-435, 
SKBr3, MDA-MB-453, and 435.eB (a positive control ErbB2 transfectant of MDA-MB-435). 
Activation of p34Cdc2 was previously shown to be required for taxol-induced apoptosis, and over-
expression of ErbB2 blocks the taxol-induced apoptosis by inhibiting p34Cdc2 activation. Their 
data indicated the Herceptin antibody treatment down-regulated ErbB2, reduced the inhibitory 
phosphorylation of Cdc2 on Tyr-15 (improving the molecular requirements for taxol sensitivity). 
Herceptin plus Taxol treatment led to higher levels of p34Cdc2 kinase activity and apoptosis in 
vitro, and more effectively inhibited the growth of human tumor xenografts in mice with 
enhanced in vivo apoptosis. It was concluded that Herceptin treatment of ErbB2-overexpresing 
cells allows effective p34Cdc2 activation and induction of apoptosis upon taxol treatment.  
 
In 2005, a team of scientists at the Jules Bordet Institute (Brussels, Belgium) studied the 
use of Trastuzumab, a recombinant monoclonal antibody against HER2, against advanced breast 
cancers over-expressing HER2 (Piccart-Gebhart et al., 2005). The objective was to investigate 
efficacy and safety after excision early-stage breast cancer and completion of chemotherapy. 
This study was an international, multicenter, randomized trial that compared one or two years of 
trastuzumab given every three weeks with patients with HER2-positive and either node-negative 
or node-positive breast cancer, who had previously completed locoregional therapy and at least 
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four cycles of chemotherapy. The total study consisted of 1,694 women with two years of 
trastuzumab treatment, 1,694 women with one year of trastuzumab, and 1,693 controls. The 
published findings here pertained only to the one year observation. Recurring breast cancer or 
death was observed in 347 events (127 events in the trastuzumab group and 220 in the 
observation group). Severe cardiotoxicity developed in 0.5% of the women who were treated 
with trastuzumab. Disease-free survival at two years would be about 8.4%. The authors of this 
investigation concluded that one year of treatment with trastuzumab after adjuvant chemotherapy 
significantly improves disease-free survival among with HER2-positive breast cancer patients. 
 
 In 2007, a team of scientists in the Department of Microbiology at the College of 
Physicians and Surgeons, Columbia University (New York, NY) published a study to determine 
whether passive immunotherapy (providing antitumor antibodies against HER-2/neu antigen) 
can induce active tumor immunity via the opsonic enhancement of immunogenicity of tumor 
antigen in breast cancer patients (Taylor et al., 2007). The study assessed whether immune 
sensitization to the HER-2/neu tumor antigen occurs during treatment with the anti-HER-2/neu 
monoclonal antibody trastuxumab.  27 breast cancer patients were treated with trastuzumab and 
chemotherapy, then were assayed for the induction HER-2/neu – specific immunity. The 
assessment was done by obtaining sera and peripheral blood mononuclear cells before and after 
trastuzuma therapy; these patient cells were compared for the presence of anti-HER-2/neu 
endogenous antibodies and HER-2/neu – specific CD4 responses (indicating immune activation) 
by ELISA and enzyme-linked immunospot.  In the overall population, anti-HER-2/neu humoral 
responses significantly increased during therapy (p<0.001). Anti-HER-2/neu antibodies were 
detectable in 29% of patients before treatment and in 56% of patients during treatment.  
Interestingly, in ten evaluable individuals, six showed elevated HER-2/neu – specific CD4 T-cell 
responses during therapy, indicating activation of the patient’s immune system against Her2, not 
just a passive immune response by the added antibodies. Of the twenty-two individuals treated 
for metastatic disease, those showing improved clinical responses contained higher levels of 
HER-2 antibodies. The authors concluded that humoral immune sensitization indeed occurs 
during treatment with chemotherapy and trastuzumab, but more studies are required to determine 
whether the newly induced immune responses contribute to the patient outcomes.  
 
 
Antibodies Against CD22 for Leukemia 
 
         CD22 (cluster of differentiation-22) is a transmembrane protein located on the surface of 
mature B-cells (and somewhat on immature B-cells) whose N-terminal immunoglobulin-like 
domain specifically binds sialic acid residues (reviewed in Macauley et al., 2014).  CD22 is a 
member of the Siglec immunoglobulin superfamily of proteins, and is an inhibitory receptor that 
once bound to ligand prevents over-activation of the immune system and the development of 
autoimmune diseases (Otipoby et al., 2001). Because CD22 is located on B-cells, antibodies 
against it are sometimes used to treat leukemia where B-cells are over-produced. 
 
  In 2012, Dr. Hagop Kantarjian and his colleagues at the MD Anderson Cancer Center 
(Houston, TX) published the results of their Phase 2 clinical trial (Kantarjian et al., 2012).  This 
group designed an antibody against surface protein CD22 highly expressed in patients with acute 
lymphocytic leukemia (ALL). The antibody was conjugated to the toxin calecheamicin to kill the 
CD22 cells.  They treated 49 ALL leukemia patients, 9 patients (18%) had a complete response, 
19 (39%) had a marrow response, 19 (39%) had resistant disease, and only 2 (4%) died.  The 
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most frequent side effects were fever (20 patients), hypotension (12 patients), and liver related 
toxic effects (12 patients).  It would be interesting in an interview with the authors to see how 
they think their CD22 targeting approach compares with the CD19 approach of killing leukemic 
B-cells. 
 
 One year later in 2013, Dr. Kantarjian published a follow-up study (Kantarjian et al., 
2013) using their inotuzumab (a CD22 mAb bound to toxin calicheamicin) shown in their 
previous study to be active against patients with ALL. For this study, 90 patients with refractory-
relapsed ALL received inotuzumab. The first group of 49 patients received a single-dose of 
inotuzumab i.v. at doses of 1.3 to 1.8 mg/m2 every three to four weeks. The second group of 41 
patients received inotuzumab weekly at a dose of 0.8mg/m2 on day one, and a dose of 0.5mg/m2 
on days 8 and 15, every three to four weeks— based on their earlier observations of higher in 
vitro efficacy with more frequent exposures. The overall response rate was 58% (19% achieved a 
complete response, 30% had a complete response with no platelet recover (CRp), and 9% had a 
bone marrow complete recovery). The response rates were similar between the two groups. The 
median survival was 6.2 months, 5.0 months with the single-dose, and 7.3 months with the 
weekly dose schedule. The median remission duration was seven months. Some of the adverse 
side effects observed were reversible bilibrubin elevation, fever, and hypotension. The authors 
concluded that inotuzumab as a single-agent therapy was highly active, safe, and convenient in 
patients with refractory-relapsed ALL. A weekly dose schedule proved to be equally effective as 
a single-dose schedule, and was less toxic. 
 
         In 2013, Dr. Dieter Hoelzer of Frankfurt, Germany, was sole author on a review article in 
Cancer, 119: 2671-2674, entitled “CD22 Monoclonal Antibody Therapies in 
Relapsed/Refractory Acute Lymphoblastic Leukemia” (Hoelzer, 2013). This review article 
reminds us that CD22 is present on about 60-90% of B-cell malignancies, but not 100%.  So, 
presumably antibodies against CD22 would not work in 10-40% of ALL patients.   
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Part-4:  Bivalent Antibody Experiments and  
Immune Checkpoint Inhibitors 
Isaac Vrooman 
 
  
          Bivalent (or bi-specific) antibodies recognize two different epitopes by the same antibody 
molecule. The best characterized example of this bivalent approach is antibody Blinatumomab, 
where one antibody arm recognizes CD19 on the surface of leukemic cells, and the other arm 
recognizes CD3 on the surface of T-cells to activate them.   
 
 
Blinatumomab Antibody Against CD19 and CD3 
 
          CD19 (Cluster of Differentiation-19) is a protein found on the surface of B-cells of the 
earliest recognizable B-lineage, but it is lost on mature plasma B-cells cells. Due to its specificity 
for early B-cells, its lack of expression in other tissues, and the ability of a human being to live 
without early B-cells (by passively providing antibodies to the patient), the targeting of CD19 to 
fight leukemia (where excess immature B-cells are produced) has become one of the biggest 
success stories in all of cancer vaccine research (Scheuermann and Racila, 1995). Targeting 
CD19 can be achieved by antibody therapy or by therapy with CAR cells designed against CD19 
(discussed later), and it will be interesting in interviews to have the study authors contrast the bi-
specific antibody approach with the CAR approach against CD19. 
 
          Blinatumomab (also known as AMG103) is a bivalent antibody designed with one arm 
directed against CD19 (to destroy B-cells whose numbers are elevated in leukemia) and the other 
arm against CD3 (a T-cell receptor activator) to bind and activate T-cells so they destroy the co-
bound B-cell tumor. This antibody is a type of “bi-specific T-cell engager” (BiTE) that 
specifically binds a tumor cell (in this case a B-cell) while simultaneously binding T-cells. The 
activated T-cell destroys the co-bound cancer cell. Blinatumomab was created in the early 1990’s 
by scientists at University Hospital Utrecht (The Netherlands) (Haagen et al., 1992; Bohlen et al., 
1993; Haagen et al., 1994; DeGast et al., 1995; reviewed in Weiner and DeGast, 1995).  The 
antibody was further developed by Micromet, Inc. in collaboration with Lonza. Micromet was 
later purchased by Amgen, which expanded Blinatumomab’s clinical trials. On December 3, 
2014, the antibody was approved by the FDA for treating acute lymphoblastic leukemia (ALL) 
(FDA, 2014).   
 
       In 1995, extensive preclinical testing was done testing the effectiveness of bispecific 
antibody (BsAb) designed against CD3 X CD19 (De Gast et al., 1995). The team, led by Dr. De 
Gast of the Netherlands Cancer Institute, initially tested antibody effectiveness against a pre-B-
cell line, and found that the BsAb induced the killing of malignant B-cells by added resting T-
cells that had become activated by the CD3-portion of the bispecific antibody. The study was 14 
days long, and showed that BsAb required repeated administration together with IL-2 to achieve 
a 5-log kill of the B-cells by resting peripheral blood T-cells. The study then expanded into in 
vivo experiments, and the team tested 3 human patients for safety, intravenously introducing 
BsAb in 2.5 mg doses into 3 patients with B-cell non-Hodgkin’s lymphoma. The results showed 
relatively safe toxicity. Next, patients with chronic lymphocytic leukemia (CLL) were treated 
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with 0.6 mg doses intravenously, preceded by IL-2. The patients showed improved T-cell 
activation, and the toxicity remained limited. The team noted that the chemotherapy-resistant 
CLL patients with a high tumor burden showed no clear clinical effects, so the authors suggested 
treating patients with a lower tumor load in future experiments. So, these early experiments had 
modest efficacy. 
 
In 2002, Dr. Patrick A. Baeuerle and his colleagues of Micromet AG (Martinsried, 
Germany) extended the testing of the in vitro efficacy of their bi-specific single chain antibody 
directed against CD19 and against CD3 (Dreier et al., 2002).  Their data indicated that the in 
vitro lysis of the tumor cells was mostly mediated by CD8+ T-cells, and that CD19-negative cells 
(non-leukemic cells) were not harmed by the CD8+ T-cells induced by the antibody vaccine.   
 
        In 2003, Dr. Ralf Bargou and his colleagues at the Max Delbruck Center for Molecular 
Medicine (Berlin, Germany) (also authors on the 2002 paper discussed above) published their 
study of the bispecific CD3 x CD19 antibody in patients with B-cell chronic lymphocytic 
leukemia (B-CLL), the most common type of leukemia in adults in western countries (Löffler et 
al., 2003).  B-CLL patients treated with standard chemotherapies often relapse, so there are no 
current long term treatments.  CD19 appears to be a decent target because it is expressed on the 
surface of the vast majority of B-cell cancers but is not expressed on stem cells or plasma cells. 
They tested its ability to bind in vitro primary B-cells and autologous T-cells isolated from 
healthy volunteers and from chronic lymphocytic leukemia (B-CLL) patients, and showed a 
depletion of lymphoma cells in 22 out of 25 patient cases.  In addition to the CD3 activation of 
the T-cells, no further activation by IL-2 was needed.  
 
          In 2005, Dr. Baeuerle’s group (as discussed above for the 2002 study) used video-assisted 
microscopy to determine that their bi-specific CD19 x CD3 antibody vaccine stimulated the T-
cells to switch from a scanning mode into a killing mode (Hoffmann et al., 2005).  In the killing 
mode, each T-cell eliminated multiple tumor cell (CD19 B-cell) targets within a 9 hour time 
period, and the tumor cell targets were completely eliminated within 24 hours using ratios as low 
as 1:5 (T-cell to tumor cell).  This study nicely shows that their bi-specific antibody can indeed 
activate T-cells, and each activated T-cell can undergo multiple rounds of target cell lysis. 
 
 In 2007, Dr. Molhoj of the University of Connecticut and his colleagues published an 
article in Molecular Immunology titled “CD19-/CD3-bispecific antibody of the BiTE class is far 
superior to tandem diabody with respect to redirected tumor cell lysis” (Molhol et al., 2007). 
In their paper they stated that many kinds of bispecific antibodies recruiting T-cells for cancer 
therapy have now been developed, but a comparison of antibody structures had not been 
attempted. They compared the activity of monospecific and bispecific CD19/CD3 antibodies of 
the single chain format, tandem diabody (Tandab) format, and the quadroma format. Their data 
indicated that all antibodies had similar cytotoxic activities, but that under identical experimental 
conditions, the bispecific CD19/CD3 format has far superior activity compared to the 
monospecific formats. The extraordinary potency of the BiTE class (as represented by MT103) 
may translate into improved anti-tumor activity, lower dosing and lower costs of production 
compared to other antibody formats (Molhol et al., 2007). 
 
 In 2008, Dr. Ralf Bargou of the University of Wurzburg (Germany) and his team 
published an article in Science titled “Tumor regression in cancer patients by very low doses of a 
T-cell-engaging antibody” (Bargou et al., 2008). The article detailed their findings of the ability 
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of blinatumomab bispecific CD19 x CD3 antibody to engage all of the cytotoxic T-cells in 
patients and their ability to lyse cancer cells. They reported that doses as low as 0.005 milligrams 
of antibody per square meter body per day in non-Hodgkin’s lymphoma patients led to an 
elimination of all target cells in the blood (Bargou et al., 2008). Partial and complete tumor 
regression was observed at a low dose level of 0.015 milligrams. The team treated seven patients 
with relatively high dose levels of 0.06 milligrams, and 100% of the patients experienced tumor 
regression. The team also found that blinatumomab cleared tumor cells from bone marrow and 
liver. 
 
          In 2011, Dr. Gerhard Zugmaier and his colleagues at Micromet (Munich, Germany) (the 
same large research group discussed above for Drs. Baeuerle and Bargou) published their study 
in the Journal of Clinical Oncology, entitled “Targeted Therapy with the T-Cell-Engaging 
Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage 
Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged 
Leukemia-Free Survival” (Topp et al., 2011). This paper describes the team’s phase-II human 
clinical trials for efficacy of their CD19/CD3 bi-specific antibody vaccine for treating acute 
lymphoblastic leukemia (ALL).  21 patients were treated, and at the end of the study 16 of the 21 
showed a successful minimal residual disease (MRD).  12 of the 16 responders had been 
refractory to previous cancer treatments, so any improvement in their condition is significant.  
The most frequently observed side-effects were grade-3 and 4 lymphopenia, but were completely 
reversible.  So, this study shows the CD19/CD3 antibody treatment is efficacious and well-
tolerated against tumors that would otherwise cause a relapse. 
 
In 2012, the same team discussed above, but here led by Micromet’s collaborators at the 
University Hospital of Wuerzburg (Germany), published an article in Blood titled “Long-term 
follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients 
with MRD in B-lineage ALL” (Topp et al., 2012).  Twenty patients suffering from relapsing 
acute lymphoblastic leukemia (ALL) were treated in a phase-II clinical trial with the CD19/CD3 
bispecific Ab construct, and were observed for about 33 months. Their results showed 61% of 
the 20 patients had a hematologic relapse-free survival rate.  In a subgroup of 9 patients who 
progressed well enough to also receive an allogeneic hematopoietic stem cell transplant, 65% 
showed hematologic relapse-free survival (Topp et al., 2012). Of another subgroup of 6 patients, 
67% (4) showed ongoing hematologic and molecular ALL remissions. The study concluded that 
blinatumomab can induce a long-lasting (at least 33 months) complete remission in patients with 
B-lineage-persistent or recurrent ALL (Topp et al., 2012). 
 
 In 2014, Dr. Schlegel of the University of Tubingen (Germany) and his colleagues 
published a paper in Haematologica titled “Pediatric post-transplant relapsed/refractory B-
precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell 
engaging bispecific antibody blinatumomab” (Schlegel et al., 2014). Their study treated 9 post-
transplant relapsed pediatric patients with B-precursor acute lymphoblastic leukemia with 
blinatumomab on a compassionate use basis. The B-cell blast load (as an indicator of residual 
leukemia) was assessed prior to, during, and after blinatumomab cycle. The 9 patients were 
administered blinatumomab in a 4-week continuous intravenous infusion at a dosage of 5 or 15 
µg/m2/day, with a total of 18 cycles. Of the 9 patients, 4 achieved complete remission after their 
first cycle of treatment, 2 showed a complete remission after the second cycle, and the remaining 
3 patients did not respond to the treatment. After about a year, the patient’s chance of 
hematologic event-free survival was 30%. The treatment induced some side effects, with 1 
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patient experiencing grade-3 seizures and 2 patients experiencing grade-3 cytokine release 
syndrome, but those were eventually treatable.  This study shows that even patients with 
relapsing leukemia can successfully be treated with bispecific antibody treatment. 
 
           In 2015, an interesting study was published in Lancet Oncology, again by Dr. Topp’s team 
in Wurzburg, Germany (Topp et al., 2015). The study was entitled “Safety and Activity of 
Blinatumomab for Adult Patients with Relapsed or Refractory B-Precursor Acute Lymphoblastic 
Leukaemia: A Multicentre, Single-Arm, Phase-2 Study”. This clinical trial is registered at the 
website ClinicalTrials.gov (number NCT01466179). The authors treated 189 patients suffering 
from relapsed or refractory B-Precursor Acute Lymphoblastic Leukaemia (B-ALL) with the 
Blinatumomab CD19 x CD3 bispecific antibody.  After two treatments with the monoclonal 
antibody, 81 of the 189 B-ALL patients (43%) showed complete cancer remission. In a best 
practice of open data release, the study listed the negative side-effects of the vaccine. The most 
frequent adverse events were febrile neutropenia (25%), neutropenia (16%), and anemia (14%).  
2% of the patients showed grade-3 cytokine release syndrome.  3 deaths due to sepsis from E. 
coli and Candida were thought to result from the treatment, as they are hindering the patient’s 
ability to produce antibodies, so this topic is worth following up in interviews as to how to 
minimize these opportunistic infections.  Although this vaccine produced several documented 
side-effects, saving the patient’s life likely is of more direct concern, but it will be important to 
verify that the side effects were treatable. 
  
 
Other Bi-Specific Antibodies 
   
In addition to therapies against CD19 on B-cells, other bispecific antibodies have been 
designed against other tumor markers. Examples of non-CD19 bispecific antibodies include: 
CD3 T-cell activator x anti-glioma marker (Nitta et al., 1990), folate receptor on ovarian cancer 
cells x CD3 T-cell activator (Canevari et al., 1995), CD16 x CD30 for Hodgkin’s disease 
(Hartmann et al., 1997), CD319 x CD28 for B-cell lymphomas (Daniel et al., 1998), CD64 x Fc-
Receptor for B-cell lymphomas (Honeychurch et al., 2000), CD30 x CD64 for Hodgkin’s 
lymphoma (Borchmann et al., 2002).   
 
In 1990, a study was done by Dr. Nitta of the Juntendo University School of Medicine 
(Japan) in which 10 patients with malignant glioma received lymphokine-activated killer (LAK) 
cells treated in vitro with bispecific antibody against CD3 T-cell activator and anti-glioma 
marker (Nitta et al., 1990). 10 glioma patients were treated with LAK cells activated by the 
bispecific antibody, and 10 patients received untreated LAK cells.  While 9 patients relapsed 
(and 8 died within 4 years) in the control group, in the antibody-treated group 0 patients relapsed 
(in 18 months), 4 showed tumor regression and 4 showed tumor eradication. This study showed 
that bi-specific antibodies can be effective against gliomas, and warrants further research in the 
field. It would be interesting to find out if there were any side effects associated with the study.  
 
In 1995, a study was done on patients with ovarian carcinoma who relapsed after 
chemotherapy. The study was led by Dr. Canevari in Italy using autologous peripheral blood T-
lymphocytes that were retargeted in vitro using a bispecific antibody against the folate receptor 
present on ovarian cancer cells and the CD3 T-cell activator (OC/TR) (Canevari et al., 1995). 
Before treatment, the patients underwent surgery to reduce the tumor load, and were then given 
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five daily intraperitoneal infusions of the antibody, a second similar treatment, and IL-2. Of the 
19 patients evaluated, 3 showed complete responses (lasting an average of 22 months), 1 showed 
complete intraperitoneal response with progressive disease in the lymph nodes, 3 showed partial 
responses, 7 had stable disease, and 5 showed progressive disease. They concluded that immune-
therapy of ovarian cancer with bispecific mAb-retargeted T-lymphocytes can result in tumor 
regression with transient and mild toxicity.  
 
In 1997, Dr. Hartmann of Detmold Germany and his team published an article in Blood 
detailing their findings treating patients with refractory Hodgkin’s disease with a bispecific 
monoclonal antibody against natural killer cell activator CD16 and tumor marker CD30 
(Hartmann et al., 1997). They treated 15 Hodgkin’s patients where chemotherapy and/or 
radiation therapy had failed. Their results varied greatly, with 1 patient experiencing complete 
remission lasting 16 months, one patient experiencing partial remission lasting 3 months, 3 had 
minor responses, and 1 mixed response. Side effects were rare, and consisted of fever, lymph 
node pain, and a rash. Despite the varying results, the data are promising but requires more 
research to determine optimal antibody dose. It would be interesting to pursue in interviews why 
they believe their results were so varied. 
 
In 2002, Dr. Borchmann of the University Hospital of Cologne (Germany) and his 
colleagues published an article in Blood titled “Phase 1 trial of the novel bispecific molecule 
H22Ki-4 in patients with refractory Hodgkin lymphoma” (Borchmann et al., 2002). Their study 
targeted CD30 rather than CD19 in the immunotherapy of Hodgkin lymphoma (HL), and also 
targeted immune activator CD64.  Ten patients with refractory CD30+ lymphoma were treated 
with different doses (1.0, 2.5, 5.0, 10.0, and 20.0 mg/m2/d) administered intravenously on days 
1, 3, 5, and 7. The main study objectives were to determine the maximum tolerated dose and the 
dose-limiting toxicities.  The observed side effects were transient and mild.  The most serious 
were hypotension (4 of 10), tachycardia (6 of 10), fatigue (10 of 10), and fever (2 patients with 
grade-I, and 3 patients with grade-II). The administered antibody half-life was about 11.1 hours, 
resulting in a significant antibody accumulation. The response included 1 complete remission, 3 
partial remissions, and 4 with stable disease (Borchmann et al., 2002). 
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Immune Checkpoint Vaccines 
 
          One of the most exciting advances in cancer vaccine research in the past decade is the 
discovery that T-cells which have migrated into a patient’s tumor in the body’s attempt to fight 
the tumor often become inactivated by the tumor.  Proteins present on the tumor surface (such as 
PD-1 and CTLA-4) engage inhibitory receptors on the surface of the T-cells to inactivate them 
(reviewed in: Toplian et al., 2012). To overcome this immune suppression, scientists are 
researching the use of antibodies against the inhibitory receptors to “block the blocker” and 
stimulate the T-cells to attack the cancer. The immune system blockers discovered to date 
include programmed death-1 (PD-1) and cytotoxic T-lymphocyte-associated protein-4 (CTLA-
4).  This approach provides a new and exciting approach to cancer vaccines that is different than 
the previously discussed cases.   
 
However, the technique has some problems that must be solved.  By stimulating the 
immune system, some patients develop autoimmunity (the immune system is stimulated to react 
with the body’s own tissues) or inflammation (Melero et al., 2007).  So the topics of autoimmune 
or inflammatory side-effects are worth asking about in interviews. Some scientists have observed 
promising synergistic effects when they combine vaccines directed against tumor antigens with 
vaccines directed against PD-1, so this future topic of mixed vaccines is also worth follow-up 
questions in interviews. 
 
 
PD-1 and PD-L1 Vaccines 
 
          Programmed death-1 (PD-1) is an inhibitory receptor present on the surface of activated T-
cells (Freeman et al., 2000).  When the PD-1 receptor is engaged by its ligand (programmed 
death-ligand-1, PD-L1), signal transduction events decrease T-cell function and limit immune 
memory. Activation of PD-1 suppresses T-cell migration, T-cell proliferation, secretion of 
cytotoxic mediators, and restricts tumor cell killing (Herbst et al., 2014).  Thus, activation of PD-
1 to suppress immunity is often an important reason that growing tumors “avoid” the patient’s 
immune system (Hirano et al., 2005; Topalian et al., 2012; Sznol and Chen, 2013; Herbst et al., 
2014). The purpose of delivering antibodies against PD-1 is to bind and inactivate the PD-1 
receptor to allow T-cell functions to remain active in the patient to remove the tumor.  
  
       The most researched anti-PD-1 monoclonal antibody is Nivolumab (marketed as 
Opdivo).  It was developed by Ono Pharmaceutical and Medarex (later acquired by Bristol-
Myers Squibb), and was approved by the FDA on December 22, 2014, for treating patients with 
non-surgically treatable metastatic melanoma no longer responsive to chemotherapy. On March 
4, 2015, Nivolumab was approved by the FDA for treating squamous non-small cell lung cancer. 
Several studies have investigated the use of Nivolumab for melanomas (Topalian et al., 2014), 
Hodgkin’s lymphoma (Ansell et al., 2015), and non-small cell lung cancer (Gettinger et al., 
2015; Rizvi et al., 2015; Tanner, 2015). 
 
          In one vaccine example, Dr. Suzanne L. Topalian’s team at Johns Hopkins University 
School of Medicine conducted an ongoing clinical trial using antibody Nivolumab against PD-1 
(Topalian et al., 2014).  They assayed some of the long-term effects of the vaccine in advanced 
melanoma patients after removal of the therapy.  Their data with 107 patients showed a mean 
62 
overall survival of 16.8 months for the treated patients, with 1-year and 2-year survival rates of 
62% and 43%, respectively. They concluded that the beneficial effects were durable and 
persisted after drug discontinuation, and that antibody safety was acceptable (with toxicity rates 
similar to previous reports). So, the PD-1 vaccine approach appears to have some promise for 
extending the lifespan of patients with advanced melanomas.  It would be interesting to 
determine whether this research group has tried combining their PD-1 approach with antibodies 
against tumor proteins. 
 
          In another example, Dr. Scott N. Gettinger and his colleagues at the Yale Cancer Center in 
New Haven (CT) treated patients suffering from advanced non-small cell lung cancer (NSCLC) 
with an antibody against anti-programmed death-1 (PD-1) (Gettinger et al., 2015). Their 
previous phase-I trial showed the antibody treatment was generally well tolerated in NSCLC 
patients.  In this phase-II study, they showed in 22 NSCLC patients that the drug produced 
“durable immune responses and encouraging survival rates”.  So, this study shows that 
stimulating the immune system in a general way by blocking a protein that is suppressing the 
immune response can be an effective treatment for NSCLC. The authors also report that 14% of 
the patients showed grade-3 or -4 treatment-related adverse events, so it would be interesting in 
an interview to determine whether the observed side-effects were fully treatable. 
 
          In another recent study published in the April 3 issue of Science, Rizvi et al. (2015) 
analyzed nonsynonymous mutations (mutations producing amino acid changes, neoantigens) in 
patients with non-small cell lung cancer patients. The patients were treated with 
Pembrolizumab, an antibody against PD-1. The data showed that higher neoantigen formation 
in the tumor (presumably providing new targets for the immune system to attack) was associated 
with durable clinical benefits and progression-free patient survivals. The anti-PD-1 treatment 
was found to enhance the formation in vivo of T-cells against the neoantigens. So, this recent 
data indicates that the formation of an immune response against cancer neoantigens occurs 
naturally in some patients, is boosted by anti-PD-1 treatment, and correlates with better patient 
prognosis.   
 
          At the May 30, 2015, meeting of the American Society of Clinical Oncology in Chicago, 
scientists reported their findings of a study performed at Johns Hopkins University treating 600 
patients with non-small cell lung cancer, the most common form of lung cancer (Tanner, 2015).  
They randomly treated the patients either with Nivolumab (Opdivo) (an antibody against PD-1) 
or with docetaxel chemotherapy.  The median survival rate increased from 9 months (for the 
chemotherapy group) to 12 months (for the immunotherapy group), and the tumors shrank in 
12% of the chemotherapy patients versus 20% of the immunotherapy patients. These data may 
not seem highly significant (they are not complete cures), but any success against highly 
metastatic tumors that are so common is regarded as a success.  Dr. Richard Schilsky, Chief 
Medical Officer for the American Society of Clinical Oncology, the meeting’s organizer stated 
“These drugs are among the most promising drugs that have come along in many years” (Tanner, 
2015).   
 
 In addition to the above mentioned studies, PD-1 antibodies have also been used to treat  
diffuse large B-cell lymphoma (Armand et al., 2013), refractory solid tumors (Brahmer et al., 
2010), and melanoma (Hamid et al., 2013; Robert et al., 2014; Robert et al., 2015). 
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CTLA-4 Vaccines 
 
          Discovered in 1987 (Brunet et al., 1987), CTLA-4 (cytotoxic T-lymphocyte-associated 
protein-4) (also known as CD152) is a protein receptor located on the surface of T-cells that 
functions to down-regulate the immune system. CTLA-4 acts as an "off" switch when bound to 
ligands CD80 or CD86 on the surface of antigen presenting cells (Walunas et al., 1994).  T-cells 
that migrate to tumors (tumor infiltrating lymphocytes) sometimes become inactivated by the 
cancer through the CTLA-4 pathway, so scientists are using antibodies against CTLA-4 to 
activate the T-cells and restore their activity against the tumor (reviewed in: Peggs et al., 2006; 
Cha et al., 2014).  Early studies using anti-CTLA-4 antibodies to fight cancer were done in mice 
(for example, Chen et al., 1992), and they later progressed to human patients. 
 
 
 In 2010, Dr. Hodi and his colleagues did a study comparing the treatment of metastatic 
melanoma patients with a combination of Ipilimumab CTLA-4 mAb and gp100 (a peptide 
vaccine) to patients treated only with gp100 (Hodi et al., 2010). Their results were promising, 
with the median overall survival of patients receiving Ipilimumab + gp100 around 10 months 
compared to 6.4 months for those receiving only gp100. The side effects observed were severe in 
only 10-15% of the patients receiving both treatments, and in only 3% of the patients receiving 
gp100, although most of the side-effects were manageable.  2.1% of the patients died from the 
study, 7 related to immune adverse events. The team concluded that Ipilimumab, with or without 
a gp100 peptide vaccine, is a better method of treatment for increasing survival than gp100 
alone. It would be interesting to interview Dr. Hodi and to find out how the side-effects were 
managed, and what they believe caused the deaths in the study. 
 
In 2012, Dr. Weber and his colleagues published an article in the Journal of Clinical 
Oncology titled “Management of immune-related adverse events and kinetics of response with 
Ipilimumab” (Weber et al., 2012). The article discusses the different kinds of immune-related 
adverse events associated with Ipilimumab, and the necessary treatments to manage them. The 
article states that one of the most important aspects of side-effect treatment is early recognition. 
It would be of interest in an interview to ask Dr. Weber if the side effects were all manageable. 
 
Snyder et al. (2014) used an innovative whole-exome DNA sequencing approach on 
tumor tissue taken from melanoma patients to identify marker proteins that best correlate with 
the success of anti-CTLA-4 treatments.  A cell’s exome is that portion of the DNA that codes for 
proteins (exons). Exome sequencing is a technique that sequences all the exon sequences in a 
genome (the exome). The exons are first isolated (by a targeted capture technique) and are then 
sequenced using any high throughput DNA sequencing technology (Ng et al., 2009). Human 
DNA contains about 180,000 exons, constituting only about 1% of the human genome 
(approximately 30 million base pairs), but mutations in these exons are more likely to have 
severe consequences than mutations in the remaining 99% (Ng et al., 2009). Snyder et al. 
obtained tumor tissues from melanoma patients treated with antibodies against CTLA-4 
(Ipilimumab and Tremelimumab) and performed whole-exome sequencing. They compared 
the exome sequences from 11 melanoma patients showing a long-term clinical benefit of CTLA-
4-blockage to the exome sequences of 14 patients who showed minimal antibody benefit. They 
then used bioinformatics to determine which neoantigen profiles correlated best with a successful 
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patient outcome.  Assaying for these markers in future patients might help determine which ones 
could benefit from the CTLA-4 antibody treatments.  This study was a nice combination of state-
of-the-art cancer vaccine approaches that stimulate the immune system with second-generation 
sequencing methods for analyzing large amounts of sequence data. 
 
 In 2015, a study was done for melanoma patients who progressed after treatment of 
Ipilimumab (Weber et al., 2015). The study compared treatment of advanced melanoma patients 
who had not responded to Ipilimumab to treatments with Nivolumab (a PD-1 inhibitor antibody) 
or standard chemotherapy (ICC). The results were very positive: 38 of 120 (31.7%) of the 
patients treated with Nivolumab showed positive responses, compared to 5 out of the 47 (10.6%) 
for patients treated with ICC. The side effects of Nivolumab included increased lipase, increased 
alanine aminotransferase, anemia, and fatigue. The side effects of ICC patients included 
neutropenia, thrombocytopenia, and anemia. The study noted grade-3 to 4 serious adverse events 
in 5% of Nivolumab-treated patients, and in 9% of patients treated with ICC. There were no 
treatment-related deaths. 
  
 In 2015, Dr. Lussier and her colleagues did a study of PD-1 blockade as a therapeutic 
strategy against metastatic osteosarcoma, the most common bone cancer in children and 
adolescents (Lussier et al., 2015).  Osteosarcoma is sometimes curable by chemotherapy and 
surgical resection, but patients with metastatic osteosarcoma are sometimes refractory to 
treatment. Dr. Lussier and her colleagues researched the role of PD-1 in limiting the 
effectiveness of cytotoxic T lymphocytes (CTLs). The study showed that by blocking PD-1/PD-
L1 interactions, osteosarcoma tumor burden and overall survival was increased.  She later 
followed up this study with a combination PD-1 + CTLA-4 study, discussed below. 
 
 
Combination Vaccines (PD-1 + CTLA-4) 
 
 Some scientists have experimented with combination vaccines using both anti-PD-1 and 
antib-CTLA-4 antibodies.  This combination approach appears to be even more successful than 
using single antibody approaches. 
 
In 2013, Dr. Wolchok and his colleagues published an article in The New England 
Journal of Medicine titled “Nivolumab plus ipilimumab in advanced melanoma” (Wolchok et al. 
2013). The article detailed their investigation of treatment of melanoma patients with a 
combination of Nivolumab (PD-1 inhibitor) and Ipilimumab (CTLA-4). The combination 
treatment was rationalized because of their “distinct immunologic mechanisms of action and 
supportive preclinical data” (Wolchok et al. 2013).  53% of the patients treated with the 
combination therapy reached the objective response rate with a tumor reduction of 80% or more, 
compared to only 20% of individually or sequentially-treated patients. Grade-3 and 4 side-effects 
occurred in 53% of the combined antibody patients, and in 18% of the sequentially treated 
patients. However, the study noted that the side-effects of the concurrently treated patients were 
qualitatively similar to monotherapy side-effects, and were generally reversible.  
 
In 2013, a study was done in mice by Dr. Duraiswamy and his colleagues which 
concluded the dual treatment was superior to individual treatments. In this study, mice treated 
with antibodies against both PD-1 and CTLA-4 rejected various types of tumors injected into the 
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mice (Duraiswamy et al., 2013). When the two drugs were combined, 100% of the CT26 tumors, 
and 75% of the ID8-VEGF tumors were rejected from the mice. Their evidence further supports 
combined PD-1 CTLA-4 therapy.  
 
In 2013, Dr. Weber and his colleagues did an interesting study of sequential therapy with 
patients resistant to treatment with Ipilimumab + Nivolumab (Weber et al., 2013). The study 
took patients who were resistant to one drug and treated them with the other. They found that in 
most cases the second drug was well received and that after administration of the second drug, 
the first was also received.  
 
In 2015, Dr. Lussier of Arizona State University (mentioned above in the study of 
osteosarcoma) and her colleagues conducted a study on the combined treatment of metastatic 
osteosarcoma with CTLA-4 + PD-L1 antibodies (Lussier et al., 2015). Their results indicated 
that a combination blockade prevented tumor immune escape and led to complete control of 
metastatic osteosarcoma in a mouse model.  The mice were also resistant to any further tumor 
cell injections. 
 
So, the combination PD-1 + CTLA-4 treatment appears to be more effective than either 
antibody alone, and is a promising future method of therapy. 
 
 
Section Conclusions and Problems 
 
Overall, the use of antibodies against tumor antigens has proven to be a successful 
approach in cancer therapies, and have provided complete cancer remissions in some 
experiments.  The use of antibodies against CD19 on B-cells has been quite promising, and this 
antigen appears to be an especially good target for removing early stage B-cells in leukemia.  
Other successes have been achieved with difficult to treat cancers such as gliomas and ovarian 
cancers.  Especially promising are the use of bi-specific antibodies that combine in one antibody 
molecule a reactivity against a tumor antigen (like CD19) with a reactivity against an immune 
activator (like CD3 on T-cells).  This bi-specific approach uses the antibody molecule itself to 
bring the tumor cell into close proximity with the T-cell that will kill it. Of equal promise is the 
use of antibodies against immune checkpoint inhibitors, such as PD-1 and CTLA-4, which 
remove the immune suppression provided by the tumor.  Recent experiments have also shown 
that tumors as they grow and divide often produce new DNA mutations, and if those mutations 
occur in exon portions of the genome, they encode new neo-antigens that act as excellent targets 
for the antibody therapies.  Strong patient antibody responses to neo-antigens correlate strongly 
with better patient prognosis. Some scientists have observed promising synergistic effects when 
they combine vaccines directed against tumor antigens with vaccines directed against PD-1, so 
this future topic of mixed vaccines is also worth follow-up questions in interviews. 
 
However, the antibody approaches appear to have some problems that should be followed 
up in interviews.  In some cases, grade-3 and 4 (serious) side-effects appear to be caused by the 
vaccine, although most of the side-effects appear to be relatively mild, transient, and are 
treatable.  Also, when stimulating the immune system by PD-1 or CTLA-4 antibodies, some 
patients developed autoimmunity (the immune system is stimulated to react with the body’s own 
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tissues) or inflammation. So, for labs doing immune stimulation experiments the topics of 
potential autoimmune or inflammatory side-effects should be asked about.  
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Part-5:  DC Cancer Vaccines:  
Animal Experiments and Provenge 
Derek Brinkman 
 
 
Dendritic Cells (DCs) 
 
Discovered in 1973 in mice (Steinman and Cohn, 1973), dendritic cells (DCs) are 
important components of the mammalian immune system.  They get their name from their 
branched appearance at specific stages of their development. DC’s are potent “professional” 
antigen-presenting cells; their main function is to recognize foreign antigens (usually small 
epitope domains of proteins) on the surface of invading pathogens (and sometimes cancer cells), 
process the antigen within the cell, and then present it on its surface to other cells of the immune 
system (T-cells and B-cells) so they can commit to recognizing that particular foreign antigen 
and attack the tumor to reduce its mass (Banchereau and Steinman, 1998; Sallusto and 
Lanzavecchia, 2002; Trombetta and Mellman, 2005). Half of the 2011 Nobel Prize in Physiology 
or Medicine went to Ralph M. Steinman "for his discovery of the dendritic cell and its role in 
adaptive immunity" (The Nobel Prize, 2011). Because of this antigen presentation function, DCs 
are used in some types of cancer vaccines to induce an immune response against an antigen on 
the surface of a patient’s tumor cell.   
 
DCs are present in tissues that contact the external environment, such as skin (in that 
location they are called the Langerhans cell), and the inner lining of the nose, lungs, stomach and 
intestines. DCs can also be found in an immature state in the blood. Once activated by a foreign 
antigen, they migrate to the lymph nodes where they interact with the T-cells and B-cells to 
initiate the adaptive immune response against the foreign antigen.  As discussed in the 
Immunology section of this IQP, the migration of DCs to the lymph nodes to engage T-cells and 
B-cells distinguishes them from the non-migrating follicular dendritic cells.  
 
 
Dendritic Cells and Cancer Vaccines 
  
          With respect to cancer, tumor cells themselves in the body are poor antigen-presenting 
cells. Tumor cells are derived from normal cells by DNA mutation. So, most of the proteins on 
the surface of cancer cells look like “self” to the immune system, and are ignored allowing the 
tumor to grow.  Only a small portion of the cancer DNA mutations create “neo-antigens” that are 
unique to the patient’s tumor, and these provide excellent candidates for cancer vaccine designs.   
 
 Even when tumor cells contain unique neo-antigens on their surface, DC cells are still 
required to process the neo-antigen and present it to the immune system to generate active B-cell 
and T-cell responses against the tumor (Palucka and Banchereau, 2012). Animal experiments 
(discussed below) have shown that DC cells are a required component of the body’s immune 
attack against cancer, and are required for activating CD8+ T-cells that infiltrate and attack the 
tumor.   
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          The aim of the DC-type tumor vaccine is to induce DC cells to present tumor antigens on 
the cell surface to stimulate the formation of immune cells, especially CD8+ tumor infiltrating 
lymphocytes (TILs) or cytotoxic T-lymphocytes (CTLs) that recognize, infiltrate, and attack the 
tumor (Davis et al., 2003; Steinman and Banchereau, 2007; Koski et al., 2008; Schuler, 2010; 
Ueno et al., 2010). In an ex vivo approach, the DC cells are usually isolated from a cancer 
patient’s peripheral blood mononuclear cells (PBMCs) using a variety of techniques, cultured to 
expand their numbers, and are then “pulsed” (mixed) with foreign tumor antigen (either purified 
antigen or entire tumor cells themselves). The treated DCs (that have processed the foreign 
antigen) are then injected back into the patient where they hopefully migrate to the lymph nodes 
to engage B-cells and T-cells to commit them against the tumor antigen. In a less used in vivo 
approach, DC cells in the body are induced to take up tumor-specific antigens, and the antigen-
presentation is done naturally to stimulate the T-cells. 
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DC Vaccine Animal Experiments 
 
          Animal experiments have been crucial for the current human patient clinical successes of 
DC cancer vaccines.  In some cases, animal experiments have provided the use of controlled 
experiments not possible in humans, while in other cases they provided initial tests of new DC 
therapies prior to moving into humans.  A few key experiments done on mice with DC vaccines 
are discussed below as examples. 
 
 In 2004, a team of scientists in the Department of Molecular Preventive Medicine in the 
School of Medicine at the University of Tokyo, experimented with DC precursor cells containing 
a surface protein “signature” of CD11-pos, B220-neg, F4-neg, CCR1-pos, CCR5-pos (Zhang et 
al., 2004).  In previous studies, the team showed the DC precursor cells rapidly mobilized into 
the circulation in mice infected with a test bacterium (Propionibacterium) and were recruited into 
inflammatory tissue by hormone MIP-1-alpha binding CCR1 and CCR5 receptors on the DC 
surface.  In this study, the team showed that mice genetically engineered to lack CCR1 or CCR5 
recruited less DC cells into the circulation than WT mice.  They also showed that injecting MIP-
1-alpha into the mice mobilized the DC cells, and that DC cells pulsed with B16 tumor lysates 
produced a strong anti-tumor response in vitro and in vivo.  So, this study shows that hormone 
MIP-1-alpha and its receptors are important in the DC response, and this hormone is worth 
asking about in DC vaccine interviews. 
 
 In 2006, a team in the Lymphocyte Biology Section of the Laboratory of Immunology, 
National Institute of Allergy and Infectious Diseases, NIH (Bethesda, Maryland) showed that the 
interaction of CD8+ T-cells and CD4+ helper T-cells with DC cells is important in the vaccine 
response (Castellino et al., 2006).  They also showed that the immunization process upregulates 
CCR5 receptor on naïve T-cells allowing their attraction to the DC and helper T-cell sites in the 
lymph nodes.  So, this paper also shows the importance of CCR5 type signaling in the DC 
vaccine process. 
 
In 2008, a team of scientists at the Institute of Health Sciences, Shanghai Institutes for 
Biological Sciences, Chinese Academy of Sciences (Shanghai, China) (containing some of the 
same team members from the 2004 study above) identified a different type of precursor DC cell 
in mice with the following surface signature: CD11c-pos, B220-neg, CCR5-neg, CCR1-neg, 
CCR6-pos (He et al., 2008).  These precursor DC cells differentiated into mature DC cells when 
treated with GM-CSF, IL-4, and TNF-alpha.  And hormone MIP-3-alpha treatment of the mice 
mobilized this subset of DC cells.  They showed that a combined treatment of MIP-1-alpha and 
MIP-3-alpha elicited strong anti-tumor responses, suggesting that a combination hormone 
strategy may improve vaccine effectiveness. 
 
          Modern animal experiments allow scientists to delete specific types of receptors on cells to 
determine whether those receptors and cells are required for a particular biological response. In 
the case of the immune system trying to suppress the growth of cancer cells, scientists showed 
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using mice that type I interferons (IFN-alpha and IFN-beta) are required to initiate the anti-tumor 
response (Diamond et al., 2011).  Using mice engineered to have DC cells lacking interferon 
type-1 receptors, they also showed that a DC cell response to the interferons is required for 
producing activated CD8+ T-cells against the tumor.   
 
This same result of the importance of type-I interferons in the anti-cancer response was 
shown in mice independently by another lab in the same year (Fuertes et al., 2011). So, these 
animal experiments show that DC cells are a critical part of the body’s attack on cancer, and 
underscore the importance of using them in immunotherapy treatments. 
 
Over the last 15 years, multiple studies have been performed on the relationship between 
natural killer (NK) cells and DCs. The results hypothesized that NKs play a role in DC 
maturation by killing immature DCs, leaving fully activated mature DCs. This was shown in 
vitro, but until recently, studies were lacking in vivo.  In a recent study of this relationship, 
researchers from the Department of Experimental Medicine at the University of Palermo, Italy, 
showed this DC cell lysis was indeed performed by NK cells in vivo in mice (Morandi et al., 
2012). The team reported a substantial decrease in CD11c+ immature DC cells in lymph nodes 
inoculated with YAC-1 cells, a MHC-negative cell line used to activate the NKs. The NK killing 
of immature DCs was dependent on perforin, as perforin-knockout mice failed to diminish the 
DC numbers.  The NK killing was also shown to increase the effectiveness of a cancer vaccine, 
increasing the CTL expansion against the tumor when the NKs were activated by the YAC 
injection.  Although the types of NK cells responsible for the immature DC killing and the sites 
of elimination are still unclear, the data show that activating NK cells may help improve the 
effectiveness of a cancer vaccine by helping mature DCs, leading to a strong activation of CTLs.  
A clearer picture of this relationship will hopefully be the subject of future experiments. 
 
In a 2014 study, conducted at the Campbell Family Institute for Breast Cancer Research, 
Princess Margaret Cancer Center, University Health Network (Toronto, Canada), a team created 
a transgenic mouse model for testing the effectiveness of various cancer vaccine strategies 
(Dissanayake et al., 2014). They engineered mice to express a target antigen on the surface of 
pancreatic islet cells, and measured the ability of different immune vaccine protocols to induce a 
response against the target antigen (as measured by the induction of diabetes).  They found that a 
DC vaccine using DC cells primed against the target antigen was far more effective than 
injecting the target antigen itself, with or without an adjuvant.  And in further important findings, 
the best vaccine allowed the primed DC cells to mature prior to infusion and occurred when the 
DC cells were primed against more than one epitope. 
 
In June of 2015, an interesting study was done by a team of scientists in the Department 
of Medicine, Weill Cornell Medical College (New York, NY) in mice, identifying a new 
pathway in DC cells that inhibits their function (Cubillos-Ruiz et al., 2015).  Previous studies had 
shown that endoplasmic reticulum (ER) stress response factor XBP1 directly promotes tumor 
cell growth, but it was not known whether XBP1 affected the DC cells that had migrated to a 
tumor.  In a mouse model of ovarian cancer, the team showed that XBP1 becomes activated 
within the DC cell in response to reactive oxygen species (ROS) and lipid peroxidation, limiting 
their ability to support anti-tumor T-cells.  And in an experiment that could only be done in 
animals, not humans yet, they showed that deleting XBP1, or inhibiting it by siRNA, restores DC 
function and induces a type-1 anti-tumor response. This study offers a new unique approach for 
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restoring the function of DC cells by blocking an inhibitory pathway, and perhaps could be 
combined with the use of tumor-specific antigens as a vaccine. 
 
Although some scientists argue that cancer vaccines as a whole have yet to produce high 
efficacy levels in clinical trials, using animal models, much knowledge is being gained about 
improving vaccine effectiveness and for determining exactly which immune cells are involved. 
Scientists have learned much about DCs and their immunological role in the body. From the 
groundwork laid with animal studies, hopefully the ongoing clinical trials will be informed by 
their findings to improve the results in human patients. 
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DC Cancer Vaccine for Prostate Cancer: Provenge 
 
          The first cancer vaccine approved for use in the U.S. by the FDA was Provenge (also 
called Sipuleucel-T or APC8015). Provenge is a DC-type vaccine designed for prostate cancer.  
In the U.S., prostate cancer is the second leading cause of cancer death in men (after skin 
cancer).  According to the National Cancer Institute (2015), an analysis of the data from 2008-
2012 prostate cancer cases showed approximately 137.9 new cases (and 21.4 deaths) per year per 
100,000 men. About 14.0% of all men will be diagnosed with it during their lifetime, and there 
are approximately 2,795,592 men living with it in the U.S. 
 
          Provenge was developed in the early 1990’s by two scientists: Edgar Engleman, an 
immunologist at Stanford University (who had been studying cancer vaccines for lymphomas), 
and Samuel Strober.  In 1992, those two scientists founded Dendreon Corporation (Seattle, WA). 
In spite of Engleman’s early success in animals with lymphomas, they chose to pursue prostate 
cancer, in part because more people have it, and also because men can live without a prostate, so 
if anything went wrong with the vaccine and it destroyed healthy prostate tissue it would not be 
fatal (Ledford, 2015). 
 
          Provenge consists of autologous (taken from the same patient) peripheral blood 
mononuclear cells (PBMCs) (a cell mixture that includes DCs) taken from the patient by 
leukapheresis. The PBMCs are cultured to increase their numbers, and are then mixed for 2 days 
in vitro with a recombinant fusion protein (PA-2024).  PA-2024 contains prostatic acid 
phosphatase (PAP) (expressed in a majority of prostate adenocarcinomas) (Goldstein, 2002) 
linked to granulocyte macrophage colony stimulating factor (GM-CSF) (to help activate the 
immune system). After the DCs are pulsed or primed against PA-2024, the DCs process the 
antigen within the cell and present it on their surface. The DC cells are perfused back into the 
same patient over a 30 minute period.  Once in the body, the DCs migrate to the lymph nodes 
and present the tumor antigen to B-cells and T-cells to activate them against the prostate cancer.   
 
In 2010, Provenge made history by being the first cancer vaccine approved by the FDA 
for use in the U.S. (Ledford, 2015). Dendreon Corporation was the first company to show that 
complex cell treatments prepared fresh from each patient could be made reactive against an 
antigen on the surface of prostate cancer cells, could be expanded in vitro, and could be placed 
back in the same patient without rejection.  Provenge is usually touted as the main early success 
story of DC-type cancer vaccines. 
 
          Provenge has already undergone several clinical trials in human patients. Small et al. 
(2000) performed a combined Phase-I and -II clinical trial of Provenge on a small number of 
patients with hormone-refractory (androgen resistant) prostate cancer. The main point of the 
study was safety, not efficacy, and the patients appeared to tolerate the treatment well. The most 
common side-effect observed was fever, occurring in about 14.7% of the patients. All of the 
patients developed an immune response against the PA-2024 recombinant stimulatory protein 
mixed with the DCs. Three patients showed a 50% decline in PSA levels (an indicator of prostate 
cancer lowering). 
 
          In 2000, scientists at the Mayo Clinic (Rochester, MI) performed a phase-I test of 
Provenge on 13 patients with progressive hormone-refractory metastatic prostate carcinoma 
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(Burch et al., 2000). The purpose of the phase-I test was safety, and the treatment appeared to be 
well tolerated.  The patients experienced only mild grade-1 and -2 side effects, such as fever, 
chills, myalgia, pain, and fatigue.  Only 1 of the 13 patients developed grade-3 fatigue.  
Circulating levels of PSA dropped in 3 patients, an indicator of cancer lowering. T-cells drawn 
from patient blood after the treatments, but not before the treatments, could be stimulated in vitro 
with components of the DC antigen mix (GM-CSF and PAP), indicating the patient’s had 
overcome their previous self-tolerance of those key proteins, and had now created T-cells 
committed against those tumor antigens. 
 
          In 2004, the same Mayo Clinic group performed a phase-II test of Provenge on 21 patients 
suffering from androgen-independent prostate carcinoma (Burch et al., 2004). Most of the side-
effects were grade-1 and -2, with only 4 of the 21 patients showing grade-3 or 4 side-effects.  2 
of the 21 patients showed a 25-50% drop in PSA levels, and one patient dropped PSA to 
undetectable levels and resolved his cancer.  It is not clear in this study why only 2 of 21 patients 
lowered their PSA levels, so perhaps this indicates the Provenge vaccine should be combined 
with other vaccines to stimulate the immune system. 
 
          In 2005, scientists at the MD Anderson Cancer Center (Houston, TX) performed a phase-II 
test of Provenge on 18 patients with non-metastatic prostate cancer who had not responded to 
previous treatments (Beinart et al., 2005). 13 of the 18 patients slowed the rate of increase of 
their serum PSA levels, with a median increase in doubling time of 62% (4.9 months before 
treatment, 7.9 months after treatment, p=0.09). So, in this experiment a higher percentage of 
patients responded to the vaccine, and it appeared to be well tolerated. 
 
          In 2009, scientists at the Seattle Cancer Care Alliance published the results of a Provenge 
phase-III clinical trial (Higano et al., 2009).  The trial was a randomized, double-blind, placebo-
controlled phase-III clinical trial of Provenge, testing a total of 225 patients suffering from 
advanced prostate cancer. The patients were treated with Provenge (147 patients) or placebo (78 
patients). They found an average 33% reduction in death for the patients receiving Provenge 
versus the placebo (p=0.011), a significant outcome. The beneficial effects of Provenge remained 
strong even after correcting for baseline prognostic factors, post-study chemotherapy, and non-
prostate cancer deaths. The most common Provenge-induced side-effects were chills, pyrexia 
(fever), headache, asthenia (weakness), dyspnea (labored breathing), vomiting, and tremor, all of 
which were only grade-1 or -2, with short durations of only 1-2 days.  So, in this experiment the 
vaccine caused only modest toxicity while showing statistically significant clinical 
improvements for the patients. 
 
          In 2010, scientists at the Dana Farber Cancer Institute (Boston, MA) performed a different 
phase-III test on 512 patients with metastatic castration-resistant (androgen-independent) 
prostate cancer (Kantoff et al., 2010).  In a double-blind, placebo-controlled, multi-center trial, 
Provenge was given to 341 patients (administered intravenously every 2 weeks for a total of 3 
infusions), and a placebo was given to 171 patients. The Provenge patients saw an average 22% 
reduction of death, with survival extending from 21.7 months to 25.8 months (an improvement 
of 4.1 months). Adverse effects included chills, fever, and headache. Overall, the phase-III 
results were not as dazzling as hoped for, but did provide a proof-of-principle that cancer 
vaccines can improve lifespan in a large cohort of patients. 
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 In 2011, scientists in the Laboratory for Tumor and Transplantation Immunology, 
University Hospital of Cologne (Cologne, Germany) performed a systematic review of the 
literature on 17 DC clinical trials for prostate cancer to determine whether there is a significant 
link between the immune responses induced by the vaccine and improved clinical outcomes 
(Draube et al., 2011).  Overall, a clinical benefit (stable disease) was observed in 54% of the 
prostate cancer patients receiving the vaccine that significantly correlated with a T-cell immune 
response against the tumor.  High DC doses also significantly correlated with clinical benefit. 
 
          But in spite of Provenge’s U.S. approval and measurable (but minor) efficacy, Dendreon 
Corporation (Seattle, WA) (the innovative biotech company who developed Provenge) 
financially collapsed (Ledford, 2015). The company was strained by the long 18-year wait from 
its initial foundation in 1992 to the 2010 approval by the FDA. Although the procedure was 
approved by Medicare in 2011, confusion over reimbursement by private insurance companies 
left many U.S. doctors reluctant to use the expensive procedure (about $73,000 per treatment), so 
revenues came in far below the company’s initial estimates. And at the same time, the vaccine 
results were not as dazzling as they hoped for.  As discussed above, one phase-III study showed 
the vaccine only extended survival time by a median of 4.1 months (Kantoff et al., 2010).  
 
On February 23, 2015, the rights to the Provenge vaccine and the assets of the bankrupt 
Dendreon were purchased by Valeant Pharmaceuticals (Laval, Canada). Valeant hopes to 
continue to develop and use Provenge. 
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DC Vaccines for Melanoma 
 
          The DC vaccine approach has also been applied to patients with malignant melanoma. 
Melanoma is a type of skin cancer that forms from pigment-containing melanocytes in the skin 
(Bajetta et al., 2002). Although it is less common than other types of skin cancers, melanoma is 
much more deadly if not detected early, causing the vast majority (75%) of skin cancer deaths 
(Jerant et al., 2000). In 2012, melanoma occurred in about 232,000 people worldwide, resulting 
in 55,000 deaths (World Cancer Report, 2014). Its incidence is strongly related to exposure to 
ultraviolet (UV) light (Wang et al., 2001; Kanavy and Gerstenblith, 2011) relative to the amount 
of skin pigmentation to protect from UV exposure (Jost, 2003), so it is especially common in 
Caucasians living in sunny climates.  If found early, the typical treatment is surgical removal of 
the tumor.  If completely removed, the chance of survival is high. But if the melanoma recurs or 
spreads deep, other treatments are used including chemotherapy or radiation therapy. 
 
          One of the earliest attempts to treat melanoma patients with DC cells was in 1998 by a 
group of scientists at the University of Zurich Medical School (Switzerland) (Nestle et al., 1998).  
In a clinical pilot study, these scientists treated 16 patients with advanced melanoma.  The 
patient DC cells were pulsed with either tumor lysate from the same patient, or were pulsed with 
a mixture of peptides known to be recognized from animal studies against melanoma.  The 
vaccinations appeared to be well tolerated, and did not generate any visible autoimmune 
responses.  11 of the 16 patients showed immune responses against the vaccine and the 
recruitment of CTLs to a challenge site.  Regression of metastases was observed in 5 of the 16 
patients. 
 
 In 2000, Dr. Andreas Mackensen and his group published their findings in an 
International Journal of Cancer article entitled “Phase I study in melanoma patients of a vaccine 
with peptide-pulsed dendritic cells generated in vitro from CD34+ hematopoietic progenitor 
cells” (Mackensen et al., 2000). They vaccinated 14 patients with peptide-pulsed DC cells 
generated in vitro from hematopoietic progenitor cells. Each patient received at least 4 
vaccinations, and was monitored before each vaccination and 4 weeks after the final vaccination.  
Of the 14 patients, 4 showed strong immunological responses. 2 of the 14 showed anti-tumor 
responses, including regression of metastasis. 1 patient developed vitiligo, but that skin 
discoloration was minor and treatable. This early study appears to show a modest vaccine 
success, but did provide proof-of-principle that DC vaccines can cause remissions in some 
patients. 
 
In 2001, a group of scientists from the Rockefeller University published their findings on 
the immune effects of subcutaneous injections of progenitor-derived DC vaccines (Banchereau et 
al., 2001). 18 patients were vaccinated with melanoma peptide-pulsed DCs four times. The 
peptides used for the pulsing were derived from 4 different melanoma specific antigens. The 
vaccine seemed to be well tolerated, except 2 patients showed progressive vitiligo (skin 
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discoloring). 16 of the 18 patients showed enhancement of CD8+ T-cell immunity. The scientists 
further analyzed 12 of these patients and published their results in 2004 (Paczesny et al., 2004). 
According to their study, 9 out of 12 vaccinated patients with metastatic melanoma expanded 
their cytolytic CD8+ T-cell precursors. After single re-stimulation by melanoma peptide-pulsed 
DC cells, these precursors differentiated into cytotoxic T-lymphocytes (CTLs) that were able to 
kill melanoma cells. So, 9 of 12 patients developed CTLs capable of destroying melanoma cells.  
3 of the patients who did not show melanoma-specific CTLs had early disease progression.  
 
In 2005, a team of scientists in the Division of Hematology-Oncology, Department of 
Medicine, Massachusetts General Hospital (Boston, MA) treated 12 patients suffering from 
advanced melanoma with DC cells pulsed with tumor-specific peptide G280-9V.  The patients 
were treated every 3 weeks with 6 doses of cells, in an escalating dose regime.  67% of the 
patients showed CD8+ cells reactive against peptide G280, and 9 of 9 patients tested had T-cells 
that were able to lyse tumor cells in vitro.  3 of the 9 patients tested showed stable disease, and 2 
showed partially stable disease.  This study shows that peptide G280 appears to be a good 
candidate for pulsing DC cells against melanoma. 
 
In 2006, Dr. Salcedo’s group at the IDM Research Laboratory (Paris, France) published 
their finding on the immune responses to a DC vaccine loaded with allogeneic (genetically 
unrelated) tumor cell lysates (Salcedo et al., 2006). Instead of using tumor cells from the same 
patient, they made a tumor cell bank from a M17 tumor cell line that is known to express high 
level tumor-specific antigens, and used that cell line as the source of tumor lysates. DC vaccines 
pulsed with allogeneic tumor lysates appeared to be more reproducible and had a better control 
of quality compared with autologous tumor lysate-pulsed vaccines. 15 patients were included in 
this study, and 9 of them received all four doses of vaccine. 11 of the 15 showed enhancement of 
immune responses against targeted antigens. 2 out of 9 evaluable patients showed clinical 
responses and received more vaccines. Of these two patients, one showed complete cancer 
regression, the other one showed disease stabilization. One patient had no evidence of disease 
after resection surgery.  Because some scientists had debated whether it is best to use mature 
DCs (Adema et al., 2005; Nestle et al., 2005), Dr. Salcedo’s team compared DCs matured ex 
vivo and non-matured DCs in another study, and suggested that there is no difference in the 
immune response rates. They believe that other ways of DC maturation, however, could result in 
improvement of vaccine efficacy. 
 
In 2009, a team of scientists in the Department of Oncology at Herlev Hospital (Herlev, 
Denmark) performed a data review of 38 published articles using DC vaccines to treat a total of 
626 patients with malignant melanoma (Engell-Noerregaard et al., 2009). Their data showed that 
improved clinical responses appeared to correlate with the use of peptide antigens to pulse the 
DC cells (p=0.03), the use of adjuvant (p=0.002), and the induction of antigen-specific T-cells 
(p=0.0004).  No specific route of vaccination administration was superior to another. 
 
In 2011, a group of scientists in the Department of Medical Oncology at the Nijmegen 
Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre (Nijmegen, 
The Netherlands) published their paper entitled “Cell Vaccine–Induced Antigen-Specific T Cells 
in Advanced Melanoma Patients” (Lesterhuis et al., 2011). 43 patients were vaccinated with 
peptide-loaded DCs via intradermal or intranodal injection. In 7 out of 24 patients, no DC 
redistribution was found at all after intranodal vaccination, whereas in all of the intradermally 
vaccinated patients at least a small percentage of injected DCs migrated to other lymph nodes. 
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Both intranodal and intradermal vaccinations induced melanoma-specific T-cells, but intradermal 
vaccinations more often induced functional T-cells that could recognize tumor cells.  This study 
indicates that intradermal injection may be superior to intranodal injection for inducing 
immunological responses.  
 
          In 2013, Dr. Beatriz Carreno and her team at Washington University School of Medicine 
(St. Louis, MO) published their findings of the clinical outcomes of 7 patients with stage IV 
(advanced) melanoma (Carreno et al., 2013). The patients were vaccinated with DC cells pulsed 
against cancer antigen gp100.  Six of the 7 patients showed sustained T-cell responses (against 
the tumor); of those 6 patients, 1 patient showed complete remission, and 2 showed partial 
remission. Strong improvement correlations were observed for patients perfused with DC cells 
producing the hormone IL-12, and for patients with strong T-cell responses to the vaccine.  So, 
this paper indicates that screening for DC cells that are functional enough to produce IL-12 (or 
supplementing the vaccine with IL-12) might help improve vaccine outcome.  This IL-12 
conclusion was also discussed by the same team in their 2013 review article of DC vaccines 
published in Oncoimmunology (Linette and Carreno, 2013). They indicate that although the early 
DC-based cancer vaccines produced disappointing results in clinical trials, the newer data shows 
the efficacy can be improved if the patients (or DC vaccine cells) produce the hormone 
interleukin-12 (IL-12).   
 
          Very recently, Carreno’s group also published a paper in the May 15 issue of Science, 
entitled “A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-
specific T cells” (Carreno et al., 2015). In this paper, the authors provided a landmark proof-of-
principle demonstration that a DC vaccine could be designed against “neo-antigens” present only 
in a patient’s own tumor cells (not naturally occurring).  In an interview with The Scientist on 
April 2, 2015, senior author Dr. Carreno stated that the problem with making a normal vaccine 
against shared antigens (those that are over-expressed in tumor cells but also present in normal 
cells) is the “immune response is not so strong” (Azvolinsky, 2015).  The team used new 
sequencing technologies to identify neo-antigens present only in the patient’s tumor cells, not in 
normal cells. The team performed exome sequencing (sequenced the protein encoding exon 
portion of the genome) on surgical tumor samples taken from 3 patients with stage-III 
melanoma. They then used bioinformatics and prediction algorithms to identify missense 
mutations present in the tumors but not in healthy tissue. They restricted the list of neo-antigens 
to those with an affinity for HLA-type HLA-A*02:0, a type of antigen-presenting receptor 
present in 45% of Northern Europeans that are more prone to melanomas. They then selected 
about 7 neo-antigens per patient, synthesized them chemically, mixed the cocktail with the 
patient’s DC cells, and injected the primed DC cells back into the respective patients (Carreno et 
al., 2015). The purpose of this initial study was not to assay vaccine efficacy but to assay the 
immune responses for proof-of-principle the neo-antigen approach works.  After 3 rounds of 
vaccines over 20 weeks, the team extracted mononuclear cells from the patient’s blood and 
assayed them in vitro for T-cell responses. The data showed that T-cell responses were generated 
against some, but not all 7 of the neoantigens, present in the vaccine, indicating the neo-antigens 
are not alike in their ability to induce an immune response.  The results also showed that the 
vaccine expanded the patient’s own immune response against the neo-antigens, likely because 
TILs had been primed against them already in vivo. This study proves that new rapid DNA 
sequencing technologies can be used to identify neo-antigens present in the patient’s tumor, and 
that priming the DC’s against them may make the DC vaccines more effective by minimizing 
immune responses against normal shared antigens. When asked their comments on this landmark 
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study, Dr. Nina Bhardwaj, Director of Immunotherapy at the Tisch Cancer Institute at Mount 
Sinai Hospital (New York City) (not involved with the work) stated, “The work is an early proof 
of principle that immunization against these neo-antigens results in patient immune responses” 
(Azvolinsky, 2015). And Jeffrey Weber, a tumor immunologist at the Moffitt Cancer Center in 
Tampa (Florida) (also not involved in the study) stated that, ”Scientifically and immunologically, 
this was a tour de force as the first example of a personalized vaccine strategy” (Azvolinsky, 
2015).  
 
          With respect to the problem of neo-antigens producing different levels of immune 
responses, 2015 study co-author Dr. Elaine Mardis, Co-Director of the Genome Institute at 
Washington University said that “We need to improve [our] immunogenicity-predicting 
algorithm by training [it] on real data obtained from patient responses” (Azvolinsky, 2015).  So, 
this seems to be an important future direction to focus on: using actual patient immune responses 
against specific tumor neoantigens to help formulate guidelines for making more accurate 
predictions of which tumor neo-antigens are likely to be more immunogenic, and thus are the 
best candidates for designing the vaccine against. With respect to the immune responses being 
relatively low, lead author Dr. Carreno reminded us that the purpose was to establish proof of 
principle, stating, “There were activated T-cells in the blood after the vaccination that were not 
there before vaccination - these were not high in number, but they were there” (Azvolinsky, 
2015).  So, perhaps a future direction for the use of neo-antigens would be to use a combination 
vaccine against neo-antigens combined with antibodies against immune blockers CTLA-4 or PD-
1, as discussed in the previous vaccine section.  One important future direction will be the speed 
of the overall approach.  The types of neo-antigens created in a patient’s tumor varies from 
patient to patient, so the neo-antigens must be assayed for every new patient (unless that type of 
cancer has an excellent marker protein shared by all patients). Jeffrey Weber (mentioned above) 
reminded us that the time it takes to produce individualized vaccines is critical, “melanoma 
patients do not have multiple months to wait on vaccine production”. So, future research likely 
will need to improve the speed at which we identify neoantigens from each patient, and improve 
the speed at which the patient’s extracted DC cells can be amplified in vitro. 
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DC Treatment of Glioblastomas 
 
Glioblastoma (GBM) is the most common and aggressive primary brain tumor for adults 
(Stupp et al., 2005). About 23% of primary brain tumors are GBMs in the US (IRSA, 2015). 
GBMs arise from star shaped glial cells that form supportive tissues in the brain. GBMs usually 
contain multiple cell types. Some traditional therapies may kill parts of the GBM, but have little 
effect on other cells of the tumor.  So, GBM treatments usually have several steps, usually tumor 
resection (if possible) followed by radiotherapy or chemotherapy. Because GBMs have a finger-
like shape that protrudes into healthy tissue, it is very difficult to completely remove the tumor 
by surgery without damaging healthy brain tissue (ABTA, 2014). The median survival time after 
standard treatment is less than 2 years (Johnson and O’Neill, 2012). 
 
In 2001, Dr. Yu’s group at the Maxine Dunitz Neurosurgical Institute, Cedars-Sinai 
Medical Center (Los Angeles, CA) published their findings on treating GBM with DC vaccines 
(Yu et al., 2001). They vaccinated 9 patients with DCs loaded with peptides isolated from the 
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surface of tumor cells. DCs were amplified from the patients’ blood stem cells ex vivo. No 
serious side effects were seen. 4 out of 7 evaluated patients showed sustained CTL responses 
against the tumor.  4 patients that had signs of tumor progression underwent reoperation. Strong 
cytotoxic and T-cell infiltrations were observed near the tumors in 2 of the 4 relapsing patients 
after re-perfusions. The median survival time of the study group was 455 days, which was 
considerably longer than the control group (257 days). This study demonstrates that DC 
vaccinations can positively correlate with longer patient survival. 
 
One study showed that the time required to prepare peptide-pulsed DC vaccines is limited 
by the time needed to extract antigens from the patient’s tumor cells (Yu et al., 2004). The 
extraction is also more difficult if the patient received radiotherapy. To avoid these limitations, 
Dr. Yu’s team chose to load DCs with tumor lysates isolated from the same patient. 14 patients 
were included in this study. The vaccines appeared to be well-tolerated, and no evidence of 
autoimmune disease was seen. 6 of 10 evaluated patients showed robust T-cell responses against 
the tumors. 4 out of 9 patients showed significant expansion of antigen-specific T-cells against 
tumor associated antigens such as mege-1 or gp100. 6 patients underwent another round of 
vaccination. Of those 6 patients, significant T-cell infiltration of the tumors was detected in 3 
patients. This study demonstrates that DC vaccines pulsed with autologous tumor lysate appears 
to be a safe, feasible way to induce strong cytotoxic immune responses against brain tumors, and 
that antigens mege-1 and gp100 appear to be excellent candidate antigens. 
 
In 2005, Dr Liau’s group in the Division of Neurosurgery at the Brain Research Institute 
of the David Geffen School of Medicine, UCLA (Los Angeles, CA) published their findings on 
the ability of DC vaccines to induce immune and clinical responses in GBM patients (Liau, et al., 
2005). They had previously shown that DC vaccines can induce antitumor responses against 
GBM’s in animal experiments. 12 patients with grade-4 GBM’s were vaccinated with tumor 
peptide-pulsed DCs, and the patients were followed for 5 years. 1 out of 12 patients had clinical 
response, as documented by MRI. 6 had measurable systemic antitumor CTL responses, but the 
immune responses did not translate into clinical responses or prolong survival. Of 8 patients that 
received second vaccines, 4 showed increased tumor infiltration by cytotoxic cells.  The 
secretion of TGF-β2 into the blood often correlates with GBM tumor progression (Derynck et al., 
2001), and these results showed that T-cell infiltration increased with lower TGF-β2 expression.  
 
Another paper from UCLA in the Department of Neurosurgery, Brain Research Institute 
(Los Angeles, CA) attempted to identify which GBM patients were most likely to respond to a 
DC vaccine (Prins et al., 2011). In this study, 23 patients with grade-4 GBM were vaccinated 
with tumor lysate-pulsed DCs accompanied by adjuvant. The vaccines appeared to be well 
tolerated, with a median survival time of 31.4 months.  They determined that patients whose 
tumors showed a mesenchymal-like gene expression had longer overall survival and higher 
CD3+ and CD8+ T-cell infiltrations into the tumor. Thus, mesenchymal gene expression profiles 
may help the patient eliminate the tumor. 
 
In 2011, Dr. Okada’s group at the Hillman Cancer Center (Pittsburgh, PA) published 
their findings on the clinical and immune responses induced by alpha-type-1 polarized DC cells 
(αDC1) loaded with glioma-associated antigen (GAA) supplemented with synthetic adjuvant 
polyinosinic-polycytidylic acid [poly(I:C)] stabilized by lysine and carboxy-methylcellulose-
[poly-ICLC] (Okada et al., 2011). αDC1 cells can produce high levels of IL-12 which can 
strongly boost the type-1 immune response (cellular and humoral immunity). Their previous 
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experiments with poly-(I:C) stabilized with poly-ICLC showed it can enhance the efficacy of 
glioma antigen-targeting vaccinations in animal experiments (Zhu et al., 2007). This was the first 
study to treat recurrent human malignant gliomas with the combination of αDC1 cells and 
adjuvant. The vaccines were well-tolerated. Of 19 evaluable patients, 58% had positive immune 
responses against glioma associated antigen. 9 patients had no sign of tumor progression for at 
least 12 months. And 1 patient showed sustained complete remission. Thus, replacing standard 
mature DC cells with αDC1 cells might improve vaccine response and efficacy. 
 
Some scientists argue that cancer stem cells (cells with stem cell characteristics found 
within the tumor) survive chemotherapy and are responsible for tumor survival post-chemo 
treatments (Yao et al., 2011). A group of scientists in the Department of Neurosurgery at Wuhan 
University (China) investigated whether pulsing DC cells with glioma stem cell lysate increases 
the anti-tumor effects of the T-cells (Ji et al., 2013). The DCs were obtained from murine bone 
marrow cells, and glioma stem cells were cultured from the glioma cell line U251. Previous 
studies showed that heat-treating the cultured tumor cells for 3 hours at 44℃ up-regulates heat-
shock protein expression which increases the immunogenicity of the cell lysate. So, the team 
heat-shocked their cultured stem cells prior to making a lysate by repeated freeze/thawing.  The 
lysate was then used to pulse their DC cells. The data showed that the stem cell antigen-pulsed 
DCs can significantly stimulate the formation of tumor-specific T-cells that kill glioma cells 
more effectively than DCs in the control group. This study shows that reacting the DC cells 
against cancer stem cells, a key component of glioma tumors, has the potential to improve DC-
based vaccines. 
 
In 2015, a group of scientists from Duke University published a paper entitled “Tetanus 
toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients” (Mitchell et 
al., 2015). The team randomized GBM patients to pre-conditioning with non-pulsed DCs or to 
tetanus toxoid Td (to generally boost the immune system). They then vaccinated mice or patients 
with cytomegalovirus phosphoprotein-65 (pp65) RNA-pulsed DCs.  The data suggested that 
patients in the Td + DC group had considerably greater DC migration to the vascular draining 
lymph nodes (VDLNs) (where presumably they would induce a strong immune response) and a 
longer progression-free and overall survival compared with patients treated only with non-pulsed 
DCs. To fully understand the mechanism for improved patient survival, the team performed 
similar experiments on mice. The Td pre-conditioned group had a threefold increase of DCs 
within inguinal lymph nodes, whereas no increase of DC migration occurred in the control 
group. Injection of CD4+ Helper T-cell-dependent protein antigens could also induce DC 
migration, and therefore the authors indicated that this could be a generalizable event that would 
apply to human patients. Thus, a recall response against tetanus toxoid appears to improve DC 
migration to a lymph node location required for a strong immune induction, and should be 
considered for future DC vaccines.  
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Improving DC Vaccine Strategies 
 
          Some scientists argue that the early DC vaccine clinical trials produced disappointing 
results, and that a full potential of DC cancer vaccines has not yet been achieved (Koski et al., 
2008).  Our Lit Review identified several potential areas for improvements: 
  
1. Stimulatory Hormones: Include full knowledge of the immune system in the vaccine, and 
especially include the use of stimulatory hormones such as IL-12, and knowledge of how DC 
cells engage other cells of the immune system (Topalian et al., 2011). 
 
2. Combination Vaccines: Create combination vaccines composed of DC’s primed to tumor 
antigens plus antibodies against immune blockers such as PD-1 and CTLA-4 to stimulate the 
immune system.  Recent vaccine success stories have taught us the importance of the tumor 
environment suppressing the immune response, so it is important to overcome this 
suppression by stimulating the immune system (Topalian et al., 2011). 
 
3. Cellular and Humoral Immunity: The vaccine should not only stimulate CD8+ T-cell 
responses (cellular immunity), but also B-cell responses (humoral immunity) to make full use 
of the immune system. 
 
4. Personalized Medicine: The tumor antigens used to prime the DC cells should be determined 
for each patient using rapid DNA sequencing technologies and bioinformatics to identify 
mutations specific for that patient. Neo-antigens produced in the patient’s tumor by gene 
mutation should be assayed and targeted to make a personalized therapy (Rajasagi et al., 
2014). 
 
5. The tumor disease stage best suited for immunotherapy (the stage at which it is best 
eliminated) should be identified and targeted in the patient if possible. 
 
6. Speed: The speed of the entire process should be improved, especially when treating tumors 
with rapidly poor prognosis, such as advanced stage melanomas. 
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7. DC Developmental Stages: Investigations of how DCs generate immune responses, and 
which DC developmental stage can bring the best results should be investigated. A key 
questions is whether DCs should be matured before injection. Most DCs are isolated as 
CD14+ monocytes from the patient’s peripheral blood, but those DCs are immature. Is the 
use of immature DC’s best?  Some scientists have shown that expanding peripheral cells with 
hormone Flt3L is better than isolating CD14+ cells. Other scientists have shown that 
isolating alpha-DC1 cells works better than regular DCs. (Andrews et al., 2008) 
 
8. Tumor Heterogeneity: Some cancers are very heterogeneous, containing many types of cells. 
The presence of cancer stem cells is especially important as they are thought to seed tumor 
growth following chemotherapy (Pollack et al., 2002). So, designing the vaccines against 
tumor neo-antigens and against cancer stem cell markers might provide a strong vaccine. 
 
9. Adjuvants: Synthetic polymers poly-(I:C) and poly-IC-LC are adjuvants that can effectively 
improve immune responses. So, adding these adjuvants to a DC vaccine might result in a 
stronger immune response (Ammi et al., 2015). Other adjuvants such as T-cell stimulator 
anti-CD173 or CpG also have the potential to improve DC vaccine responses (Cheever, 
2008).   
 
10. Pre-Injections: Tetanus toxoid Td pre-injection has been shown to increase DC migration to 
lymph nodes, which improves the immune response.  Patients pre-treated with Td also have a 
longer median survival time and longer progression-free survival (Mitchell et al., 2015). 
 
11. Patient Selection: Some patients seem to be better suited for cancer vaccines than others.  
Identifying markers for those patients more likely to have immune response to DC-based 
vaccines would enable those patients to be treated first while trying other treatment for those 
patients likely not to be helped. 
  
12. Tumor Evasion:  Some tumors are not eliminated by cancer vaccines, so the process of tumor 
evasion should be further investigated.  In resistant cases, perhaps activating other arms of 
the immune system, such as natural killer cells (NKs) would help. One study has shown that 
adding protein NKG2D activates NK cells against cancer (Deng et al., 2015).  
 
 
References for DC Vaccine Strategies 
 
Ammi R, De Waele J, Willemen Y, Van Brussel I, Schrijvers DM, Lion E, Smits EL (2015) 
Poly(I:C) as cancer vaccine adjuvant: knocking on the door of medical breakthroughs. 
Pharmacol Ther, 2015 Feb; 146: 120-131.  
 
Andrews DM, Maraskovsky E, Smyth MJ (2008) Cancer vaccines for established cancer: how to 
make them better? Immunological Reviews, 2008 Apr; 222: 242-255.  
90 
 
Cheever MA (2008) Twelve immunotherapy drugs that could cure cancers. Immunological 
Reviews, 2008 Apr; 222: 357-368.  
 
Deng W, Gowen BG, Zhang L, Wang L, Lau S, Iannello A, Xu J, Rovis TL, Xiong N, Raulet 
DH (2015) Antitumor immunity. A shed NKG2D ligand that promotes natural killer cell 
activation and tumor rejection. Science, 2015 Apr 3; 348(6230): 136-139. 
 
Koski GK, Cohen PA, Roses RE, Xu S, Czerniecki BJ (2008) Reengineering dendritic cell-based 
anti-cancer vaccines. Immunological Reviews, 2008 Apr; 222: 256-276. 
 
Mitchell DA, Batich KA, Gunn MD, Huang MN, Sanchez-Perez L, Nair SK, Congdon K5, Reap 
EA, Archer GE, Desjardins A, Friedman AH, Friedman HS, Herndon JE 2nd, Coan A, 
McLendon RE, Reardon DA, Vredenburgh JJ, Bigner DD, Sampson JH (2015) Tetanus toxoid 
and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature, 2015 Mar 
19; 519(7543): 366-369. 
 
Pollack IF, Finkelstein SD, Woods J, Burnham J, Holmes EJ, Hamilton RL, Yates AJ, Boyett 
JM, Finlay JL, Sposto R; Children's Cancer Group (2002) Expression of p53 and prognosis in 
children with malignant gliomas. New England Journal of Medicine, 2002 Feb 7; 346(6): 420-
427. 
 
Rajasagi M, Shukla SA, Fritsch EF, Keskin DB, DeLuca D, Carmona E, Zhang W, Sougnez C, 
Cibulskis K, Sidney J, Stevenson K, Ritz J, Neuberg D, Brusic V, Gabriel S, Lander ES, Getz G, 
Hacohen N, Wu CJ (2014) Systematic identification of personal tumor-specific neoantigens in 
chronic lymphocytic leukemia. Blood, 2014 Jul 17; 124(3): 453-462. 
 
Topalian SL, Weiner GJ, Pardoll DM (2011) Cancer immunotherapy comes of age. Journal of 
Clinical Oncology, 2011 Dec 20; 29(36): 4828-4836. 
 
  
91 
Part-7: TIL-Type Cancer Vaccines 
Eric Williams 
 
 
Introduction to TIL Cells 
 
          T-cells (also termed T-lymphocytes) are a type of nucleated white blood cell that functions 
in cellular immunity, a key arm of the immune system. T-cells are distinguished from other 
lymphocytes, such as B-cells and natural killer cells (NK cells), by the presence of a T-cell 
receptor (TCR) on their cell surface. They are called T-cells because they mature in the thymus 
(although some T-cells also mature in the tonsils) (Alberts et al., 2002). There are several types 
of T-cells, each with a different function: helper (CD4+), cytotoxic (CD8+), memory, 
suppressor, mucosal associated, and gamma delta T-cells. 
  
          With respect to cancer vaccines, tumor infiltrating lymphocytes (TILs) are a type of T-
cell found in tumors that help kill it. High levels of TILs in tumors are often associated with a 
better clinical outcome for the patient (Vanky et al., 1986). TILs isolated from tumors usually 
include both CD4+ (helper T-cells) and CD8+ (cytotoxic killer T-cells, CTLs).  TILs circulate 
through the bloodstream, recognize the tumor and infiltrate it.  The CD4+ cells secrete cytokines 
to stimulate the immune system, while the CTLs directly lyse the tumor cell. Naïve T-cells have 
an amazing capacity for reacting with pathogens (or tumor antigens), by differentiating into 
effector T-cells that recognize other cells containing that pathogen or antigen, massively 
expanding themselves by cell division, and migrating throughout the body to clear the infection 
(or tumor) with minimal damage to surrounding tissue (Zhang and Bevan, 2011). 
 
          T-cell therapy, sometimes referred to as adoptive cell therapy (ACT), has several 
advantages over those forms of immunotherapy that rely on the production of T-cells in vivo 
(Rosenberg and Restifo, 2015): 
 
1. Very large numbers of T-cells can now be grown in vitro (up to 1011 cells). 
2. The T-cells can be selected in vitro for those that recognize tumor antigens. 
3. T-cell growth in vitro by-passes any negative regulation those cells might encounter in vivo. 
4. The patient can be treated with traditional chemotherapy to support the tumor therapy prior to 
the cell infusion. 
5. The engineered T-cell receptors do not rely on MHC-type antigen presentation but recognize 
the antigen directly. 
6. The T-cells can be genetically engineered in vitro to express T-cell receptors (TCRs) or 
chimeric antigen receptors (CARs) that specifically recognize tumor proteins. CAR cells 
“merge the exquisite targeting specificities of monoclonal antibodies (engineered T-cell 
receptors given mAb-binding sites against tumor antigens) with the potent cytotoxicity, 
expansion potential, and long-term persistence of cytotoxic T-cells” (Lee et al., 2012). 
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T-Cell Therapy for Melanoma 
 
          The use of TILs to treat cancer was pioneered by Dr. Steven Rosenberg at the National 
Cancer Institute (for a review, see Rosenberg and Dudley, 2009). In this technique, autologous 
lymphocytes are isolated from a patient’s tumor and grown to very large numbers in vitro. In 
some cases, prior to the TIL treatment the patients are given chemotherapy to deplete native 
lymphocytes that can suppress the function of the perfused TILs. Once lympho-depletion is 
completed, patients are then infused with their own TILs supplemented by hormones such as 
interleukin-2 (IL-2).   
 
The vast majority of research on TIL cells, and several ongoing clinical trials have been 
conducted using TILs to treat patients with metastatic melanoma. In some cases, the teams have 
observed 50% tumor reduction in about half the patients (Dudley et al., 2008; Besser et al., 2010; 
Radvanyi et al., 2012; Pilon-Thomas et al., 2012), and in one study, 22% of the melanoma 
patients even experienced complete cancer remission with no detectable tumor 3 years after the 
treatment (Rosenberg et al., 2011). 
 
          In 1994, Steven Rosenberg’s team designed an experiment to correlate the characteristics 
of TIL cells versus the patient responses (Schwartzentruber et al., 1994). They analyzed 41 
patients with metastatic melanoma receiving TIL cells plus IL-2 hormone.  9 of the 41 patients 
(22%) achieved complete or partial cancer remissions.  Parameters such as patient age, sex, sites 
of disease, or prior therapies appeared to be similar in both the responders and non-responders.  
However, the responders appeared to receive 33% more TILs, showed higher lysis abilities in 
vitro (30% versus 15%), and contained TILs that produced GM-CSF following in vitro 
stimulation with tumor cells. These data indicate that functional TILs (such as those secreting 
GM-CSF hormone and those with high lysis abilities) correlate with patient improvements. 
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          In 2002, a research group at the Fred Hutchinson Cancer Research Center (Seattle, WA) 
performed an adoptive T-cell therapy phase-I clinical trial on 10 patients with metastatic 
melanoma (Yee et al., 2002).  They isolated CD8+ T-cells reactive against tumor antigens 
MART1 and gp100 from each patient, expanded the T-cells ex vivo, and then perfused the 
expanded T-cells back into the same patient. The purpose of the phase-I experiment was to 
evaluate the safety, in vivo persistence and efficacy of the treatment.  43 cell infusions were 
performed on the 10 patients.  No serious toxicity was observed, the T-cells persisted in vivo at 
least 21 months (using IL-2), and the T-cells localized to the tumor and helped eliminate antigen-
positive tumor cells. 
 
In 2002, Mark E. Dudley and his group of researchers from Rosenberg’s team performed 
an adoptive transfer of TIL cells to 13 patients with metastatic melanoma (Dudley et al., 2002). 
The TILs were selected to target overexpressed self-derived differentiation antigens. The patients 
all received pre-treatment with cyclophosphamide and fludarabine chemotherapies for 7 days. 
The results indicated that of the 13 patients, 6 exhibited significant regression of metastatic 
melanoma, and 5 exhibited the onset of anti-melanocyte immunity. These results are a success to 
some of the team’s previous experiments where the patients did not show any responses to 
treatment, nor did they show any persistence of the TILs. The results from this test show that the 
destruction of metastatic tumors can be achieved by treatment with autologous T-cell transfer 
and high-dose IL-2 therapy. 
 
          In 2006, Steven Rosenberg’s group performed TIL therapy on 15 patients with metastatic 
melanoma with TILs that had been genetically engineered to express a retroviral encoded T-cell 
receptor (Morgan et al., 2006).  Their data showed that the infused TILs resulted in a durable 
engraftment, with 10% presence in the peripheral blood lymphocytes positive for the TILs two 
months after injection.  2 of the 15 patients showed high levels of circulating TILs one year after 
injection, and observable tumor regression.  This study provides evidence that TILs can be 
genetically engineered to improve effectiveness. 
 
In 2008, Mark E. Dudley (of the Rosenberg team) and colleagues performed a study to 
evaluate the safety and efficacy of two TIL therapies accompanied by increased-intensity 
myeloablative lympho-depleting chemotherapy and radiation regimens (Dudley et al., 2008). The 
patients were given a pre-treatment with cyclophosphamide and fludarabine accompanied by 
either 2 or 12 Gy of total-body irradiation. This was followed by the TIL therapy.  The results 
showed that 49% of the TIL patients had an objective response accompanied by just the 
chemotherapy, adding 2 Gy of irradiation increased the response to 52%, and increasing the 
radiation to 12 Gy raised the response rate to 72%. The conclusion of this experiment was that 
treating metastatic melanoma patients with TILs accompanied by strong doses of radiation can 
provide positive tumor decreases in up to 72% of the patients. 
 
In 2010, Dr. Besser and his team at the Ella Institute of Melanoma, Sheba Medical Center 
(Tel-Hashomer, Israel) performed a study to test the efficacy and toxicity of TIL cells following 
lympho-depleting chemotherapy in 20 metastatic melanoma patients that were refractive to 
previous treatments (Besser et al., 2010). The results indicated that 50% of the patients achieved 
an objective clinical response, comprising 2 complete remissions, and 8 partial remissions. They 
concluded that refractory melanoma can show tumor regression in 50% of patients treated with 
chemotherapy followed by TIL cells, with manageable toxicity. 
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          In 2011, the Rosenberg team studied 93 patients with metastatic melanoma treated with 
autologous TIL cells (isolated from each patient’s tumor and expanded in vitro) and IL-2 
(Rosenberg et al., 2011).  The patients were pre-treated with chemotherapy or radiation regimes 
to improve their prognosis.  95% of the patients had ongoing cancer from prior chemotherapy 
treatments. Their data provide a great success story, showing that 20 of the 93 patients (22%) 
achieved complete tumor regression, and 19 of the 20 regressions remained beyond 3 years! The 
3 and 5-year survival rates for the 20 remission patients were 100% and 93%, respectively.  The 
likelihood of achieving a complete remission was similar regardless of prior therapies, but the 
success correlated with longer TIL cell telomeres (to allow more population doublings in vivo), a 
higher number of TILs infused, and the persistence of the TILs in the circulation at one month. 
 
In 2012, Dr. Radvanyi and a group of researchers in the Department of Melanoma 
Medical Oncology, at the University of Texas MD Anderson Cancer Center (Houston, TX) 
investigated the use of TIL cells in 31 patients with metastatic melanoma (Radvanyi et al., 2012). 
Each patient was treated with chemotherapy followed by his or her expanded TILs, and two 
cycles of high-dose interleukin (IL)-2 therapy. 15 of the 31 (48.3%) patients in the study had an 
objective clinical response. Of those 15, two patients had a complete response. They concluded 
that immunotherapy with expanded autologous TIL cells can achieve durable clinical responses 
in patients with metastatic melanoma, and that CD8+ T-cells in the TILs are important for the 
response.  
 
In 2012, a team led by Dr. Shari A. Pilon-Thomas at the Donald A. Adam 
Comprehensive Melanoma Research Center in the H. Lee Moffitt Cancer Center and Research 
Institute (Tampa, FL) performed a clinical trial on 19 patients with metastatic melanoma treated 
with a combination therapy of non-myeloablative chemotherapy plus TIL cells and IL-2 (Pilon-
Thomas et al., 2012). Of the 19 patients enrolled, 13 of them successfully completed treatment. 
Out of these 13 patients, 2 had complete responses, and 3 had partial responses. In addition, 4 
patients had stable disease. This study concluded that adoptive therapy with infiltrating 
lymphocytes is possible and can be effective, but is labor intensive. 
 
          In 2013, Steven Rosenberg’s group performed TIL therapy on 69 patients with metastatic 
melanoma (Dudley et al., 2013).  34 patients received TILs not selected for any marker protein, 
and 35 patients received TILs enriched for CD8+ cells.  12 patients receiving the unselected TILs 
responded to the therapy, while only 7 responded to the CD8+-enriched TILs.  This data 
indicated that the significant amount of time and cost associated with enriching for CD8+ cells is 
likely not worth the effort. 
 
          In 2013, Rosenberg’s team developed a new screening approach to identify newly mutated 
proteins present in melanomas (Robbins et al., 2013). The method used whole-exome DNA 
sequencing of tumor DNA followed by bioinformatics to identify mutations present in the tumor 
protein-coding regions not present in normal tissue. The method avoided the labor-intensive 
methods of synthesizing and screening cDNA libraries. They synthesized the neo-antigens 
synthetically, and tested their recognition by patient TILs.  They also extended the approach to 
identify melanoma neo-antigens that when targeted by TILs have a higher probability of causing 
a full tumor regression.  These neo-antigens were present in about 40% of long-term survival 
melanoma patients (5-years after TIL therapy). The team identified 3 specific TIL cell lines with 
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high capacity for therapy.  The authors speculate that their technique can be applied to any type 
of cancer. 
 
          In 2014, Rosenberg’s group analyzed the phenotypic traits of TIL cells isolated from 6 
melanoma tumors (Gros et al., 2014). They used deep sequencing techniques to determine which 
cancer antigens the TIL cells recognized and whether any TILs expressed inhibitory receptors.  
Their data indicated that all 6 tumors contained TILs positive for mutated neo-antigens, 
indicating that neo-antigens might be the best target for future experiments.  And all 6 tumors 
contained TILs positive for negative immune receptors PD-1, LAG-3, and TIM-3, indicating that 
the TILs in their in vivo state were functionally impaired by the tumor.  Thus, antibody therapy 
designed against the negative regulators might improve vaccine effectiveness.   
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Examples of Fighting Other Cancers with TIL Therapy 
 
          Besides melanoma, TIL cells have been used to treat other kinds of cancer, including 
epithelial and ovarian cancers (discussed below), and two ongoing clinical trials will investigate 
a variety of other cancers (Clinical Trial NCT01174121; Clinical Trial NCT01585428). Trial 
NCT01174121 aims to determine whether TILs can shrink tumors resulting from tumors of the 
digestive tract, urothelial cells, breast, and ovarian/endometrial cancers. In addition to testing the 
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effectiveness of the treatment, the trial will also focus on TIL safety. The ongoing trial has an 
estimated enrollment of 260 patients, and is expected to be completed in December of 2019. 
Eligible participants will first undergo surgery to remove tumors and TILs will be extracted from 
the tumors. Patients may also be subjected to leukapheresis if additional white blood cells are 
required. The patients will return to the clinic for additional tests to record progress and potential 
side-effects. 
 
Trial NCT01585428 will focus on the use of TILs to shrink HPV-related cervical and 
non-cervical cancers. Similar to the other ongoing trial, white blood cells will be extracted from 
the patient’s tumors, will be grown in vitro, and will be then given back to the patients. The 
estimated enrollment for this trial is 73, and is expected to end in December of 2017. After 
receiving the treatment, the patients will return for physical exams and tests to review progress 
and side-effects. The exams will occur every 1-3 months for the first year, and then every 6 
months to 1 year thereafter. 
 
          Steven Rosenberg’s team that originally pioneered the use of TIL’s for treating melanoma 
has also used the TIL approach on patients with epithelial cancer (Tran et al., 2014).  Prior to 
the study, it was not clear whether T-cells isolated from patients with metastatic cholangio-
carcinoma are directed against mutated neo-antigens in the tumor.  So, the team performed whole 
exome sequencing (discussed previously) on TILs isolated from epithelial tumors, and showed 
the TILs specifically reacted against tumor erbb2-interacting protein (erbb2ip).  When treated 
with a TIL cell population where 25% were specific for erbb2ip, the patient showed a decrease in 
lesions and disease stabilization.  After a relapse, the patient was retreated with a TIL population 
where 95% were against erbb2ip, and showed a tumor regression. 
 
          TIL cells have also been used to fight ovarian cancer.  In 2013, Dr. Jason H. Bielas’ team 
at the Fred Hutchinson Cancer Research Center (Seattle, WA) published a study in Science 
Translational Medicine, entitled “Digital Genomic Quantification of Tumor-Infiltrating 
Lymphocytes” (Robins et al., 2013). The team designed a new digital DNA-based assay (termed 
QuanTILfy) to count TIL cells and assess their clonality (percent activity against various 
antigens) in tissue samples (including tumors). They applied the approach to metastatic ovarian 
tumor tissue, and demonstrated an association between higher patient TIL counts and improved 
patient survival, which is consistent with previous findings that those parameters are meaningful 
patient prognostic factors. They also found a diverse TIL repertoire for all their tumors, with no 
apparent strong clonal expansions against a specific type of antigen for the ovarian tumors, so 
this makes designing a specific type of TIL (or CAR) against ovarian cancer more difficult, and 
may necessitate the need for a more complex vaccine. 
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Part-7 Summary, Problems and Questions 
 
With respect to TIL cell treatments, most of the studies performed to date are with 
melanoma cancer, performed by Steven Rosenberg’s team at the National Cancer Institute who 
pioneered the TIL approach.  In interviews, it would be interesting to determine why the team 
chose that particular cancer for so many of the early experiments.  Was the cancer chosen 
because of its high fatality rate after metastasis and lack of response to traditional treatments?  
 
Some of the melanoma TIL clinical trials resulted in patients with complete cancer 
remissions.  The best patient survivals appear to occur in patients with the highest TIL load in the 
tumor, so does this emphasize the importance of growing large numbers of the TILs prior to 
infusion?  And some of the best remissions occurred by enriching the TILs for those cells 
committed to the tumor-specific neo-antigens, so should this type of enrichment be done 
routinely, or just for resistant cases?  
 
In a few studies, TILs have also been used to treat epithelial and ovarian cancers. But in 
ovarian cancer, the TILs appear to be committed to a variety of neo-antigens, not just one type.  
So, will these ovarian cases require the enrichment and expansion of all TIL clones to be 
effective, or will expanding only one type of TIL be sufficient for remission? 
 
Besides the published TIL experiments with melanoma, ovarian, and epithelial cancers, it 
is not yet known whether the TIL therapy works with other types of cancer, so the ongoing 
clinical trials testing other cancers will be important.  
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Part-8: CAR-Type Cancer Vaccines 
Zhuohao Ling 
 
 
Chimeric antigen receptors (CARs) (also known as chimeric T-cell receptors or 
chimeric immune-receptors), are artificially engineered T-cell receptors (TCRs) that provide a 
specific binding affinity to the T-cell containing it. In the case of cancer immunotherapy, CARs 
are typically engineered to have a monoclonal antibody-like affinity for a specific tumor antigen.  
An engineered CAR gene is delivered inside the T-cells in vitro using retroviral vectors, and then 
the engineered T-cells are delivered back into the same patient (reviewed in: Pule et al., 2003; 
Lipowska-Bhalla et al., 2012; Curran et al., 2012).  Genetically altered T-cells were first 
developed in the 1980s by Prof. Zelig Eshhar and his colleagues at the Weizmann Institute of 
Science in Rehovot, Israel.  By 1989, they had created the first functional CAR T-cells (reviewed 
in: Urba and Longo, 2011). 
  
       The current CAR structure (Figure-1, right side) often fuses together: 1) a monoclonal 
antibody single-chain variable fragment (scFv) derived from an anti-tumor mAb (which 
recognizes the tumor) (orange in the diagram), 2) a co-stimulatory domain (like CD28 that 
activates the T-cells and helps them survive in vivo) (white in the diagram), 3) a hydrophobic 
domain that spans the lipid bilayer on the surface of the CAR cell (purple in the diagram), and 4) 
one to three cytoplasmic tail domains (like TCR-zeta) that activate the CAR cell once it engages 
the tumor cell (blue, yellow, and green in the diagram).  
 
Figure-1:  Diagram of the Typical Structure of a CAR Cell.  Shown are first-
generation, second-generation and third-generation CAR cells, panels left to right, 
respectively.  The T-cell is shown in the lower half of each panel, and the cancer cell the 
upper half (green).  Gray denotes the cancer antigen targeted by the engineered T-cell 
receptor in the CAR cell.  Orange represents the monoclonal antibody variable fragment 
that recognizes the tumor antigen, purple represents the hydrophobic transmembrane 
domain.  Blue, orange, and green denote cytoplasmic tail activation domains that signal 
the T-cell to activate when the receptor is engaged by the tumor cell.  White denotes a co-
stimulatory domain, such as CD28, that binds ligands present on antigen presenting cells 
to help the CAR cells divide and survive in vivo.  Figure is from Brower, 2015. 
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Thus, structurally, CARs combine the powerful properties of highly specific antigen 
recognition and T-cell activation in a single fusion receptor molecule (Sadelain et al., 2009). The 
first generation CARs (diagram left panel) used CD3-zeta with no co-stimulatory domain, but 
these molecules failed to enable T-cell proliferation and survival in vivo. So, newer designs 
(diagram middle and right panels) often use a CD28 co-stimulator domain (white in the diagram) 
plus the CD3-zeta for the cytoplasmic domain (Sadelain et al., 2009). The engineered CAR gene 
is preceded by a signal sequence to target the receptor to the cell surface.  When this CAR is in 
place on the cell membrane, once it binds its tumor cell target, it sends a signal inside the T-cell 
to activate it to kill the tumor cell. 
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Early CAR Animal Studies 
 
          The early foundation for the CAR field was laid by Israeli immunologist Zelig Eshhar 
who began the CAR work in mice while on sabbatical in Palo Alto (CA). He later returned to the 
Weizmann Institute of Science (Rehovot, Israel) and continued his studies (reviewed in Couzin-
Frankel, 2013; Eshhar, 2014). Dr. Eshhar’s goal was to determine whether T-cells could be 
reprogrammed to recognize and latch onto an antigen they would normally ignore (like a cancer 
antigen). He eventually realized that the best way to do this was to insert foreign DNA into the 
T-cells encoding an engineered receptor that specifically recognizes the antigen. His early work 
frequently failed because most T-cells do not readily accept foreign DNA, but in the late 1980’s 
he learned to transform a type of immortalized T-cell that more easily accepts foreign DNA. 
Other big-name cancer researchers like Steven Rosenberg (National Cancer Institute), Carl 
June (University of Pennsylvania), and Michel Sadelain (Memorial Sloan-Kettering Cancer 
Center) picked up on this early work, and continued improving the technique and adapting it to 
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their patients.  Commenting on the technique for transforming the T-cells with foreign DNA, 
Michel Sadelain stated, “It took me 3 to 4 years to learn to transfer genes [into T-cells] at more 
than 0.5%.  Today we can take a high school student and in an afternoon they know how to take 
T-cells and blast genes into all of them” (Couzin-Frankel, 2013). 
 
         The early pre-clinical CAR studies in mice focused on determining the optimum CAR 
structure and the best methods for activating T-cell signaling (Bendle et al., 2009). They focused 
on designing high-affinity receptors that could overcome the immune tolerance induced by the 
cancer environment, improving the efficiency of the gene transfer into the T-cells using lentiviral 
vectors, and improving the methods for expanding the T-cells in vitro by using co-activation 
receptors or domains and by adding various hormones (reviewed in Kalos and June, 2013).  
 
With respect to activation, the early mouse experiments used CARs containing only one 
cytoplasmic tail activating domain, usually TCR-zeta. But the use of a single activation domain 
resulted in low levels of T-cell activation and low homing to the bone marrow to produce more 
T-cells. More recently, second and third-generation CARs containing multiple activation 
domains (TCR-zeta plus CD28 and/or CD137) show enhanced activation signals, better T-cell 
proliferation, higher levels of cytokine production, and stronger effector T-cell function (tumor 
killing).  
 
          In addition, the use of a “co-stimulatory signal” receptor also placed on the CAR cell was 
an important advance that enabled the CAR cells to divide and survive long-term in the patient.  
Steven Rosenberg’s group and Michel Sadelain’s group use CD28, while Carl June’s team uses 
4-1BB (CD137). CD28 (Cluster of Differentiation 28) is a receptor protein expressed on the 
surface of T-cells that binds ligands CD80 or CD86 present on antigen presenting cells engaged 
by the T-cells.  Binding of APC ligand to T-cell CD28 produces co-stimulatory signals required 
for T-cell activation and survival.  The CAR cells can contain CD28 receptor as a separate co-
stimulatory molecule, or can merge the co-stimulatory domains directly into the T-cell receptor, 
in the latter case the viral treatment is with only one gene. 
 
          An example of an early mouse experiment was in 2003 by Dr. Eshhar’s group who tested a 
CAR treatment (termed by their lab as a T-body approach) against erbB2 on the surface of 
human prostate cancer cells xeno-engrafted into immunocompromised mice (Pinthus et al., 
2003). The study was titled “Immuno-gene therapy of established prostate tumors using chimeric 
receptor-redirected human lymphocytes”. The CAR therapy was supplemented by systemic 
administration of IL-2, and the results slowed tumor growth in all mice, prolonged mouse 
survival, and provided complete tumor remission in several mice.   
  
          Clinical trials with the newer CAR’s show some complete remissions in patients with B-
cell leukemias, and are also being used for lymphoma, ovarian cancer, and neuroblastoma 
(Lipowska-Bhalla et al., 2012).  
 
 
CAR Vaccines and Melanoma 
 
          One of the earliest human clinical trials using genetically engineered T-cells was by the 
Rosenberg team at the National Cancer Institute, the same team that pioneered the use of TIL 
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cells to treat melanoma.  In 2006, they expanded their earlier TIL approach by transforming the 
T-cells cells with a retrovirus encoding a specific T-cell receptor, so the cells presented the 
receptor on their surface (Morgan et al., 2006). They treated 15 patients with metastatic 
melanoma. The CAR cells survived in the peripheral blood for at least 2 months, and survived 
for at least one year in two patients who showed significant tumor regression. So, this study with 
first-generation CAR cells showed some success. 
 
 
CAR Vaccines and Ovarian Cancer 
 
          In another early clinical trial using first-generation CAR cells, Steven Rosenberg’s team 
also treated patients with ovarian cancer using CAR cells engineered against the α-folate 
receptor, a normal cell antigen upregulated in ovarian cancer (Kershaw et al., 2006).  In their 
study entitled “A phase I study on adoptive immunotherapy using gene-modified T cells for 
ovarian cancer”, they treated 14 patients with the CAR cells, but none of the patients showed 
tumor reduction. PCR analysis showed that the engineered T-cells were present in the circulation 
within the first 2 days, but they quickly declined to undetectable levels only one month after 
treatment. So, this early experiment did not show patient improvement, but showed the 
importance of seeking new ways for improving CAR cell survival in the body, including using 
dual activation domains to stimulate T-cell replication and activation. 
 
 
CAR Vaccines and Renal Cell Carcinoma 
 
          Another early attempt to treat cancer using CAR cells was in 2006 by a team of scientists 
at Erasmus University Medical Center (Rotterdam) (Lamers et al., 2006).  The team treated 3 
patients with metastatic clear cell renal cell carcinoma (RCC) with T-cells engineered to express 
a T-cell receptor against G250, a carboxy-anhydrase-IX (CAIX) epitope, frequently over-
expressed in RCC. Although initially the T-cell treatment appeared to be well tolerated, after 4-5 
infusions, each patient developed liver toxicity, the treatment had to be discontinued, and the 
patients continued to show progressive disease.  The authors speculated that the liver toxicity 
likely resulted from antibodies against G250 in liver bile duct epithelial cells.  So, this study was 
not a success, and reminds us of the importance of selecting cancer-specific antigens not present 
in normal tissues. 
 
 
CARs and CD20 Lymphoma 
 
A pilot clinical trial done in the Clinical Research Division of the Fred Hutchinson 
Cancer Research Center (Seattle, WA) showed that CAR cells have the potential to cause 
remissions in lymphoma patients (Till et al., 2008). Four patients participated, and three received 
lymphoma-specific CAR cells after pre-treatment with cyclophosphamide lympho-depletion. 
The treatment was relatively well tolerated. Two patients became progression-free, with no 
measurable disease at 12 and 24 months. The third patient initially had a measurable remission, 
but relapsed at 12 months. The trial demonstrated that modification of T-cells with a CAR 
receptor was well tolerated, and was associated with antitumor activity. 
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CARs and CD19 Leukemia 
  
       By far, the most successful application of CAR vaccines to date is against CD19 on the 
surface of leukemic B-cells (reviewed in: Kochenderfer and Rosenberg, 2013). Engineering T-
cells to target CD19 has provided some of the most striking successes in the entire cancer 
vaccine field. Several labs converged on the CD19 antigen for good reasons: 1) it is universally 
expressed on the surface of all leukemic B-cells, and 2) although normal B-cells are also killed 
by the anti-CD19 treatment, such cells are not absolutely required for patient survival (antibodies 
can be provided passively, or the patient can undergo a bone marrow transplant after ridding the 
cancer cells).  So CD19 is an excellent target. 
 
          One example of an early experiment was performed in 2009 by Carl June’s group at the 
University of Pennsylvania, one of the founders of the CAR field (Milone et al., 2009). In this 
study the team addressed one of the early problems with the CAR cells which was their lack of 
long term persistence in the body.  They hypothesized this resulted from a lack of T-cell 
activation, so they designed a new generation CAR gene containing 2-3 activation domains 
(CD28 and/or CD137, and TCR-zeta). A lentiviral vector was used to introduce the CAR gene 
into human T-cells isolated from a humanized mouse containing lymphoblastic leukemia cells.  
More than 85% of the treated T-cells expressed CD19 TCR on their surface indicating the 
lentiviral treatment worked efficiently to deliver the CAR gene, and the cells survived at least 6 
months. They identified a previously unknown antigen-independent effect for CAR cells 
containing the CD137 tail, and recommended using this activation domain in the future. 
 
          The first successful clinical treatment of leukemia with CD19 CAR cells was in 2010 by 
Steve Rosenberg’s team in their study entitled “Eradication of B-lineage cells and regression of 
lymphoma in a patient treated with autologous T cells genetically engineered to recognize 
CD19” (Kochenderfer et al., 2010). The team first pre-treated one patient with advanced 
follicular lymphoma with preparative chemotherapy to destroy the patient’s own bone marrow 
cells, then perfused patient with CAR cells containing a CD28 co-stimulatory signal. Following 
the CAR treatment, the results indicated that all B-cell precursors were eliminated from the bone 
marrow, and peripheral B-cells were absent at least 39 weeks, despite the healthy rebound of 
other blood cell components. Consistent with the eradication of B-cells, the serum levels of 
antibodies also decreased to very low levels. Importantly, the patient’s B-cell lymphoma 
underwent a dramatic regression, providing a proof-of principle that the CAR approach can 
work, even if the normal B-cells are also eliminated.  The results of this paper were 
controversial, and competitor Carl June later claimed the success could have resulted from the 
use of chemotherapy used to make room for new cells, not from the CAR cells (Couzin-Frankel, 
2013). 
 
          The breakout year for CAR treatments was 2011. Early studies with CAR cells had shown 
some success, but in 2011, Carl June’s group at the University of Pennsylvania (one of the 
founders of the CAR field) published two studies on their design of a CAR against CD19 and its 
use to treat 3 patients with advanced chronic lymphocytic leukemia (CLL). The first study 
entitled, “Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia” (Porter et 
al., 2011), described the team’s construction of CAR cells engineered to express a T-cell receptor 
that recognizes CD19 on the surface of B-cells and leukemia cells.  The CAR cells also 
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contained a CD137 (4-1BB) co-stimulatory signal, and a TCR-zeta cytoplasmic tail to activate 
the T-cells once bound to ligand. The data showed that the CAR cells expanded at least 1000-
fold, migrated to the bone marrow, and continued to produce functional CARs for at least 6 
months, well beyond the trivial survival of earlier CAR cells.  Each CAR cell was calculated to 
destroy about 1,000 cancer cells. One CLL patient showed complete remission. The second 
2011 paper entitled, “T cells with chimeric antigen receptors have potent antitumor effects and 
can establish memory in patients with advanced leukemia” (Kalos et al., 2011), expanded the 
earlier approach to 3 CLL patients. Two of the 3 patients showed complete remission.  Normal 
B-cells expressing CD19 on their surface were also destroyed in this process, resulting in grade-3 
and 4 B-cell aplasia (although in theory this could be treated with a traditional bone marrow 
transplant later on). These two 2011 studies were later attributed by Carl June as breaking open 
the funding for his research team.  He fielded 5,000 requests from patients and their families for 
the therapy, and 800 media outlets world-wide covered the story (Couzin-Frankel, 2013). After 
these two articles were published, the National Cancer Institute reversed their earlier moratorium 
on funding CAR research, and funded Dr. June’s lab with nearly $500,000 a year for 4 years to 
create engineered T-cells for patients. The two patients in remission from his CAR treatment 
were still in complete remission in June of 2013 (Couzin-Frankel, 2013). 
 
Also in 2011, a group of researchers, headed by Dr. Renier Bretijens and Isabelle Rivière, 
part of Dr. Sadelian’s team in the Department of Medicine of the Memorial Sloan-Kettering 
Cancer Center (New York, NY) published their findings on 10 patients with chemotherapy-
refractory chronic lymphocytic leukemia (CLL) or relapsed B-cell acute lymphoblastic leukemia 
(ALL) treated with autologous CAR cells (Brentjens et al., 2011). The data showed that eight of 
the nine CAR-treated patients tolerated T-cell infusions well. Three of four evaluable patients 
with CLL who received prior conditioning with cyclophosphamide showed a significant 
reduction. They concluded that genetically engineering T-cell with CAR was a promising 
approach, and is more likely to show clinical benefit with prior chemotherapy conditioning and 
low tumor burden. 
           
          In 2013, Dr. Stephan A. Grupp’s team at the Children’s Hospital of Philadelphia, and Dr. 
Carl H. June’s team of the University of Pennsylvania published an article in the New England 
Journal of Medicine (Grupp et al., 2013). The team treated two children with relapsed and 
refractory acute lymphoblastic leukemia (ALL) (normally a very poor prognosis) using CAR 
cells targeting CD19 to reduce the proliferation of leukemic B-cells in the blood. The data 
showed that the CAR cells expanded to levels at least 1,000 times higher than the levels injected, 
and were found in the bone marrow and cerebrospinal fluid. Of the 2 children treated, complete 
remission was observed in one patient, while the other patient showed initial remission, but then 
had a relapse with his B-cells no longer expressing CD19 (the CAR cells would not kill them). 
The patients developed grade-3 and -4 adverse events, including a cytokine release syndrome, 
but those events were fully treatable with cytokine blockade antibodies. The authors concluded 
that so-long as the target antigen CD19 remains expressed on the tumor cells, the CAR therapy is 
capable of providing a complete remission. But the emergence of tumor cells during treatment 
that no longer express the target antigen can be a problem, and this study shows the need to 
perhaps target more than one antigen in the tumor.  
 
          Also in 2013, a team of scientists at Memorial Sloan-Kettering Cancer Center (New York, 
NY) headed by headed by Drs. Michel Sadelain and Renier Brentjens, published an article in 
Science Translational Medicine (Brentjens et al., 2013). The team treated 5 patients with 
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relapsed B-cell acute lymphoblastic leukemia (B-ALL) that normally has a very poor prognosis. 
They treated the patients with autologous T-cells transformed with a gene encoding a CD-19-
specific second-generation dual-signaling (containing both a CD28 co-stimulatory signal, and 
CD3-zeta cytoplasmic signaling tail) chimeric antigen receptor (CAR) (termed 19-28z). 
Amazingly, all 5 patients showed a rapid tumor eradication, and appear to have no residual 
disease as assayed by deep sequencing PCR, although one patient eventually relapsed. With 
respect to side-effects, some patients showed significant cytokine elevations, but those 
incidences were treatable with steroid therapy. So, the treatment appeared to be generally well 
tolerated.  
 
Additionally, in 2013, a team headed by Dr. Kochenderfer (of Steven Rosenberg’s team 
at the National Cancer Institute), published their findings of a clinical trial of allogeneic T-cells 
genetically engineered to express CAR targeting the B-cell antigen CD19 (Kochenderfer et al., 
2013). Their study tested 10 patients that had malignancy persisting after initial bone marrow 
transplants and standard lymphocyte infusions. No new chemotherapy was done to any of the ten 
patients prior to the CAR T-cell infusions, so the patients were not lymphocyte-depleted at the 
time of infusions. The data showed that three of the 10 treated patients had regressions of their 
previously untreatable malignancies. One patient with chronic lymphocytic leukemia (CLL) 
obtained complete remission after the T-cell infusion, while another CLL patient had tumor lysis 
syndrome as his leukemia regressed. They discovered that none of the patients developed graft-
versus-host disease (GVHD). PCR showed the presence of the CD19-CAR gene in the blood of 
eight of the ten patients. This study showed that the CAR approach can cause regression of B-
cell malignancies previously resistant to standard treatments without causing graft versus host 
disease. 
 
          In 2014, this same team from the Memorial Sloan-Kettering team discussed above 
published their continuation study on 16 patients with refractory B-ALL treated with the 19-28z 
CAR cells (Davila et al., 2014). They found that 88% of the patients responded well enough to 
the therapy to transition to receive a “routine” allogenic stem cell transplant. They also defined 
the diagnostic criteria for predicting which patients will develop a severe cytokine release 
syndrome (sCRS) that sometimes occurred within the first 21 days of the cell perfusion.  When 
this occurred, the patient was treated with corticosteroids and IL-6-receptor antibodies. The data 
showed that serum C-reactive protein (CRP) can serve as a reliable marker for the severity of the 
CRS, which might help predict which patients will need corticosteroid interventions to lower the 
cytokines.  It was not clear from this study whether the severe cytokine release syndrome is 
restricted to B-ALL type leukemia, or is predicted to occur with other cancers. 
 
          In 2014, Dr. Grupp’s team at the Children’s Hospital of Philadelphia and their main 
collaborator Dr. Carl June of the University of Pennsylvania, also published a paper in the New 
England Journal of Medicine, entitled “Chimeric Antigen Receptor T-Cells for Sustained 
Remissions in Leukemia” (Maude et al., 2014). The team treated 30 patients (children and 
adults) with relapsed acute lymphoblastic leukemia (ALL) with CAR cells transduced with a 
lentiviral vector encoding a CD19-directed chimeric antigen receptor CTL019. Their data 
showed that complete remission was achieved for 27 of the 30 patients (90% remission), with 
67% event-free at 6 months!  This is quite a success story compared to the relatively weak data 
obtained in the early cancer vaccine papers.  The infused cells proliferated in vivo, and were 
detectable in blood, bone marrow, and cerebrospinal fluid.  With respect to side-effects, all 30 
patients developed cytokine-release syndrome (CRS), 27% with severe CRS, but the problem 
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was effectively treated with anti-interleukin-6 receptor antibody (tocilizumab), and the patients 
remained in cancer remission.  
 
In 2014, Dr. Maude’s team at the Children’s hospital of Philadelphia and Perelman 
School of Medicine, University of Pennsylvania, published a paper entitled “Managing cytokine 
release syndrome associated with novel T-cell-engaging therapies” (Maude et al., 2014). They 
described a cytokine release syndrome (CRS) that correlates with both toxicity and efficacy in 
patients receiving CAR therapies. They demonstrated that T-cell activation by the cell treatment 
can produce abnormal macrophage activation. But they also discussed an effective way to 
manage the CRS, the IL-6 blockade by tocilizumab was effective at reversing CRS without 
inhibiting the vaccine efficacy.  
 
          In 2015, scientists at the National Cancer Institute published their findings of a phase-I 
trial for children and young adults with refractory B-cell cancers treated with CD19-CAR cells 
(Lee et al., 2015) (registered as clinical trial NCT01593696).  21 patients were treated with 
autologous CD19-CAR cells engineered by the team’s 11-day manufacturing process. The 
authors included the most recent vaccine designs into their study: the CAR molecule used both 
TCR-zeta and CD28 signaling domains to improve cell activation. The patients also received 
fludarabine and cyclophosphamide chemotherapy treatments prior to CAR infusion. They also 
tested different CAR doses. The maximum tolerable dose was determined to be 1 x 106 cells per 
kg, because all the side-effects were reversible at that dose. The most severe side-effects were a 
grade-4 cytokine release syndrome observed in 3 of the 21 patients (14%). The authors 
concluded from their phase-I data that at 1 x 106 cells per kg, the vaccine is safe, and likely will 
proceed to a phase-III trial. 
  
       Although the release of cytokine hormones from the engineered CAR cells is normally 
viewed as desirable and is one measure of their successful in vivo function, the production of 
very high levels of cytokines is viewed as a “cytokine storm” which can be fatal.  One 2010 
paper from Rosenberg’s team reported the death of a patient five days after receiving second-
generation CAR T-cells (Morgan et al., 2010).  The patient had colon cancer that had 
metastasized to the lungs and liver, and was treated with a CAR containing the monoclonal 
antibody Trastuzumab (Herceptin) against ERBB2 (HER-2/neu, CD28). The patient received 
cyclophosphamide chemotherapy followed by 1010 (100-fold higher than the optimum dose 
described above) T-cells intravenously, and within 15 minutes experienced respiratory distress 
with pulmonary infiltrate. Despite intensive medical intervention, the patient died 5 days later. 
Consistent with a cytokine storm, the patient’s serum samples showed high levels of cytokines 
gamma-interferon, granulocyte macrophage-colony stimulating factor, tumor necrosis factor-
alpha, interleukin-6, and interleukin-10. The authors speculated that the large number of perfused 
T-cells localized in the patient’s lung immediately after the perfusion, triggering cytokine release 
by recognizing low levels of ERBB2 on lung cells (Morgan et al., 2010).  So, this study 
emphasizes the importance of restricting T-cell infusions against neo-antigens that are specific 
for the tumor cells whenever possible.  The T-cell perfusions are not cleared from the body as 
fast as antibody infusions, so their experiments should be monitored closely. 
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Neuroblastoma and GD2 CAR Cells 
 
In 2011, a team headed by Dr. Louis at the Center for Cell and Gene Therapy, Baylor 
College of Medicine, Texas Children's Hospital (Houston, TX) published their long-term clinical 
consequences of CAR T-cell infusion for neuroblastoma patients. The paper was titled 
“Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients 
with neuroblastoma” (Louis et al., 2011). The team generated CAR T-cells against the GD2 
antigen expressed by neuroblastoma tumor cells. Three of 11 patients with active disease 
achieved complete remission and showed the persistence of CAR T-cells. They concluded that 
the CAR cells designed against GD2 can induce complete tumor remissions in some patients 
with active neuroblastoma. 
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Strategies for Improving T-Cell Vaccines 
 
          Overall, with respect to CAR vaccines, as stated in a 2013 review of the topic, “although 
some scientists are urging caution, it is hard not to be swept up in this moment. Despite the small 
numbers of patients tested so far, many oncologists believe that [what these studies show], and 
what others are replicating is unprecedented.  No cell therapy has proliferated in the body as 
well, endured so well, and slain cancer quite like this therapy (Couzin-Frankel, 2013). 
 
          But no therapy is perfect, and one of the purposes of this IQP is to identify potential 
problems of cancer vaccines and discuss future directions. Although researchers are newly 
energized with recent success stories, some scientists argue the development of a totally effective 
T-cell vaccine remains elusive, and there is room for improvement. We have identified the 
following areas for improvement, discussion in interviews, and future directions: 
 
● More Patients:  Almost everyone agrees that more patients need to be tested, and we need to 
follow their success long-term.  In the case of CAR vaccines, because those treatments are so 
recent, only a handful of patients have been followed for more than a year. 
 
● Which Cancers?  Can the treatments work on solid tumors as well as they work for 
leukemia? 
 
● Which Antigens?  According to Carl June, one of the founders of the CAR field, “The major 
challenge currently facing the [cancer vaccine] field is to increase the specificity of the 
engineered T-cells for tumors, because targeting shared antigens leads to off-tumor toxicities, 
as observed in recent trials” (Kalos and June, 2013).  This means we need to identify which 
tumor antigens are best to prime T-cells against to increase their ability to control a tumor.  
Recent studies indicate that T-cell activity directed against newly formed neo-antigens 
(natural proteins altered by DNA mutations in the exon portions of DNA, and present on the 
tumor surface) represent a major predictor of which TIL or CAR cells will be effective 
(Schumacher and Schreiber, 2015).  Because the neo-antigens were not present during the 
patient’s own fetal development (when his immune system was forming), the neo-antigens 
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are not viewed as “self”, and this increases the likelihood of their being recognized as 
“foreign” by TILs. A recent study with patients with non-small cell lung cancer showed that 
a high amino acid substitution rate in tumors (to create neo-antigens) was associated with 
durable clinical benefits and progression-free patient survival (Rizvi et al., 2015).  So, we 
need to improve our methods for rapidly identifying neo-antigens to avoid immune attack on 
healthy tissue, and we need to develop algorithms to help predict which neo-antigens will 
actually be antigenic in vivo (Lee et al., 2012; Curran et al., 2012; Lipowska-Bhalla et al., 
2012; Robbins et al., 2013; Rajasagi et al., 2014; Delamarre et al., 2015). As an example, in 
the Carreno et al. (2015) study of melanoma patients, their DNA sequencing identified 
several hundred mutations in exons in the tumor DNA, but only a small fraction of those 
were presented by MHC-1 and -2, and of the 7 used for vaccination only 3 turned out to 
actually be antigenic!  So, we need to continue to better improve our bioinformatics 
computer algorithms based on more data obtained from real patient responses. 
 
 What Correlates with the Best Protection?  We need to more clearly define the “correlates of 
protection” for specific cancers (Appay et al., 2008).  Do the patients that show the longest 
survival have the highest number of TIL and CAR cells in vivo?  Do they have CAR cells 
that target multiple tumor antigens, or one tumor antigen? 
 
● Loss of Tumor Antigens.  In some cases, a tumor may no longer express a neo-antigen that 
was expressed earlier, so any immune vaccine would no longer be effective against that 
patient’s tumor (Delamarre et al., 2015).  Perhaps more experiments need to be performed to 
understand this loss of antigenicity, and the vaccines should be designed against multiple 
antigens if possible. 
 
● Personalized DNA Sequencing: The exact type of neo-antigen present in a patient’s tumor 
varies from patient to patient.  So, we need to apply the new technologies of rapid DNA 
sequencing to identify the mutations present in each tumor, and design a personal vaccine 
against this specific neo-antigen.  But this type of personalized medicine increases the 
expense of the vaccine, so who pays for this?  Also, one famous patient Emily Whitehead (6 
years old in 2013) a survivor of end-stage leukemia, treated in Carl June’s lab with CAR 
cells, developed an immune over-drive following her treatment (Couzin-Frankel, 2013).  
Near death in the hospital’s intensive care unit, the doctors realized she was over-producing 
IL-6, and managed to save her life by giving her an arthritis drug that disables IL-6.  When 
her DNA was sequenced, the doctors realized that Emily had a mutation that causes a 
hyperactive immune response. So, perhaps these mutations should be screened for prior to T-
cell therapies, to know in advance whether to expect an adverse side-effect from the vaccine. 
 
● Speed of T-Cell Amplification: Some types of cancer develop faster than others. For 
example, malignant melanoma if diagnosed in stage-IV can kill a patient within weeks, while 
prostate cancer usually develops over several years. So, when treating patients with rapidly 
growing tumors, speed is critical, and we need to develop methods for accelerating the 
production of T-cells.  Carl June of the University of Philadelphia says that one major 
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engineering challenge [for the cancer vaccine field] is the development of automated cell 
culture systems (Kalos and June, 2013), so perhaps this would help accelerate the process. 
 
● Overcoming Immune Suppression: Recent studies have shown that the tumor environment 
suppresses the immune system to allow the tumor to survive, and recent successes have been 
achieved blocking this suppression using antibodies against PD-1 or CTLA-4 (Topalian et 
al., 2011; Curran et al., 2012; Sharma and Allison, 2015). Steven Rosenberg’s lab showed 
that TILs isolated from patient melanoma tumors (i.e. those that successfully targeted the 
tumor) were PD-1 positive (suppressed) (Gros et al., 2014). So, perhaps combination 
vaccines comprised of T-cells against neo-antigens plus PD-1 antibody should be tested. 
 
● Patient Pre-Treatments:  Recent clinical trials have demonstrated that chemotherapy 
treatment of leukemia patients prior to T-cell transfer helps reduce the number of B-cells in 
the patient, allowing the engrafted T-cells to expand. This pre-treatment appears to improve 
the effectiveness of the vaccine (Curran et al., 2012).  Would this pre-treatment be effective 
for all kinds of tumors? 
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METHODS 
 
 
To accomplish objective-1, we performed a review of the current research literature, 
including reputable academic journal articles, relevant books, scholarly websites, newspaper 
articles, and other pertinent materials. 
 
To accomplish objective-2, we conducted a set of interviews with various academic 
researchers who have performed cancer vaccine research on animals or in human clinical trials, 
or scientists who have used traditional cancer fighting technology, to determine their range of 
opinions on the strengths and weaknesses of this new technology and whether other techniques 
could accomplish the same goal of eliminating cancer. 
 
Who:  The stakeholders included academic experts on cancer vaccines and on traditional 
cancer therapies, and general health experts on cancer. These experts helped answer questions 
resulting from our Lit Review search, and helped us prioritize any remaining problems. Some of 
the stakeholders were initially identified by referral from the project advisor, David Adams, 
while other interviewees were identified from the published literature as authors on key scientific 
papers, or by referral from the initial interviewees. 
 
Where and When: Once contact had been made with a potential interviewee (see 
below), a time and place was set up for the interview to be performed at the interviewee’s 
workplace. Whenever possible, interviews were conducted in person, although most were 
conducted by email, phone, or Skype. 
 
How:  Initially, an interviewee was contacted by email and/or phone.  If no response was 
received, we used follow-up emails or phone calls.  We developed our interview questions (see a 
list of questions in the Appendix) based on our review of the literature, and tailored the questions 
to the interviewee’s expertise. Based on the interviewee’s initial responses to our first questions, 
we designed follow-up questions to best obtain information from that person.  We informed the 
interviewee about the purpose of our project, and asked for permission to quote them (see 
interview preamble in the Appendix). When necessary, we explained how we would protect their 
confidentiality, by giving them the right to review any quotations used in the final published 
report, explaining that the interview is voluntary, and explaining that they may stop the interview 
at any time or refuse to answer any question.  After the interview, we asked for permission to 
follow-up with them at a later date if needed to fill in any gaps in the information, and sometimes 
asked their guidance for other potential stakeholders we might interview.  With respect to the 
total number of interviews needed for our project, we stopped interviewing additional subjects 
when sufficient information had been obtained representing all sides of the cancer vaccine story, 
and when all unclear points had been clarified. 
 
To accomplish objectives-3 and 4, the group synthesized all of the information collected 
in the literature research, interviews, and follow-up interviews, to ascertain the strength of the 
evidence on cancer vaccines and to create recommendations for further research. 
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RESULTS / FINDINGS 
 
 
Cancer        Anthony Kassas 
 
 This section of the IQP project focused on a general introduction to cancer.  One problem 
identified in the review of the literature in this area was the need for a universal cancer vaccine 
that could treat all types of cancers.  Most cancer vaccines target either a specific antigen on the 
surface of a tumor cell known in advance, or target a mixture of antigens present during the cell 
“charging” stage.  But these antigens vary depending on the type of tumor.  To gain insight into 
whether it is feasible given our current approaches to cancer vaccines to make a universal 
vaccine, we interviewed world-famous cancer researcher Dr. Robert A. Weinberg of the 
Whitehead Institute for Biomedical Research (Cambridge, MA).  We identified Dr. Weinberg as 
a corresponding author on a 2011 paper in Cell, Mar 4; 144(5): 646-674, entitled “Hallmarks of 
cancer: The next generation”.  When asked whether he thought it would be feasible to design a 
universal cancer vaccine that would target all types of tumor cells at this time, he stated “Thanks 
for your interest. I must say that at present it seems unlikely that we will have a universal anti-
cancer vaccine, given the variability in the antigens that are displayed by different types of 
tumors. One should never say "never", but to my mind, it seems unlikely that a universal vaccine 
will be developed”.  So, Dr. Weinberg indicates that based on our current knowledge of tumors it 
is not likely a universal vaccine will be developed.  So, we should celebrate our recent successes 
with targeted therapies. 
 
This same important question of the possibility of a universal cancer vaccine was asked 
of Dr. Giuseppe Curigliano of the Viale Romagna, 43 20133 (Milano, Italia).  Dr. Curigliano 
was one of the authors of a 2012 paper published in Expert Opinion on Investigational Drugs, 
February 2012, Vol. 21 (2): 191-204, entitled "Targeting the Subtypes of Breast Cancer: 
Rethinking Investigational Drugs."  When asked about universal cancer vaccine design, he 
replied “A universal vaccine should be driven by a specific target expression. You can develop a 
peptide vaccine to enhance immune response against a specific antigen potentially expressed in 
multiple tumors but, in any case, you need the expression of the antigen that should be targeted 
by your adaptive immune response”.  So, Dr. Curigliano indicates that it might be feasible to 
design a cancer vaccine against multiple tumors, if those tumors all expressed the same protein 
targeted by the vaccine.  But this is not the same as a truly universal cancer vaccine that would 
target.  Perhaps an example would be a vaccine targeting CD19 on the surface of B-cells that 
might be effective against any type of B-cell tumor, but that vaccine would not work on non-B-
cell tumors, so would not truly be universal. 
 
 Another problem identified in the cancer Lit Review section was the application of new 
second-generation sequencing technologies to identify a specific mutated surface target protein 
for the cancer vaccine to be designed against.  Questions arose concerning personalized 
medicine, and whether this sequencing approach can be fast enough to help a patient with 
advanced cancer, whose prognosis is limited.  To obtain more information on the subject, we 
interviewed Dr. Jin-Tang Dong of 1365-C Clifton Road NE (Atlanta, GA).  Dr. Dong is the 
author of a 2006 paper published in the Journal of Cellular Biochemistry, 2006 Feb 15; 97(3): 
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433-447, entitled “Prevalent mutations in prostate cancer.” In that study, the team used new 
generation sequencing methods to identify mutations common in human prostate cancers.  When 
asked, based on his experience with second generation sequencing methods, whether he thought 
the new technologies were fast enough to provide a protein target information for a patient with 
advanced cancer so the vaccine could be delivered fast enough, he stated that “sequencing can be 
done fast enough nowadays to apply to a specific patient.”  However, he did not mention specific 
lengths of time required for this type of analysis. 
 
 
Peptide Injections and Monovalent Antibody Vaccines     Muhammad Siddiq 
 
 This section of the project focused on cancer vaccines composed of peptides injected in 
vivo to induce an immune response, or cancer vaccines using monovalent antibodies (designed 
against one target).  One problem encountered in this section was it was unclear what constitutes 
a successful versus an unsuccessful cancer vaccine design.  To gain more insight, we interviewed  
Dr. James C. Paulson, President and CEO (Acting), and the Departments of Cell and Molecular 
Biology, Immunology and Microbial Science, and Physiological Chemistry, Scripps Research 
Institute, MB-202, 10550 N. Torrey Pines Road (La Jolla, CA).  Dr. Paulson was senior author 
on a 2014 paper in Nature Reviews Immunology, 2014 Oct; 14(10): 653-666, entitled “Siglec-
mediated regulation of immune cell function in disease”. The Siglec immunoglobulin 
superfamily of proteins are complex.  Some members like CD22 are inhibitory receptors that 
once they are bound to their ligand prevent over-activation of the immune system and prevent 
the development of autoimmune diseases. Because CD22 is located on B-cells, antibodies 
against it are sometimes used to treat leukemia where B-cells are overproduced.  When asked his 
opinion about the basis for the effectiveness of his Siglec CD22 vaccine and whether early 
interventions are important, he stated “I am happy to hear that our publication is of interest to 
you.  We believe that Siglecs have an advantage as targets for some types of leukemia and 
lymphoma because they are expressed on very few cell types. This allows highly selective 
targeting of chemotherapeutic agents. Many siglecs are also endocytic receptors that take the 
antibody or nanoparticle into the cell once it binds. As for the timing of the cancer treatment, 
earlier is always better than trying to treat a late stage of the disease. But otherwise, I think that 
siglec-targeted therapies do not have an advantage over others based on the treatment timing”. 
So, Dr. Paulson indicates that siglecs in general are excellent targets for some forms of leukemia 
and lymphoma because they are expressed almost exclusively on those cells, so there would be 
little damage to normal tissue during the treatments.  It’s also interesting that many siglecs are 
also endocytic receptors, so items bound to them are internalized in the cell by endocytosis in 
vesicles, and can be used for drug delivery (although this is not the subject of our project). Dr. 
Paulson also indicates that in cancer therapies, earlier treatments are always better, whether 
targeting siglecs or any other cancer target. 
 
 In some interviews, our questions led the interviewee to point us to other published 
studies or to examples of scientific meeting where these types of topics are debated.  An example 
of this was our interview with Dr. Dieter Hoelzer, MD, PhD, of the Onkologikum, Frankfurt am 
Museumsufer, Schaubstrasse 16, D-60596 (Frankfurt, Germany). Dr. Hoelzer was sole author on 
a 2013 review article in Cancer, 119: 2671-2674, entitled “CD22 Monoclonal Antibody 
Therapies in Relapsed, Refractory Acute Lymphoblastic Leukemia”.  When asked how his 
CD22-targeting approach to B-cell tumors compares to the widely known CD-19 approach for 
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B-cell tumors, he responsed “The information about CD22 and CD19 you can see in recently 
published papers, e.g. Kantarjian et al, Lancet Oncology, 2012, but the main source for 
answering your questions are the recent abstracts of the American Society of Hematology”. 
 
Continuing to gain information on the possibility of combination vaccines, we contacted 
Professor Philippe Colombat, the Hepator-Gastro-Onco-Enterlogie Professor at CHRU de 
Tours, Hospital Trousseau, Avenue de la Republique, Chamray-les Tours, 37044 Tours Cedex 9, 
France.  Dr. Colombat was author of a paper entitled “Rituximab (anti-CD20 monoclonal 
antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor 
burden: clinical and molecular evaluation.”  In this study, the team used CD20 rituximab mAb 
against follicular non-Hodgkins Lymphoma (NHL) in 50 patients. The patients received four 
weekly infusions of rituximab at a dose of 375 mg/m2. Their data showed that molecular 
responses to the therapy could be sustained for up to 12 months, and the response highly 
correlated with progression-free survival (p<0.0001).  Professor Colombat was asked whether 
rituximab therapy might provide stronger results if used as a combination treatment with other 
types of antibodies or cells, and he responded, “In fact, at this time we know that six patients 
have been cured with this approach. I think that future will be the combined association with 
other targeted therapies with no late secondary effects for these patients who need no 
chemotherapy.” So, rituximab has been effective in treating some patients with NHL, and 
combination vaccines appear to be on the horizon. 
 
 
Bivalent Antibodies and Immune Checkpoint Inhibitors          Isaac Vrooman 
 
This area of the IQP focused on two types of cancer vaccines: 1) bivalent antibodies 
(directed against two different targets simultaneously), and 2) antibodies against proteins PD-1 
and CTLA-4 (the antibodies block PD-1 and CTLA-4 which are inhibitors of the immune 
system; blocking the blocker stimulates the immune system to fight the tumor). 
 
One problem identified in this section of the project is the targeting of the vaccine not just 
to the cancer cells but to normal cells in the body.  A good example of this is provided by the use 
of Blinatumomab, a monoclonal antibody directed against CD-19 protein on the surface of B-
cells.  Removing B-cells from the body is a desired outcome when treating various types of B-
cell tumors, such as leukemia, especially when treating acute lymphoblastic leukemia (ALL) 
with its 90% death rate.  But in doing so, normal B-cells that produce antibodies are also 
removed from the body. These B-cells help to fight infections, so the treated patients sometimes 
die from opportunistic infections from routine organisms such as E. coli or yeast. 
  
To obtain more information on this issue, we interviewed Dr. Nicola Gökbuget who is 
GMALL Chair of the University Hospital Frankfurt at Goethe University (Frankfurt, Germany).  
Dr. Gökbuget was second author on a 2015 paper published in Lancet Oncology, 16(1): 57-66, 
entitled “Safety and Activity of Blinatumomab for Adult Patients with Relapsed or Refractory B-
Precursor Acute Lymphoblastic Leukaemia: A Multicentre, Single-Arm, Phase-2 Study”.  In this 
phase-2 clinical study, the team treated 189 patients with relapsed or refractory B-Precursor 
Acute Lymphoblastic Leukaemia (ALL) with Blinatumomab, a monoclonal antibody targeting 
CD19, an antigen consistently expressed in B-lineage acute lymphoblastic leukemia cells. After 
two vaccine treatments, 81 of the 189 (43%) showed complete cancer remission, compared to a 
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standard ALL life expectancy of only 10%. The most frequent adverse events observed were 
febrile neutropenia (25%), neutropenia (16%), and anemia (14%).  2% showed a grade-3 
cytokine release syndrome, and 3 deaths resulted from sepsis from E. coli and Candida, likely as 
opportunistic infections occurring once the B-cells had been eliminated by the CD-19 vaccine.  
When asked about some of the adverse events seen with their CD-19-targeting cancer vaccine, 
Dr. Gökbuget stated “Acute lymphoblastic leukemia [ALL] in relapse is a life threatening 
disease. Survival is less than 10%. The standard therapy is intensive chemotherapy which is 
associated with adverse events in more than 90% of the patients; nearly all patients experience 
cytopenias. There is also a considerable mortality e.g. due to [opportunistic] infections. 
Compared to this standard, and given the poor overall outcome [of ALL patients], the adverse 
event profile of blinatumomab is really acceptable”.  So, in this interview the author verifies that 
indeed some side-effects are seen with their Blinatumomab antibody treatment, including 
occasional death by opportunistic infection, but the side-effects also routinely seen during all 
treatments for acute leukemias, and are negligible considering the usual death rate of 90%.  So, 
their 43% complete remission success rate is a strong improvement for acute leukemia 
treatments. 
  
Patients with chronic lymphocytic leukemia often relapse after traditional chemotherapy 
treatments, and currently there are no long-term cures. Patients with chronic lymphocytic 
leukemia face horrific odds with a less than 10% survival rate. In recent years, research has 
begun testing bi-specific antibody vaccines. One of the best characterized bi-specific treatments 
targets CD19 (expressed on the surface of most B-cell cancers) and CD3 (expressed on T-cells).  
To gain more information on the CD19/CD3 approach, we interviewed Dr. Ralf Bargou of the 
Max Delbruck Center for Molecular Medicine, Robert-Rossle-Str. 10, 13125 (Berlin, Germany). 
Dr. Bargou and his colleagues published an article in 2003 in Leukaemia entitled “Efficient 
Elimination of Chronic Lymphocytic Leukaemia B-Cells by Autologous T-Cells with a Bi-
Specific Anti-CD-19 / Anti-CD3 Single Chain Antibody Construct”. In their article, the team 
discussed their compound’s ability to bind in vitro primary B-cells and autologous T-cells 
isolated from healthy volunteers and from chronic lymphocytic leukemia (B-CLL) patients. 
Their results showed a depletion of lymphoma cells in 22 out of 25 patient cases. In our 
interview with Dr. Bargou, we asked him to compare his team’s BiTE bi-specific antibody 
approach with the CAR approach against CD19.  In response, Dr. Bargou stated that “he hoped 
to bring his bi-specific antibody tests to clinical trials very soon”. He also answered “How does 
the BiTE approach [his team’s bi-specific drug] compare to CARs? The future will show. Both 
are very similar approaches to utilize T-cells for cancer therapy and show similar clinical results. 
Maybe in the future one will test a new target antigen in the first step with the BiTE approach, 
because it is safer. And then in the second step by CARs. One might also speculate on 
combination approaches utilizing different immunotherapies and different target antigens.” So in 
this interview Dr. Bargou indicated that his bi-specific antibody approach works well enough to 
enter clinical trials, and that it would be interesting to use BiTE in combination with a CAR 
vaccine, either targeting the same antigens or different antigens. 
 
To obtain more information, we interviewed Dr. Patrick Baeuerle of Amgen Research 
in Munich, Germany. Dr. Baeuerle was a senior author on a 2002 paper in the International 
Journal of Cancer entitled “Extremely Potent, Rapid, and Costimulation-Independent Cytotoxic 
T-Cell Response Against Lymphoma Cells Catalyzed by a Single-Chain Bispecific Antibody”. 
In their research, the authors tested the efficacy in vitro of the same vaccine that was tested by 
Dr. Bargou and his colleagues. Dr. Baeuerle and his team found that the lysis of the tumor cells 
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in vitro was mediated by CD8+ T-cells, and that CD19-negative cells (non-B-cells) were not 
harmed by the CD8+ T-cells induced by the antibody vaccine.  In our interview with Dr. 
Baeuerle, we asked him if thought the bi-specific antibody approach was as specific in vivo as in 
vitro. In his response, Dr. Baeuerle said “The bivalent antibody approach is not a vaccination!  
Any CD8+ T-cells, regardless of T-cell receptor specificity, will be physically bound for lysis. 
There may be a vaccination effect once tumor tissue is destroyed by redirected polyclonal T-
cells, but we never explored this in detail.” So, this response indicates this team does not term 
their passive delivery of a bispecific antibody into a patient as a “vaccine”, because it does not by 
itself induce an adaptive immune response against the tumor.  Instead, the antibody physically 
connects a tumor cell to any T-cell (regardless of its commitment) to activate the T-cell to lyse 
the tumor. The T-cell does not undergo a response to produce a T-cell receptor against the tumor 
cell, it is simply physically bridged to the tumor cell. This physical bridging is an important 
concept with bi-specific antibodies. 
 
The physical behavior of blinatumomab was further confirmed by our next interviewee, 
Dr. Matthias Klinger of BiTE Immunology at Amgen Research in Munich, Germany. Dr. 
Klinger was the corresponding author on a recent 2015 paper in Molecular Immunology entitled: 
“Clinical overview of anti-CD19 BiTE® and ex vivo data from anti-CD33 BiTE® as examples 
for retargeting T-cells in hematologic malignancies”.  The authors describe their clinical 
programs to treat B-precursor acute lymphoblastic leukemia (ALL) and B-cell non-Hodgkin 
lymphoma (NHL). For the ALL patients, they found a relapse-free survival (RFS) rate of 60% 
with sustained negative minimal residual disease (MRD) at 31 months. The remissions were seen 
in both pediatric and adult patients, and have allowed the patients to progress to successful 
allogeneic hematopoietic stem cell transplantation (HSCT). The antibody also resulted in durable 
responses in low-grade B-cell NHL. Blinatumomab recently gained approval in the United States 
by the U.S. Food and Drug Administration for treatment of Philadelphia chromosome-negative 
B-precursor relapsed/refractory acute lymphoblastic leukemia. The authors also describe their 
AMG 330, an investigational anti-CD33 BiTE® antibody construct. This antibody has not been 
used in patients yet, but has worked against cells taken ex vivo from patients with acute myeloid 
leukemia (AML). In the interview with Dr. Klinger, we asked to clarify his lab’s hypothesis on 
the CD3 targeting. We also asked if the bispecific antibody physically brings together activated 
T-cells with the target B-cell to facilitate the killing, or if CD3 engagement also helps activate 
the T-cells. In response, Dr. Klinger wrote “Blinatumomab bridges T-cells to B-cells by 
simultaneously binding to CD3 and CD19, thereby activating T-cells and leading to redirected 
lysis of bound B cells.” So, Dr. Klinger validated that the bi-specific antibody Blinatumomab 
directed against CD3 on T-cells and CD19 on B-cells makes a “bridge” that physically holds the 
two cells together, thus activating the T-cells to kill the B-cell (which in this case is a leukemia 
cell).  
 
With respect to PD-1 inhibitors such as Nivolumab, one interesting idea we quickly 
settled on was combining checkpoint inhibitor antibodies (like anti-PD-1, to activat the immune 
system) with antibodies targeting specific tumor antigens.  This approach might be more 
successful than using a singular approach.  To obtain more information on this, we chose to 
speak with Dr. Suzanne Topalian of the Department of Surgery in Johns Hopkins University 
School of Medicine (Baltimore, Maryland). Dr. Topalian was the first author on a 2014 study 
published in the Journal of Clinical Oncology, entitled “Survival, Durable Tumor Remission, 
and Long-Term Safety in Patients with Advanced Melanoma Receiving Nivolumab”. This article 
was a continuation of the author’s ongoing clinical trials with Nivolumab, an antibody against 
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programmed cell death-1 (PD-1), but here they assayed some of the long-term effects after 
removing the antibody. The purpose of Nivolumab is to bind and inactivate PD-1 to allow T-cell 
functions to remain active.  The authors of this paper analyzed 107 patients with advanced 
melanoma.  Their data showed a mean overall survival of 16.8 months for the treated patients, 
with 1-year and 2-year survival rates of 62% and 43%, respectively.  They concluded that the 
effects were durable and even persisted after drug discontinuation, and safety was acceptable 
(toxicity rates similar to previous reports). In our interview with Dr. Topalian, we asked if she 
and her team had tried combining the PD-1 approach with antibodies directed against tumor 
proteins and if the surface proteins specific for melanomas were identified yet. In her response, 
Dr. Topalian stated that “Combination therapies based on anti-PD-1 or anti-PD-L1 are now 
moving into clinical testing.  This includes combinations with tumor-specific antibodies.  One 
example is anti-PD-1 plus Herceptin in breast cancer. For melanoma, it has been difficult to find 
antibodies that are truly melanoma-specific and do not target other tissues.” This was very useful 
information.  First we determined that indeed our idea of combination approaches have appealed 
to other scientists, and some labs are starting to combine the PD-1 approach with other immune 
responses against tumor antigens (she gave the example of breast cancer and PD-1 and 
Herceptin).  And we also learned that as we expected, tumor-specific antigens for melanoma 
have not yet been identified. 
 
 
DC Vaccines: Animal Experiments and Provenge     Derek Brinkman 
 
With continued research in the field of dendritic cells (DCs) and their immunological 
properties, their relationships with other immune system components are consistently being 
discovered by researchers that help shed light on the pivotal role DC’s play in antitumor 
immunity. Important connections and discoveries continue to be made within the DC vaccine 
subfield that are opening doors for future treatment possibilities. However, one of the challenges 
our team recognized while researching DC cancer therapies is what defines the effectiveness of 
these treatments in tumor regression. Relationships with DCs with natural killer cells (NKs) was 
recently identified, but how this interaction could benefit cancer vaccines was unclear. And all 
the interactions occurring in between various cells of the immune system often fail to eliminate 
the tumor, so the role of checkpoint inhibitors becomes very important. Even if all other 
processes succeed to create T-cells specific for tumor antigens, these cells can become inhibited 
by immune checkpoint proteins in the tumor cells engaging receptors on the T-cells. This 
discovery has helped our team understand just how easily one inactivation step can lead to 
ultimate vaccine failure.  
 
 A problem that we encountered in the DC section is those vaccines do not seem to have 
the same spectacular successes as the TIL and CAR vaccines.  Provenge was the first DC 
vaccine approved by the FDA, but its effectiveness is somewhat controversial.  The interactions 
DC’s produce within the immune system have proven to be important, but after decades of 
investigation, the question remains whether scientists believe in the viability of DC-based cancer 
treatments when used alone. 
 
 To assist our team with this query, we contacted Dr. David Raulet who is a Co-Chair in 
the Department of Molecular and Cell Biology at the University of California Berkeley. Dr. 
Raulet was the senior author on a 2015 paper published in Science, 348: 136-139, entitled: “A 
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Shed NKG2D Ligand That Promotes Natural Killer Cell Activation and Tumor Rejection.” In 
this publication, the team discusses the traditional method of immune-surveillance used by 
natural killer cells (NKs) to identify and eliminate cancer cells. The paper was aimed at 
investigating a model in which tumors are able to evade detection by shedding a membrane 
protein that links to NK receptor NKG2D to inactivate the NKs. Raulet’s study demonstrated 
that in murine subjects, a shed form of MULT1 actually enables the NK cells to create an 
immune response when bound with NKG2D, which promotes tumor rejection in both 
subcutaneous and peritoneal tumor types. Based on this successful finding, our team inquired 
about the future of combinations of NK and DC vaccines, most importantly whether DC 
vaccines would be used jointly or if the NK vaccines would become the new “gold standard.” To 
this, Dr. Raulet speculated that, “ultimately most immunotherapies will be used in combinations. 
Whether DC therapies are the way to go will require more experimentation. It is too soon to have 
a strong opinion about that. DCs do seem to be important for activating NK cells, so it is a 
reasonable approach to consider.” Here Dr. Raulet states his belief that vaccine combinations are 
a very likely option for future experimentation. He also states that while not enough is known 
about DC vaccine methods to make concrete determinations, he feels it is a promising avenue to 
explore.   
 
 To supplement the above information on NK and DC cells, our team turned to Dr. Guido 
Ferlazzo for his input on the subject. Dr. Ferlazzo works both as a Professor in the Human 
Pathology Department and researcher in the Immunology and Biotherapy Lab at the University 
of Messina (Messina, Italy). In addition to over 80 other scientific publications, Ferlazzo was the 
corresponding author on a 2012 paper in PLoS ONE, 7(6): e39170, entitled: “Dendritic Cell 
Editing by Activated Natural Killer Cells Results in a More Protective Cancer-Specific Immune 
Response.” In this study, the team demonstrated for the first time the cause-effect relationship 
when DCs are activated in vivo and NKs subsequently kill off immature DCs to create a more 
effective immune response. The team achieved this result by injecting YAC cells into mice, 
which lack the MHC-1 component so they activate NK cells. The study showed that an NK cell-
mediated killing of DCs resulted in higher cytotoxic T lymphocyte (CTL) expansion against the 
invading tumor cells. To understand the magnitude to which this NK-DC-CTL relationship could 
be utilized, we contacted Dr. Ferlazzo to ask him whether this YAC cell injection method that 
activated NKs to kill immature DCs could be used to treat all forms of cancer or only specific 
subsets. Ferlazzo responded stating that, “the single limitation I can see is a poor immune-
genicity of the tumor. The one described in the paper is an experimental model with an immune-
dominant epitope expressed by cancer cells employed for vaccination. What we show is that the 
interaction between activated NK cells and DCs can improve the T-cell response, most likely 
because of a better antigen presentation secondary to DC editing by NK cells.  So, in general 
there would be no limitation for thet use of this approach on tumor types as long as the tumor 
cells present some antigenicity.”  So, here our team learned that as long as the tumor is 
immunogenic (it can provoke an immune response) Ferlazzo believes that the NK activation 
approach would work for any type of tumor.  By jointly using NKs and DCs, not only are the 
strongest DC’s surviving to maturity, but the NKs are also performing intricate edits to the DCs 
to promote more effective T-cell responses. 
 
 Often times, even when using a combined vaccination effort, an immune response can 
ultimately fail due to the activation of checkpoint inhibitors by the tumor. Understanding what 
causes these inhibitors to nullify immune functions and how to eliminate the block led us to Dr. 
Laurie Glimcher’s lab in New York. Dr. Glimcher manages a team of researchers in the 
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Department of Medicine at Weill Cornell Medical College (New York, NY). She is also the 
corresponding author on a 2015 paper in Cell, entitled “ER Stress Sensor XBP1 Controls Anti-
Tumor Immunity by Disrupting Dendritic Cell Homeostasis.” Previous studies identified that the 
endoplasmic reticulum (ER) stress response factor XBP1 directly promotes tumor growth. 
Glimcher and her team discovered that it does so by becoming active in DCs that migrate 
towards the tumor thus inhibiting the T-cell support that DCs typically provide. The team used a 
mouse model of ovarian cancer to demonstrate this inhibitory effect, and showed that by deleting 
the stress factor, it allows the DCs to function again to induce an anti-tumor response. So, by 
blocking this XBP1 inhibitory pathway, the team showed that DCs could regain their function to 
attack the cancerous cells. When asked about the possibility of vaccinating with tumor-specific 
antigens to improve treatment efficiency, first author of the study Dr. Juan Cubillos-Ruiz 
responded. In his reply he stated that, “We have observed that these DC are capable of engulfing 
tumor-derived proteins in vivo. The problem is that the DCs are unable to properly process and 
present the antigenic peptides to T-cells in the tumor microenvironment. We have never tested 
your idea because it has been difficult to identify ovarian cancer-specific antigens that can be 
used as an effective “vaccine”.” He goes on to add that if they performed vaccinations with 
immune-dominant tumor antigens, that these could “prime and elicit tumor-specific T cells (both 
effector and memory), which can migrate to tumor sites.” From this interview, our team learned 
that the use of cancer-specific antigens for vaccination is not currently an option with ovarian 
cancer because none have been identified yet. However, Dr. Cubillos-Ruiz believes that in some 
cases, this treatment can be effective if immunodominant antigens are used.  This paper and 
Cubillos-Ruiz’s insight has demonstrated that it is possible to eliminate or nullify checkpoint 
inhibitors, but more research is required to direct the immune activation against 
immunodominant tumor-specific antigens. 
 
 Based on the knowledge our team gained from the publications and interviews, we can 
draw conclusions about what future research in this subfield will likely focus on. Clearly the 
trend is to use combination vaccines.  This is demonstrated in the studies performed by Raulet 
and Ferlazzo on the key interactions between NKs and DCs. From the literature review, we can 
say that type-I interferons are necessary to mount an effective anti-tumor response, and DC 
involvement is necessary to process tumor antigens to produced activated CD8+ T cells. So, 
although the subtopic of this section is DC vaccines, their effectiveness would not be possible 
without other relevant immunity components. Another topic of importance is that of immune 
process editing. At all times, the immune system is evolving to counteract the expanding 
cancerous cells. The relevance of this adaptation factor is shown in Dr. Ferlazzo’s study where 
NKs modify DCs to promote the most mature cells and enhance the overall effectiveness of the 
immune response. In other cases, checkpoint inhibitors evolve to inhibit DC functions that, if not 
restored, can cause the entire anti-tumor response to fail. If researchers can study the constant 
evolution of both tumors and the evolving immune responses, it will hopefully lead to more 
effective eradication of cancerous cells before severe damage is done.  
 
 
DC Vaccines for Melanomas and Glioblastomas     Zhizhen Wu 
 
In the review of literature in this section we found that pre-conditioning patients with 
recall antigen tetanus/diphtheria (Td) toxoid could improve DC vaccine effectiveness. It was 
shown in a clinical trial that pre-conditioning the vaccine site with Td can stimulate migration of 
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DCs to the lymph nodes (where they function to present antigens to T-cells), and the DC vaccine 
significantly prolonged patient survival. This finding introduces a question whether this pre-
conditioning approach would work with other recall antigens and with other types of cancer.  To 
obtain more information about this question, we interviewed Dr. John H. Sampson, the Chief of 
Neurosurgery Division of the Department of Surgery of Duke University Medical Center.  Dr. 
Sampson was the senior author on a paper published in a 2015 issue of Nature (519: 336-369), 
entitled "Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma 
patients”. In this blinded clinical trial, the team randomized 12 newly diagnosed glioblastoma 
patients and pre-conditioned them with Td or un-pulsed DCs. Then all patients were vaccinated 
with DCs pulsed with Cytomegalovirus phosphoprotein 65(pp65) RNA. The successful 
accumulation of injected DCs in the lymph nodes (where they can process antigen and present it 
to T-cells) and overall patient survival was higher for the patients pre-conditioned with Td. 
When asked about the potential use of other recall antigens’, Dr. Kristen Batich, another co-
author of the same paper, stated, “In a pre-clinical setting in mice, we have tried two other 
protein antigen formulations, the pedvax hib vaccine and the prevnar-13 strep pneumo 
formulation. We found that these other pre-conditioning vaccines worked well for facilitating the 
migration of our DC vaccine.” Thus, in this interview the author verified that they have indeed 
tested two other recall antigens in mice, but they have not yet tested those antigens’ ability to 
stimulate anti-tumor responses or improve survival in humans. So Td pre-conditioning remains 
the most effective approach for now. 
 
In our review of the literature, we also identified a problem that while some studies 
showed the stimulation of anti-tumor immune-responses, the patients actually show the same 
level of improvement as with traditional therapies.  To obtain more information of this issue, we 
interviewed four scientists. We first interviewed Dr. Philip W. Kantoff, who is the Vice Chair 
and Chief of the Division of Solid Tumor Oncology, Department of Medical Oncology, Dana-
Farber Cancer Institute, the Jerome and Nancy Kohlberg Professor of Medicine, Harvard 
Medical School. He was the first author on a 2010 paper published in the New England Journal 
of Medicine, 363(5): 411-422, entitled “Sipuleucel-T Immunotherapy for Castration-Resistant 
Prostate Cancer”. In this study, the team vaccinated 341 advanced prostate cancer patients with 
the Provenge (Sipuleucel-T) vaccine and 171 patients with placebo. The risk of death of the 
sipuleucel-T group was reduced by 22% compared with the placebo group. The median survival 
was prolonged by 4.1 months. When asked about potential ways to improve the vaccine efficacy, 
Dr. Kantoff stated, “The most promising way would be to add a checkpoint inhibitor.” So in this 
interview the author pointed out that using antibodies against PD-1 or CTLA-3 to block the 
receptor that leads to an inhibition of T-cell responses by the cancer environment has high 
potential for improving the vaccine. This approach should be further tested for its ability to 
improve the vaccine efficacy. 
 
We then interview Dr. Evelien L.J. Smits of the Center for Oncological Research, 
University of Antwerp. Dr. Smits was the corresponding author of a 2015 paper published in 
Pharmacology & Therapeutics, 146, 120-131, entitled “Poly (I:C) as cancer vaccine adjuvant: 
Knocking on the door of medical breakthroughs”.  In this paper the author summarized studies 
using poly (I:C) as a cancer adjuvant. According to their study, poly (I:C) has the potential to 
improve immunotherapy.  In the discussion section of the paper, the authors stated “Hence, 
additional selective blocking of inhibitory molecules might be able to improve the adjuvant 
effect of poly (I:C)/poly-ICLC in cancer vaccination strategies”. When asked whether they have 
tested this “blocking of inhibitory molecules” approach, Dr. Smits stated “We are currently 
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testing pI:C in combination with immune checkpoint inhibitors and in combination with 
hypoxia-inducible factor inhibition. The tests are conducted in vitro, so we have no human or 
mouse data yet”. In this interview, the author pointed out that pI:C application in combination 
with checkpoint inhibitors is a promising way to further improve cancer vaccine effectiveness.  
  
We also interviewed Dr. I. Jolanda M. de Vries from the Nijimengen Centre for 
Molecular Life Sciences, Radboud University Nijmegen Medical Centre. Dr. de Vries was 
corresponding author on a 2011 paper published in Clinical Cancer Research, 17(17): 5725-
5735, entitled "Route of Administration Modulates the Induction of Dendritic Cell Vaccine–
Induced Antigen-Specific T-Cells in Advanced Melanoma Patients". In this study, the team 
vaccinated 43 patients with peptide-loaded DCs via intradermal or intranodal delivery. The 
results showed that both intranodal and intradermal vaccinations can stimulate T-cell responses 
against tumors, but intradermal vaccinations tend to induce more functional T-cells than 
intranodal. When interviewed about other strategies for improving cancer vaccines, Dr. Kalijn 
Bol of the same college as Dr. de Vries responded, stating, “One can think of ways to improve 
the maturation of the DC’s (e.g. with TLR ligands) or the loading of antigens on DCs. Further, 
we started using naturally occurring DCs instead of monocyte-derived DC’s, and believe they are 
more potent.”  Thus, in this interview the author stressed that the choice of DCs, the method of 
DC maturation, and how they are loaded with antigens all play crucial parts in improving DC-
based cancer vaccines.  
 
We then interviewed Dr. Hideho Okada, currently of the University of California San 
Francisco, Department of Neurological Surgery, 505 Parnassus Ave, M-779 San Francisco, CA.  
Dr. Okada was corresponding author on a 2013 paper published in the Journal of Clinical 
Oncology, 29(3): 330-336, entitled “Induction of CD8+ T-Cell Responses Against Novel 
Glioma-Associated Antigen Peptides and Clinical Activity by Vaccinations With α-Type 1 
Polarized Dendritic Cells and Polyinosinic-Polycytidylic Acid Stabilized by Lysine and 
Carboxymethylcellulose in Patients With Recurrent Malignant Glioma”. In this paper, the team 
vaccinated 19 patients with alpha-type-1 polarized DC’s loaded with glioma-associated antigens 
complemented with poly (I:C) adjuvant.  Nine of the 19 patients showed 12 months of 
progression-free status, and 1 patient showed sustained complete remission. When asked whether 
strategies like pre-conditioning the vaccine site with Td could help improve the vaccine efficacy, 
Dr. Okada stated “We inject DCs directly into lymph nodes, but not in the skin. So, I do not 
think we need the priming in the skin”. He then mentioned they have come up with several 
strategies for improving the vaccine, but he is unable to provide more details due to his busy 
schedule. Thus, in this interview the author stressed that Td pre-vaccine may not be very helpful 
if the DCs are injected into the lymph nodes, not the skin. For those experiments that inject DCs 
into the skin, Td pre-conditioning is still a potential way to help improve vaccine efficacy. 
 
 
TIL Vaccines       Eric Williams 
 
This section of the IQP focused on the use of tumor-infiltrating lymphocytes (TILs) as 
cancer vaccines.  In this approach, TILs that have migrated to a patient’s tumor site are isolated, 
amplified ex vivo, and injected back into the same patient.  One problem identified in this section 
was the need for the TILs to be directed against novel neo-antigens created on the surface of the 
patient’s tumor as it evolves. Identifying these neoantigens requires new second-generation 
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sequencing approaches.  One lab using this technology is Dr. Paul F. Robbins of the Surgery 
Branch, National Cancer Institute, National Institutes of Health (Bethesda, MD).  Dr. Robbins 
and his team developed a new screening method that uses bioinformatics and whole-exome 
sequence data from tumor cells to determine if there is a connection between the ability of TIL to 
mediate durable tumor regressions and their ability to recognize potent neo-antigens. Dr. 
Robbins was first author on a 2013 paper in Nature Medicine, 19(6): 747-752, entitled “Mining 
Exomic Sequencing Data to Identify Mutated Antigens Recognized by Adoptively Transferred 
Tumor-Reactive T-cells”. This paper detailed their new method and successful results. The first 
step of the process was to mine whole-exome sequence data (protein encoding areas of the DNA) 
to identify mutated proteins expressed in patient tumors. They then synthesized and evaluated 
specific mutated T-cell epitopes for recognition by TILs from the patient. These were chosen 
using a major histocompatibility complex-binding algorithm for recognition by TILs. To learn 
more about this method, we interviewed Dr. Robbins, and asked whether he had attempted to use 
this method for identifying mutated antigens in tumors other than melanomas.  He responded that 
they have done so “in colon, breast, lung and ovarian cancers”.  In addition, he said that “it 
appears that all or nearly all tumors possess immunogenic mutations”.  So, this means that the 
whole-exome sequencing approach developed by Dr. Robbins and his colleagues could be 
applied to other types of tumors, and that their data indicates it is likely that all types of tumors 
create neo-antigens that could serve as targets for therapy.  
  
Several studies done in both animals and humans show that T-cells active against neo-
antigens mediate the tumor regressions in most cancer vaccines.  The problem with this approach 
is the long time it takes to sequence a patient’s exome (exon portion of the genome) to identify 
the neoantigens.  Most indications are it takes about 10 weeks, which is a long time if the patient 
has advanced cancer.  To ask about the speed of the new neo-antigen methods, we interviewed 
Dr. Robert D. Schreiber who is director of the Center for Human Immunology and 
Immunotherapy Programs at Washington University of Medicine (St. Louis, MO).  Dr. Schreiber 
was second author on a 2015 paper published in Science, 348(6230): 69-74, entitled 
“Neoantigens in Cancer Immunotherapy”. This paper detailed some of the new technologies 
used to identify patient-specific neoantigens. We asked Dr. Schreiber how he thinks the speed of 
identifying the patient neoantigens and getting them back into the patient could be improved, and 
he responded that of the 10 weeks from tumor biopsy to vaccination, 6 of those weeks are used 
to identify and produce the synthetic long peptides. He estimated that this process could be 
reduced to 3 weeks with newer sequencing and synthesis technologies. We also asked what types 
of cancers will best be treated by neoantigens, and he said that the most susceptible tumors 
would be those with mutation rates of ~100 mutations per tumor or greater.  
 
 
CAR Vaccines        Zhuohao Ling 
 
In some cases, researchers isolating T-cells from tumors found them to be committed 
against a broad spectrum of antigens, not one type.  This implies that cancer vaccines directed 
against only one antigen might not work here.  To learn more about this broad-type response, we 
interviewed Dr. Jason H. Bielas, who is a researcher of the Human Biology Division at Fred 
Hutchinson Cancer Research Center (Seattle, Washington). Dr. Bielas was senior author (last 
author) on a 2013 paper in Science Translational Medicine, 5, 214ra169, entitled “Digital 
Genomic Quantification of Tumor-Infiltrating Lymphocytes”. The authors designed a new 
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digital DNA-based assay (termed QuanTILfy) to count TILs and assess T-cell clonality in tissue 
samples, including tumors.  They applied the approach to metastatic ovarian tumor tissue, and 
demonstrated an association between higher TIL counts and improved patient survival, which is 
consistent with previous findings that the patient’s immune response is a meaningful and 
independent prognostic factor.  Surprisingly they found a diverse TIL repertoire for all their 
tumors, with no apparent clonal expansions. When asked about whether the broad TIL response 
and lack of clonal expansion of a specific type of TIL against a specific tumor antigen is specific 
to the ovarian cancer tissues, or is likely to apply to other types of cancer, Dr. Bielas stated “The 
assay isn’t as powerful for identifying clonal expansions as NGS-based methods, nor have we 
looked at other tumor types”.  So, perhaps future experiments could analyze other types of 
tumors for this “broad-type” TIL response.   
 
This speed question for identifying neoantigens was also asked of Dr. James N. 
Kochenderfer who is a physican-scientist of Center for Cancer Research at National Cancer 
Institute (Bethesda, Maryland). Dr. Kochenderfer was the second author on a 2015 paper in 
Lancet, 385(9967): 517-528, entitled “T-Cells Expressing CD19 Chimeric Antigen Receptors for 
Acute Lymphoblastic Leukaemia in Children and Young Adults: A Phase-I Dose Escalation 
Trial”. Researchers treated 21 patients with refractory B-cell malignancies with CD19-CAR 
cells.  The autologous cells were engineered in an 11-day manufacturing process to express an 
anti-CD19 single chain antibody variable fragment.  They determined the maximum tolerated 
dose to be 1 x 10E6 CAR cells per kg weight.  Any toxicities observed were reversible. Three of 
the 21 (14%) showed grade-4 cytokine release syndrome, 9 (43%) showed fever, and 8 (38%) 
showed neutropenia.  The purpose of this phase-1 was not efficacy, but safety.  When asked if 
his current 11-day manufacturing process is fast enough to treat advanced cases and if there are 
any efforts being to decrease the time for this therapy, Dr. Kochenderfer replied “we can make 
the cells in 6 days now. Eleven days is fast enough to accommodate most patients”.  So, in this 
interview the author confirms that the 11-day manufacturing process is fast enough to treat most 
patients with CD19-type cancer. And more importantly, the process has been improved to 6 
days, which might help with other types of cancer. 
 
With respect to how universal the neoantigen approach might be, we interviewed Dr. 
James C. Yang who is a senior investigator at Center for Cancer Research at National Cancer 
Institute (Bethesda, Maryland). Dr. Yang was senior author on a 2014 paper in Science, 344: 
641-645, entitled “Cancer Immunotherapy Based on Mutation-Specific CD4+ T-Cells in a 
Patient with Epithelial Cancer”.  These researchers used a whole-exome sequencing strategy to 
show that TIL cells isolated from a patient with metastatic cholangiocarcinoma contain CD4+ 
helper cells that recognize a neoantigen mutation in Erbb2-interacting protein (ERBB2IP) 
expressed by the cancer cells.  They performed a therapy using TILs, of which 25% were active 
against this mutation, and achieved a stabilization of the cancer progression, while a second 
treatment with 95% TILs against the mutated antigen provided tumor regression.  Their data 
showed that TIL cells designed against a mutated neoantigen on the tumor cells can help mediate 
tumor regression. When asked whether the approach of identifying mutated antigens targeted by 
the TILs could be a universal protocol for treating almost any form of cancer, Dr. Yang stated 
“the immune recognition of a mutated "neoantigen" should be universal, i.e. not specific for the 
type of cancer it is expressed by, although more highly mutated cancers are more likely to have 
more target antigens. Having a recognized mutated antigen may be an important, but not 
sufficient component for inducing the immune tumor rejection.  Some cancers may have too few 
mutations, such that none get processed by the proteasome correctly or do not bind well to any of 
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the patient's HLA alleles. Others may get out to the cell surface as an epitope properly mounted 
on an HLA molecule, but the T-cell response may prove to be weak. Additionally, the mutation 
may only be on a portion of the tumor cells, not all of them as would likely be the case for a true 
"driver" mutation (such random and functionally unimportant mutations are called bystander 
mutations and T-cells against them would only treat part of the tumor). And lastly, there may be 
some powerful immunosuppressive mechanisms in the tumor microenvironment that would 
dampen even a good immune response against a good driver mutation (these factors could be 
somewhat tumor type specific--eg a tumor type that frequently secretes an immunosuppressive 
cytokine or expresses the ligand for a T-cell inhibitory receptor). Having considered all these 
things, it still remains a possibility that any human tumor could be rejected by an immune 
response against a mutated antigen, especially if combined with other agents such as a 
checkpoint blocking antibody (eg. anti-PD1). And the more mutations a tumor has, the more 
likely that one will be an important/ubiquitous driver mutation that also provokes a potent T-cell 
response.  That is probably why some tumors seem clinically "more immunogenic" than others 
(e.g. a melanoma seems immunogenic because it often has many mutations generated by UV 
irradiation).  Still the case we described had only 26 point mutations (not hundreds like the 
typical melanoma) and was successful, so sometimes you just get lucky.” Therefore, in the 
interview Dr. Yang explained that the age of the tumor is important, as older tumors have a 
higher number of neoantigen targets.  And it is important for the neoantigen to be present on 
most of the patient’s tumor cells, not just a few if that neoantigen is to be used as a target. 
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CONCLUSIONS / RECOMMENDATIONS 
 
Based on the research performed for this project, our team has made several conclusions 
and recommendations. 
 
1. For the cancer area in general, no single antigen has been identified that represents 
all cancers, and cancers evolve by mutating more genes to create neoantigens, so it is 
not likely that a universal cancer vaccine will be developed in the near future for 
curing all forms of cancer.  Although, as one of our interviewees stated “You should 
never say never”. 
 
2. In the peptide injection area, although the initial results have been relatively mild 
compared to the TIL and CAR areas, a new trend is to inject peptide mixtures.  Some 
treatments have produced longer patient survival, but relatively few long-term full 
cancer remissions.  For the monovalent antibody area, although the treatments 
sometimes prolonged a patient’s life, full cancer remissions were not common.  The 
reported “complete responses” (full immune involvement) are not the same as 
“complete cancer remissions”, as have been seen recently with TIL and CAR 
vaccines.   
 
3. The bivalent antibody area has seen some excellent success stories, especially for 
the CD19 x CD3 Blinatumomab antibody, where one study with 189 patients with 
B-cell acute lymphoblastic leukemia (B-ALL) showed that after two treatments, 81 of 
the 189 patients (43%) had complete cancer remissions. In a few cases, the patients 
showed serious side effects from the complete loss of their B-cells (and one patient 
died from an opportunistic infection), but the low percentages of these cases far 
outweighed the complete remissions seen from these diseases with very poor 
prognoses. 
 
4. The immune checkpoint inhibitor area shows great promise for re-activating TIL 
cells that have infiltrated a patient’s tumor but have become inactivated by the tumor.  
The future likely will involve combining these immune stimulators with other 
antibody or T-cell vaccines.  In this category, the patients should also be monitored 
closely for autoimmune or inflammatory reactions while the immune system becomes 
activated.  Although grade-3 and 4 side effects were often seen with these treatments, 
they were transient and treatable, and pale compared to their prognosis without 
treatment.  
 
5. For the DC cancer area, the results so far are somewhat lukewarm compared to 
those obtained with TIL and CAR cells, including for Provenge one of the best 
characterized vaccines in this area.  But future approaches will likely include 
combining the DC vaccines with checkpoint antibodies, combining the vaccines with 
immune stimulatory hormones (like IL-12), using a personalized medicine approach 
to sequence the exomes of a patient’s tumor to identify neo-antigens unique to that 
patient for priming the vaccine against (within this area it is especially important to 
identify neo-antigens that are immuno-dominant and more likely to produce an 
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immune response), improving the speed at which this DNA sequencing can be done 
to decrease the time to therapy, using adjuvants such as poly-(I:C) to boost the 
immune response, using pre-injections of a “recall antigen” such as tetanus toxoid Td 
for skin injections of DC cells (which has been shown to increase DC migration to 
lymph nodes to improve the immune response), identifying biomarkers for which 
type of patient is most likely to respond to a vaccine, supplementing the vaccines with 
other cellular components of the immune system, such as natural killer cells (NKs) 
(which have recently been shown to help other cells present antigens). 
 
6. For the TIL and CAR T-cell vaccine area, this area has provided some of the most 
spectacular successes in the entire field of cancer vaccines, including one study where 
30 patients (children and adults) with relapsed acute lymphoblastic leukemia (ALL) 
were treated with CD19-directed CAR cells, and 27 of 30 patients (90%) showed 
complete remission at 6 months!  Although all 30 patients developed cytokine-release 
syndrome (CRS) (27% with severe CRS), the problem was effectively treated with 
anti-interleukin-6 receptor antibody (tocilizumab), and the patients remained in 
cancer remission.  With respect to the future, the best patient survivals appear to 
occur in patients with the highest T-cell load in the tumor, so this underscores the 
importance of producing large numbers of T-cells for each vaccine.  Some of the best 
cancer remissions occurred by enriching the TILs from a patient with for a subset 
committed to neoantigens, so in the future although this approach is labor intensive, it 
should be tested further.  Scientists have identified neoantigens in all tumors analyzed 
for far, so the neoantigen approach should work for each tumor type.  The speed of 
the neoantigen identification technology appears to be improving, with one scientist 
indicating he has already lowed the time from tumor biopsy to vaccine to only 6 
weeks, which is sufficient for treating all but the very worst cases of cancer.  So, this 
critical neoantigen identification process appears to be improving with advances in 
DNA sequencing and synthetic chemistry.  It is also important for the neoantigen to 
be present on most of the patient’s tumor cells, not just a few, or the cancer cells will 
not be eliminated.   
 
Our overall conclusion is that some types of cancer vaccines, especially the more recent 
innovations, appear to work well, and are worth further research funding.  In some cases, the 
CAR T-cell vaccines have shown as high as 90% full cancer remissions in medium sized (30 
patient) studies.  The literature and our interviewees were full of exciting ideas for moving the 
cancer vaccine field forward, and we hope that funding continues to support research in this area. 
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APPENDIX   
 
Example Questions for Cancer Vaccine Experts: 
 
1. Antibodies Against CD19 on B-Cells:  One of the recent success stories in cancer vaccine 
research is the use of antibodies against CD19 on the surface of B-cells to fight B-cell 
cancers like leukemia.  These antibodies seem to be very well suited for removing early stage 
B-cells in leukemia, and have caused several total cancer remissions.  
a. In your opinion why is CD19 such a good vaccine candidate?  Is it because it is not 
located on healthy cells, but is located on most (if not all) leukemia cells?   
b. Does the CD19 antibody also deplete mature B-cells that produce antibodies?  If so, 
is that a serious problem, or can that be remedied?  It is our understanding that 
patients can live without B-cells. 
 
2. Bi-Specific Antibodies:  Another successful area of cancer vaccine research is the use of bi-
specific antibodies, where one arm of the antibody molecule recognizes a tumor antigen (like 
CD19 in leukemia), while the other arm of the antibody recognizes an immune system 
activator (like CD3 on T-cells) to bring the tumor cell together with the T-cell that lyses it.   
a. If your lab works with bi-specific antibodies, has your lab combined the bi-specific 
antibody approach (and its idea of cell coupling) with the use of a second normal 
antibody (i.e. against immune stimulators PD-1 or CTLA-4) to try a combined 
vaccine approach? 
 
3. Antibodies Against PD-1 or CTLA-4:  These antibodies have helped induce several complete 
cancer remissions by stimulating the immune system to over-ride the suppression caused by 
the tumor. 
a. If your lab uses this approach, have you tried combining these stimulatory antibodies 
with other antibodies against tumor specific antigens in a combined approach?  
b. Some labs have observed side-effects caused by the immune stimulation, such as 
autoimmunity (where the patient’s immune system reacted against the body’s own 
tissues) or inflammation (the body’s crude innate immune response). When doing 
immune stimulations, did your lab assay for patient autoimmunity?  Are these side 
effects treatable? 
 
 
4. Neo-Antigens:  Neo-antigens are new proteins (or portions of proteins) created on the surface 
of tumor cells by DNA mutations that form as the tumor grows.   
a. It is our understanding that antibodies and T-cells directed against tumor neo-antigens 
help facilitate tumor cell removal, and the presence of such cells in a patient 
correlates positively with improved patient prognosis.  Do you think that T-cell 
responses against tumor-specific antigens are important for vaccine success? 
b. In some cases, a tumor may no longer express a neo-antigen that was expressed 
earlier. It is our understanding that any immune vaccine would no longer be effective 
against that patient’s tumor. Do more experiments need to be performed to 
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understand this loss of antigenicity?  Should the vaccines be designed against 
multiple antigens if possible in case one neo-antigen is lost? 
 
5. Personalized Medicine: It is our understanding that the type of neo-antigens formed by a 
cancer are different for each patient, which requires a type of personalized medicine to be 
performed.  In this case, the patient’s exome (portion of DNA encoding the proteins) is 
sequenced by new rapid DNA sequencing technologies to determine surface neo-antigens, 
and then bioinformatics is used to predict which neo-antigen might be the best candidate to 
design the patient’s immunotherapy against.   
a. Cost:  Such an intensive approach must be expensive?  Are you aware of the costs of 
this type of procedure? 
b. Speed: Some types of cancer develop faster than others. For example, malignant 
melanoma if diagnosed in stage-IV can kill a patient within weeks, while prostate 
cancer usually develops slowly over several years. So, when treating patients with 
rapidly growing tumors, it seems that speed is critical.  How long does such an 
intensive personalized approach take?  Is it fast enough to treat a fast growing tumor 
with the patient’s life at stake?   
c. Bioinformatics: It is our understanding that only a portion of the neo-antigens formed 
by a tumor are actually antigenic to the body.  Do we need better bioinformatics to 
identify which neo-antigens we should make the vaccine against? 
 
6. Side-Effect Problems:  In some human experiments, the patients showed grade-3 and 4 
(serious) side-effects that appear to be caused by the cancer vaccine.   
a. In your clinical trials, have you observed any serious side effects?  Were they 
treatable?  
b. Were the side-effects transient?  
c. We assume the side-effects are far less of a problem than the original cancer? 
 
7. TIL Vaccines Against Melanoma:  Tumor infiltrating lymphocytes (TILs) are T-cells that 
have migrated to a tumor site (presumably to help fight the tumor). But in the body, these 
cells often become inactivated by the tumor, allowing the tumor to grow.  Several cancer 
remissions have recently been achieved by isolating TIL cells from a patient’s melanoma 
tumor to get the TILs away from the suppressing environment, expanding them outside the 
body, and then perfusing them back into the patient.   
a. Why were most of the early TIL studies performed with melanomas?  Is that because 
Steve Rosenberg (a pioneer of the field at the National Cancer Institute) mostly 
studies that particular cancer?  Is there something special about melanomas that work 
well with TIL treatments?   
b. It is our understanding that TILs have also been used to treat other types of cancer, 
such as epithelial and ovarian cancers.  Are you aware of any other types of cancers 
treated with TIL cells?   
c. Some of the best remissions seem to have occurred in patients with a high TIL load. 
So, is the rate-limiting problem here the ability to amplify the TIL cells?  Don’t high 
TIL loads also cause side-effect problems?   
d. Some of the best remissions occurred by enriching the TILs for a subpopulation of 
cells active against tumor-specific neo-antigens, so should this type of enrichment be 
done routinely, or just for resistant cases?  
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8. Best Correlates of Protection:  It is not clear to us what causes the best cancer remissions. 
a. For TIL and CAR experiments, some studies have indicated that the best cancer 
remissions correlate with patients having the highest surviving TIL or CAR cell 
numbers.  Other studies show the worst side effects associated with the highest cell 
doses.  What is your opinion? 
b. Do the patients with the longest survival have TIL or CAR cells that target multiple 
tumor antigens, or just one important tumor antigen? 
 
9. More Patients:  The CAR success stories are so recent that relatively few patients have been 
followed for more than a year with this approach. 
a. Do we need more CAR studies to show the long-term effectiveness of this technique? 
 
 
10. Patient Pre-Treatments:  Recent clinical trials have demonstrated that chemotherapy 
treatment of leukemia patients prior to T-cell transfer improves the patient’s prognosis. 
a. What is the basis of the success? Does the loss of lymphocytes simply allow more 
room for the TIL or CAR therapy to expand?  Does the pre-treatment reduce the size 
of the tumor as much as possible prior to cell therapy? 
b. Would this type of pre-treatment work for most tumors? 
 
 
Example Questions for Cancer Experts Not Using Immune-Vaccines: 
 
1. Are you aware of some of the recent success stories with cancer vaccines? 
2. Do you think the recent data is finally strong for this approach? 
3. Do we need more long-term survival studies?  The technology is relatively new so it appears 
that not many long-term studies have been done, especially for the CAR-type vaccines.  Or is 
cancer remission for 1 year a sufficient time to declare a success? 
4. Cancer vaccines have worked in patients that have not responded to any other traditional 
treatments. Do you think the cancer vaccine approach should be used as a back-up approach 
to the traditional therapies, or as a front-line approach? 
 
 
INTERVIEW PREAMBLE 
 
We are a group of students from the Worcester Polytechnic Institute in Massachusetts, 
and for our research project we are conducting a series of interviews to investigate problems 
associated with cancer vaccines which have recently shown some strong successes. 
 
Your participation in this interview is completely voluntary, and you may withdraw at 
any time. During this interview, we would like to record our conversation for later analysis. We 
will also be taking notes during the interview on key points. Is this okay with you?  
 
Can we also have your permission to quote any comments or perspectives expressed 
during the interview? This information will be used for research purposes only, and we will give 
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you an opportunity to review any materials we use prior to the completion of our final report, 
which will be published on-line in WPI’s archive of projects.  
 
If the subject does not agree to be quoted, we will respond as follows: “Since you would 
not like to be quoted during this interview, we will make sure your responses are anonymous.  
No names or identifying information will appear in any of the project reports or publications.” 
 
Your participation and assistance is greatly appreciated, and we thank you for taking the 
time to meet with us. If you are interested, we would be happy to provide you with a copy of our 
results at the conclusion of our study. 
 
